
<html lang="en"     class="pb-page"  data-request-id="8b02e2f3-cf86-4d05-86d0-6e2f88e4f60e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-8;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.1c00131"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine Derivatives as Highly Selective CK2 Inhibitors with Potent Cancer Cell Stemness Inhibition" /></meta><meta name="dc.Creator" content="Yuanjiang  Wang" /></meta><meta name="dc.Creator" content="Zhaodan  Lv" /></meta><meta name="dc.Creator" content="Feihong  Chen" /></meta><meta name="dc.Creator" content="Xing  Wang" /></meta><meta name="dc.Creator" content="Shaohua  Gou" /></meta><meta name="dc.Description" content="Multifunctional entities have recently been attractive for the development of anticancer chemotherapeutic drugs. However, such entities with concurrent CK2 along with cancer stem cell (CSC) inhibit..." /></meta><meta name="Description" content="Multifunctional entities have recently been attractive for the development of anticancer chemotherapeutic drugs. However, such entities with concurrent CK2 along with cancer stem cell (CSC) inhibit..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 9, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00131" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00131" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00131" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00131" /></link>
        
    
    

<title>Discovery of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine Derivatives as Highly Selective CK2 Inhibitors with Potent Cancer Cell Stemness Inhibition | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00131" /></meta><meta property="og:title" content="Discovery of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine Derivatives as Highly Selective CK2 Inhibitors with Potent Cancer Cell Stemness Inhibition" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0014.jpeg" /></meta><meta property="og:description" content="Multifunctional entities have recently been attractive for the development of anticancer chemotherapeutic drugs. However, such entities with concurrent CK2 along with cancer stem cell (CSC) inhibitory activities are rare in a single small molecule. Herein, a series of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine derivatives were synthesized using a known CK2 inhibitor, silmitasertib (CX-4945), as the lead compound. Among the resulting compounds, 1c exhibited stronger CK2 inhibitory activity with higher Clk2/CK2 selectivity than CX-4945. Significantly, 1c could modulate the Akt1(ser129)-GSK-3β(ser9)-Wnt/β-catenin signaling pathway and inhibit the expression of the stemness marker ALDH1A1, CSC surface antigens, and stem genes, showing potent CSC inhibitory activity. Moreover, 1c also displayed superior pharmacokinetics and antitumor activity compared with CX-4945 sodium salt, without obvious toxicity. The favorable antiproliferative and antitumor activity of 1c, its high inhibitory selectivity for CK2, and its potent inhibition of cancer cell stemness make this molecule a candidate for the treatment of cancer." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Multifunctional entities have recently been attractive for the development of anticancer chemotherapeutic drugs. However, such entities with concurrent CK2 along with cancer stem cell (CSC) inhibitory activities are rare in a single small molecule. Herein, a series of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine derivatives were synthesized using a known CK2 inhibitor, silmitasertib (CX-4945), as the lead compound. Among the resulting compounds, 1c exhibited stronger CK2 inhibitory activity with higher Clk2/CK2 selectivity than CX-4945. Significantly, 1c could modulate the Akt1(ser129)-GSK-3β(ser9)-Wnt/β-catenin signaling pathway and inhibit the expression of the stemness marker ALDH1A1, CSC surface antigens, and stem genes, showing potent CSC inhibitory activity. Moreover, 1c also displayed superior pharmacokinetics and antitumor activity compared with CX-4945 sodium salt, without obvious toxicity. The favorable antiproliferative and antitumor activity of 1c, its high inhibitory selectivity for CK2, and its potent inhibition of cancer cell stemness make this molecule a candidate for the treatment of cancer." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0014.jpeg" /></meta><meta name="twitter:title" content="Discovery of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine Derivatives as Highly Selective CK2 Inhibitors with Potent Cancer Cell Stemness Inhibition" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00131"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00131">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00131&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00131&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00131&amp;href=/doi/10.1021/acs.jmedchem.1c00131" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 5082-5098</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00128" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00164" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 5-(3-Chlorophenylamino)benzo[<i>c</i>][2,6]naphthyridine Derivatives as Highly Selective CK2 Inhibitors with Potent Cancer Cell Stemness Inhibition</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yuanjiang Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuanjiang Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, PR China</div><div class="loa-info-affiliations-info">Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuanjiang++Wang">Yuanjiang Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhaodan Lv</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhaodan Lv</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhaodan++Lv">Zhaodan Lv</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Feihong Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Feihong Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, PR China</div><div class="loa-info-affiliations-info">Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Feihong++Chen">Feihong Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xing Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xing Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xing++Wang">Xing Wang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Shaohua Gou</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shaohua Gou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, PR China</div><div class="loa-info-affiliations-info">Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#2f1d1d1e161d191a171f1f6f5e5e014c4042"><span class="__cf_email__" data-cfemail="3c0e0e0d050e0a09040c0c7c4d4d125f5351">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shaohua++Gou">Shaohua Gou</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0284-5480" title="Orcid link">http://orcid.org/0000-0003-0284-5480</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00131&amp;href=/doi/10.1021%2Facs.jmedchem.1c00131" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 5082–5098</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 9, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>23 January 2021</li><li><span class="item_label"><b>Published</b> online</span>9 April 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 April 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00131" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00131</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5082%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYuanjiang%2BWang%252C%2BZhaodan%2BLv%252C%2BFeihong%2BChen%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D8%26contentID%3Dacs.jmedchem.1c00131%26title%3DDiscovery%2Bof%2B5-%25283-Chlorophenylamino%2529benzo%255Bc%255D%255B2%252C6%255Dnaphthyridine%2BDerivatives%2Bas%2BHighly%2BSelective%2BCK2%2BInhibitors%2Bwith%2BPotent%2BCancer%2BCell%2BStemness%2BInhibition%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5098%26publicationDate%3DApril%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00131"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">745</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00131" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine Derivatives as Highly Selective CK2 Inhibitors with Potent Cancer Cell Stemness Inhibition&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yuanjiang&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Zhaodan&quot;,&quot;last_name&quot;:&quot;Lv&quot;},{&quot;first_name&quot;:&quot;Feihong&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Xing&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Shaohua&quot;,&quot;last_name&quot;:&quot;Gou&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;5082-5098&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00131&quot;},&quot;abstract&quot;:&quot;Multifunctional entities have recently been attractive for the development of anticancer chemotherapeutic drugs. However, such entities with concurrent CK2 along with cancer stem cell (CSC) inhibitory activities are rare in a single small molecule. Herein, a series of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine derivatives were synthesized using a known CK2 inhibitor, silmitasertib (CX-4945), as the lead compound. Among the resulting compounds, 1c exhibited stronger CK2 inhibitory activity with higher Clk2/CK2 selectivity than CX-4945. Significantly, 1c could modulate the Akt1(ser129)-GSK-3β(ser9)-Wnt/β-catenin signaling pathway and inhibit the expression of the stemness marker ALDH1A1, CSC surface antigens, and stem genes, showing potent CSC inhibitory activity. Moreover, 1c also displayed superior pharmacokinetics and antitumor activity compared with CX-4945 sodium salt, without obvious toxicity. The favorable antiproliferative and antitumor activity of 1c, its high inhibitory selectivity for CK2, and&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00131&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00131" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00131&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00131" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00131&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00131" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00131&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00131&amp;href=/doi/10.1021/acs.jmedchem.1c00131" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00131" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00131" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00131%26sid%3Dliteratum%253Aachs%26pmid%3D33834781%26genre%3Darticle%26aulast%3DWang%26date%3D2021%26atitle%3DDiscovery%2Bof%2B5-%25283-Chlorophenylamino%2529benzo%255Bc%255D%255B2%252C6%255Dnaphthyridine%2BDerivatives%2Bas%2BHighly%2BSelective%2BCK2%2BInhibitors%2Bwith%2BPotent%2BCancer%2BCell%2BStemness%2BInhibition%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D8%26spage%3D5082%26epage%3D5098%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (5)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291763" title="Noncovalent interactions">Noncovalent interactions</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/8" title="Go to Volume 64, Issue 8"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/jmcmar.2021.64.issue-8/20210422/jmcmar.2021.64.issue-8.largecover.jpg" alt="Go to Volume 64, Issue 8"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Multifunctional entities have recently been attractive for the development of anticancer chemotherapeutic drugs. However, such entities with concurrent CK2 along with cancer stem cell (CSC) inhibitory activities are rare in a single small molecule. Herein, a series of 5-(3-chlorophenylamino)benzo[<i>c</i>][2,6]naphthyridine derivatives were synthesized using a known CK2 inhibitor, silmitasertib (<b>CX-4945</b>), as the lead compound. Among the resulting compounds, <b>1c</b> exhibited stronger CK2 inhibitory activity with higher Clk2/CK2 selectivity than <b>CX-4945</b>. Significantly, <b>1c</b> could modulate the Akt1(ser129)-GSK-3β(ser9)-Wnt/β-catenin signaling pathway and inhibit the expression of the stemness marker ALDH1A1, CSC surface antigens, and stem genes, showing potent CSC inhibitory activity. Moreover, <b>1c</b> also displayed superior pharmacokinetics and antitumor activity compared with <b>CX-4945</b> sodium salt, without obvious toxicity. The favorable antiproliferative and antitumor activity of <b>1c</b>, its high inhibitory selectivity for CK2, and its potent inhibition of cancer cell stemness make this molecule a candidate for the treatment of cancer.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04285" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04285" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Casein kinase 2 (CK2), a pleiotropic, acidophilic, and highly conserved serine/threonine protein kinase, plays a crucial role in various essential and pathological biological processes.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Unlike most other kinases, CK2 is constitutively active and more than 300 substrates are phosphorylated by CK2, making it possibly one of the most pleiotropic proteins in eukaryotic systems.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> It has been confirmed that CK2 is involved in circadian rhythms, gene expression, cell cycle progression, apoptosis, cell growth and differentiation, embryogenesis, and many other cellular processes in a variety of tumors.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> As almost all cancers can be associated with CK2-dependent phosphorylation and tumors rely on CK2 for their survival, cancer cells are more sensitive to CK2 inhibition.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Significantly, CK2 is constitutively active, but tumor transformation caused by gain-of-function CK2 mutations has not been reported so far. Thus, the widely accepted view is that the increasing levels of CK2 provide a permissive cellular environment that favors malignant transformation through a mechanism referred to as “non-oncogene dependent”. Different from classical protein kinase inhibitors, CK2 inhibitors will probably affect multiple targets rather than a single target, leading to an outcome that likely favors cancer treatment.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">Consisting of two kinds of subunits, catalytic α/α′ along with modulatory β ones, CK2 has large amino acid residues, which make the ATP binding site of CK2 relatively small.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Therefore, the ATP competitive inhibitors of CK2 must satisfy two requirements: high specificity and relatively small molecular weight. Researchers have developed a number of CK2 inhibitors including <b>DRB</b>, <b>TBB</b>, <b>Emodin</b>, and <b>CX-5011</b> with sub-micromolar Ki values in the past 40 years (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14">(11−14)</a> However, due to the limited selectivity and the weak specificity and potency, apart from the possibly potential long-term toxicity, none of them did fulfill the requirement for successful clinical settings except silmitasertib (<b>CX-4945</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). To our knowledge, so far, only <b>CX-4945</b> as a small molecule inhibitor of CK2 has entered Phase I/II clinical trials.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a><b>CX-4945</b> has been found to exhibit a strong potency against CK2 with an IC<sub>50</sub> value of 1 nM; however, unfortunately, it also represses 12 other kinases in nanomolar affinity. Particularly, <b>CX-4945</b> has strong inhibition against Clk2, which is even stronger than its inhibition against CK2.<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15−17)</a> The potent inhibition of <b>CX-4945</b> on Clk2 most likely causes the altered serine/arginine-rich (SR) protein phosphorylation in cells.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Although the success of drug development does not always require absolute specificity, cell permeable inhibitors that are highly selective are invaluable tools for studying the role of phosphorylation networks of proteins in the modulation of cellular processes.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures representing known ATP-competitive CK2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">CK2 has more than 300 phosphorylated substrates that are different signal transduction cascades including Notch, JAK/STAT, PI3K/Akt, Wnt, NF-κB and Hedgehog (Hh).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Among them, Wnt/β-catenin, Notch, and Hedgehog/Gli1 are also the main signaling transduction pathways in stem cell biology, providing cancer stem cells (CSCs) with unlimited proliferative capability.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> CSCs, a small subpopulation of tumor cells, can differentiate into different phenotypes with the ability of continuous self-renewal and differentiation and are a highly tumorigenic subpopulation.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> Unlike most of the tumor cells, CSCs have similar characteristics to stem cells, which are essentially involved in tumorigenesis, tumor recurrence, cancer progression, invasion, metastasis, and therapeutic tolerance.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> Therefore, CSCs provide a new direction for modern cancer research and a critical index for prevention, diagnosis, as well as treatment of cancer.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Generally, most of the clinical chemotherapeutic drugs like cisplatin, gemcitabine, and hydroxycamptothecin acting only on common cancer cells have no effect on CSCs, and some even promote the growth of CSCs.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> As a consequence, research and development of targeting drugs to suppress CSCs have been a great challenge and formidable task in cancer research and clinical application.</div><div class="NLM_p">As stated above, we believe that it is worthwhile to make a reasonable structural modification on the framework of <b>CX-4945</b> to obtain novel compounds with increasing anticancer activity and CK2 selectivity and suitable physical and chemical properties as novel CK2 inhibitors. It has been reported that the carboxylic group in <b>CX-4945</b> can act as an acceptor or donor to form two essential hydrogen bonds with the amino acid residues near the ATP-binding site in CK2 protein, which accounts for the potent activity of <b>CX-4945</b>.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Since amide groups can also act as hydrogen bond donors and/or receptors like carboxylic acid, they were selected to modify the skeleton of <b>CX-4945</b>. In addition, ester groups were introduced to the framework of <b>CX-4945</b> as well. Previous research indicated that CK2 has large amino acid residues that make the ATP binding site of CK2 relatively small.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Upon considering the pros and cons of various strategies, some aliphatic amines/alcohols with different side chains were selected to get <b>CX-4945</b> derivatives (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Herein, we report the synthesis and biological evaluation of these compounds together with their CK2 inhibition activities and cytotoxicity against a panel of cancer cells. Among the resulting compounds, a potent bifunctional inhibitor (<b>1c</b>) was obtained. The inhibition activity of <b>1c</b> toward CK2 and CSCs as well as its <i>in vivo</i> tumor growth inhibition on an HCT-116 xenograft model was investigated.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure modification strategy for the target compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21583" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21583" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Synthesis of Target Compounds</h3><div class="NLM_p">Compounds <b>BTE</b> and <b>CX-4945</b> were synthesized following the previously documented procedures (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_001.pdf" class="ext-link">Scheme S1</a>).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Target compounds were prepared according to the ways shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Treatment of <b>BTE</b> with hydroxylamine hydrochloride in refluxing methanol afforded <b>1a</b> that precipitated from the reaction mixture upon cooling. Target compounds <b>1b</b>–<b>1o</b> and <b>2a</b>–<b>2g</b> were obtained through the condensation reaction of <b>CX-4945</b> with different aliphatic amines/alcohols. Compounds <b>1p</b> and <b>1q</b> were obtained by hydrolysis of <b>1i</b> and <b>1o</b>, respectively, in the presence of lithium hydroxide.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Target Compounds</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Physicochemical Properties and Analysis of CK2 and ClK2 Inhibitory Activity</h3><div class="NLM_p">As potential CK2 inhibitors, the inhibitory effects of all the target compounds on CK2 were first detected by a CK2 Kinase (Human) Assay/Inhibitor Screening Assay Kit with <b>CX-4945</b> as the positive control. Lipophilic ligand efficiency (LLE) is considered to be an important indicator for predicting absorption, distribution, metabolism, and excretion properties.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> To find better CK2 inhibitors as potential anticancer agents, we attempted to modulate the LLE values of target compounds while maintaining their CK2 inhibitory effect. Since Clk2 is one of the main off-targets of <b>CX-4945</b>, the Clk2 Kinase Assay/Inhibitor Screening Assay Kit was also used to detect those compounds with IC<sub>50</sub> < 2 nM against CK2. The results are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. <b>CX-4945</b> exhibited a potent inhibitory effect on CK2 but with a small selection factor (SF) for Clk2/CK2. As expected, the introduction of amide with different functional chains could remarkably adjust the CK2 activity of the resulting compounds. Particularly, those containing −(CH<sub>2</sub>)<sub>2</sub>– chains with potential hydrogen bonding donors and/or acceptors maintained or even enhanced their inhibitory effects on CK2 and decreased their inhibitory activity against ClK2. For instance, compounds <b>1c</b>, <b>1d</b>, <b>1i</b> ,and <b>1l</b> have lower IC<sub>50</sub> values than <b>CX-4945</b> against CK2, and the inhibitory effect on Clk2 was also lower than <b>CX-4945</b>. <b>1l</b> containing a morpholinoethyl group showed the most potent CK2 inhibitory activity (IC<sub>50</sub> = 0.46 nM). Significantly, its SF value for Clk2/CK2 reached 47.61, which is 136 times over that of <b>CX-4945</b>. The inhibitory activity of <b>1c</b> containing a 2-hydroxyethyl side chain against CK2 was 0.66 nM with a high selectivity for Clk2/CK2 (142 times higher than that of <b>CX-4945</b>). However, compounds <b>1g</b>, <b>1j</b>, and <b>1k</b> displayed weaker CK2 inhibitory effects with IC<sub>50</sub> values over 10 nM. Although these amide compounds contain a tertiary amine nitrogen atom that can serve as a hydrogen bond receptor, they are less capable of forming hydrogen bonds than those containing an oxygen atom. Introduction of −(CH<sub>2</sub>)<sub>2</sub>– chains with potential hydrogen bonding donors and/or acceptors like compounds <b>1m</b>, <b>1n</b>, <b>1o</b>, and <b>1q</b> seemed not to be beneficial to increase their CK2 inhibitory activity in contrast to <b>CX-4945</b>. As for the ester compounds with a −(CH<sub>2</sub>)<sub>2</sub>– chain containing hydrogen bonding acceptors like <b>2a</b>, <b>2c</b>, and <b>2e</b> and containing a 2-iodoethyl side chain (<b>2b</b>), they also exhibited stronger CK2 inhibitory activity than <b>CX-4945</b>. Especially, the IC<sub>50</sub> value of <b>2c</b> was 6.67 times less than that of <b>CX-4945</b>. However, this kind of compounds did not effectively improve their selectivity for CK2 compared with the corresponding amide compounds. Based on the above structure–activity relationship analysis, we concluded that the amide compounds with a −(CH<sub>2</sub>)<sub>2</sub>– side chain containing hydrogen bond acceptors and/or donors would be helpful to promote the inhibitory activity and selectivity of the compound against CK2.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Physicochemical Properties and CK2 and ClK2 Inhibitory Activities of the Target Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">IC<sub>50</sub> ± SD (nM)</th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">clog<i>P</i></th><th class="colsep0 rowsep0" align="center" char=".">LLE<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±">CK2</th><th class="colsep0 rowsep0" align="center">ClK2</th><th class="colsep0 rowsep0" align="center" char=".">SF<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1a</b></td><td class="colsep0 rowsep0" align="char" char=".">4.09</td><td class="colsep0 rowsep0" align="char" char=".">4.15</td><td class="colsep0 rowsep0" align="char" char="±">5.66 ± 0.38</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1b</b></td><td class="colsep0 rowsep0" align="char" char=".">4.32</td><td class="colsep0 rowsep0" align="char" char=".">4.04</td><td class="colsep0 rowsep0" align="char" char="±">9.33 ± 0.23</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1c</b></td><td class="colsep0 rowsep0" align="char" char=".">4.13</td><td class="colsep0 rowsep0" align="char" char=".">5.05</td><td class="colsep0 rowsep0" align="char" char="±">0.66 ± 0.03</td><td class="colsep0 rowsep0" align="left">32.69 ± 0.05</td><td class="colsep0 rowsep0" align="char" char=".">49.53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1d</b></td><td class="colsep0 rowsep0" align="char" char=".">4.21</td><td class="colsep0 rowsep0" align="char" char=".">4.84</td><td class="colsep0 rowsep0" align="char" char="±">0.89 ± 0.07</td><td class="colsep0 rowsep0" align="left">19.64 ± 0.02</td><td class="colsep0 rowsep0" align="char" char=".">22.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1e</b></td><td class="colsep0 rowsep0" align="char" char=".">5.42</td><td class="colsep0 rowsep0" align="char" char=".">3.27</td><td class="colsep0 rowsep0" align="char" char="±">1.78 ± 0.09</td><td class="colsep0 rowsep0" align="left">24.69 ± 0.07</td><td class="colsep0 rowsep0" align="char" char=".">13.87</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1f</b></td><td class="colsep0 rowsep0" align="char" char=".">5.27</td><td class="colsep0 rowsep0" align="char" char=".">3.10</td><td class="colsep0 rowsep0" align="char" char="±">14.28 ± 0.26</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1g</b></td><td class="colsep0 rowsep0" align="char" char=".">5.10</td><td class="colsep0 rowsep0" align="char" char=".">3.78</td><td class="colsep0 rowsep0" align="char" char="±">21.30 ± 0.08</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1h</b></td><td class="colsep0 rowsep0" align="char" char=".">5.11</td><td class="colsep0 rowsep0" align="char" char=".">3.82</td><td class="colsep0 rowsep0" align="char" char="±">18.14 ± 0.05</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1i</b></td><td class="colsep0 rowsep0" align="char" char=".">5.03</td><td class="colsep0 rowsep0" align="char" char=".">4.07</td><td class="colsep0 rowsep0" align="char" char="±">0.79 ± 0.01</td><td class="colsep0 rowsep0" align="left">9.7 ± 0.04</td><td class="colsep0 rowsep0" align="char" char=".">12.29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1j</b></td><td class="colsep0 rowsep0" align="char" char=".">5.74</td><td class="colsep0 rowsep0" align="char" char=".">2.99</td><td class="colsep0 rowsep0" align="char" char="±">16.82 ± 0.02</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1k</b></td><td class="colsep0 rowsep0" align="char" char=".">5.31</td><td class="colsep0 rowsep0" align="char" char=".">3.59</td><td class="colsep0 rowsep0" align="char" char="±">12.6 ± 0.15</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1l</b></td><td class="colsep0 rowsep0" align="char" char=".">5.09</td><td class="colsep0 rowsep0" align="char" char=".">4.24</td><td class="colsep0 rowsep0" align="char" char="±">0.46 ± 0.01</td><td class="colsep0 rowsep0" align="left">21.9 ± 0.08</td><td class="colsep0 rowsep0" align="char" char=".">47.61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1m</b></td><td class="colsep0 rowsep0" align="char" char=".">4.45</td><td class="colsep0 rowsep0" align="char" char=".">4.55</td><td class="colsep0 rowsep0" align="char" char="±">8.81 ± 0.04</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1n</b></td><td class="colsep0 rowsep0" align="char" char=".">4.53</td><td class="colsep0 rowsep0" align="char" char=".">4.19</td><td class="colsep0 rowsep0" align="char" char="±">5.32 ± 0.16</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1o</b></td><td class="colsep0 rowsep0" align="char" char=".">5.36</td><td class="colsep0 rowsep0" align="char" char=".">3.23</td><td class="colsep0 rowsep0" align="char" char="±">4.53 ± 0.15</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1p</b></td><td class="colsep0 rowsep0" align="char" char=".">4.91</td><td class="colsep0 rowsep0" align="char" char=".">3.83</td><td class="colsep0 rowsep0" align="char" char="±">9.84 ± 0.08</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1q</b></td><td class="colsep0 rowsep0" align="char" char=".">4.55</td><td class="colsep0 rowsep0" align="char" char=".">4.23</td><td class="colsep0 rowsep0" align="char" char="±">21.65 ± 0.05</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2a</b></td><td class="colsep0 rowsep0" align="char" char=".">4.53</td><td class="colsep0 rowsep0" align="char" char=".">4.68</td><td class="colsep0 rowsep0" align="char" char="±">0.61 ± 0.02</td><td class="colsep0 rowsep0" align="left">2.38 ± 0.05</td><td class="colsep0 rowsep0" align="char" char=".">3.90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2b</b></td><td class="colsep0 rowsep0" align="char" char=".">6.54</td><td class="colsep0 rowsep0" align="char" char=".">2.58</td><td class="colsep0 rowsep0" align="char" char="±">0.76 ± 0.16</td><td class="colsep0 rowsep0" align="left">1.69 ± 0.08</td><td class="colsep0 rowsep0" align="char" char=".">2.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2c</b></td><td class="colsep0 rowsep0" align="char" char=".">5.67</td><td class="colsep0 rowsep0" align="char" char=".">3.97</td><td class="colsep0 rowsep0" align="char" char="±">0.23 ± 0.04</td><td class="colsep0 rowsep0" align="left">1.06 ± 0.06</td><td class="colsep0 rowsep0" align="char" char=".">4.60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2d</b></td><td class="colsep0 rowsep0" align="char" char=".">6.02</td><td class="colsep0 rowsep0" align="char" char=".">2.92</td><td class="colsep0 rowsep0" align="char" char="±">7.29 ± 0.11</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2e</b></td><td class="colsep0 rowsep0" align="char" char=".">5.99</td><td class="colsep0 rowsep0" align="char" char=".">3.23</td><td class="colsep0 rowsep0" align="char" char="±">0.60 ± 0.08</td><td class="colsep0 rowsep0" align="left">1.54 ± 0.11</td><td class="colsep0 rowsep0" align="char" char=".">2.54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2f</b></td><td class="colsep0 rowsep0" align="char" char=".">6.50</td><td class="colsep0 rowsep0" align="char" char=".">2.24</td><td class="colsep0 rowsep0" align="char" char="±">3.43 ± 0.56</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2g</b></td><td class="colsep0 rowsep0" align="char" char=".">4.42</td><td class="colsep0 rowsep0" align="char" char=".">4.45</td><td class="colsep0 rowsep0" align="char" char="±">11.34 ± 0.34</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CX-4945</b></td><td class="colsep0 rowsep0" align="char" char=".">5.44</td><td class="colsep0 rowsep0" align="char" char=".">3.37</td><td class="colsep0 rowsep0" align="char" char="±">1.54 ± 0.07</td><td class="colsep0 rowsep0" align="left">0.55 ± 0.02</td><td class="colsep0 rowsep0" align="char" char=".">0.35</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">LLE was calculated as follows: LLE = <i>p</i>IC<sub>50</sub> (M) – cLog<i>P</i>.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">SF (selection factor) is defined as IC<sub>50</sub> (ClK2)/IC<sub>50</sub> (CK2).</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">NT = not tested.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Kinase Selectivity Profiling</h3><div class="NLM_p">To demonstrate the inhibitor’s kinase selectivity, <b>1c</b> was profiled for suppression against a panel of 208 human kinases using the ADP-Glo and HTRF kinase assay. As illustrated in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_001.pdf" class="ext-link">Table S1</a>, <b>1c</b> exhibits the expected high selectivity for CK2α within the human kinome. The activity of CK2α can be completely inhibited by <b>1c</b> at 1 μM. It is observed that the inhibition rate of <b>1c</b> on Clk2, ZAP70, EGFR(ErbB1), PLK1, and EPHA1 kinases is more than 50% but less than 78%. Among them, the highest inhibition rate of Clk2 is only about 80% (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>c). Overall, compound <b>1c</b> exhibits strong and selective inhibition against CK2α.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>1c</b> demonstrates high potency as well as selectivity for CK2α <i>in vitro</i>. (a) Graphical illustration of the kinase inhibition profile of <b>1c</b> with 208 kinases (a list of the tested kinases is shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_001.pdf" class="ext-link">Table S1</a>). The KinMap software tool provided by Cell Signaling Technology, Inc. (<a href="https://www.cellsignal.com" class="extLink">https://www.cellsignal.com</a>) was employed to map the TREEspot image. (b) Hierarchical clustering depicting the inhibition ratio of <b>1c</b> on the top 50 kinases (the higher the level, the better the inhibitory activity). (c) Kinases’ activity less than 50% in the presence of compound <b>1c</b> at 1 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Investigations on the Antiproliferative Activity <i>In Vitro</i></h3><div class="NLM_p">The antiproliferative influences of all the target compounds against five CK2-overexpressed cancer cell lines (prostate cancer, PC-3; colon cancer, HCT-116 and HT-29; breast cancer, MCF-7; and bladder cancer, T24) together with normal embryonic liver cells (LO2) were assessed by an MTT assay in which <b>CX-4945</b> was employed as a positive control. The IC<sub>50</sub> values derived from the dose–response curves are indicated in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. It was observed that the cell proliferation inhibitory activities of the target compounds were related to their effects on enzyme inhibition. Compounds <b>1c</b>, <b>1d</b>, <b>1i</b>, and <b>1l</b> with strong inhibitory potency against CK2 displayed potent antiproliferative influence against the tested cancer cells. For example, <b>1c</b> exhibited potent antiproliferative activities against five different CK2-overexpressed cancer cells, especially PC-3 cells and HCT-116 cells with IC<sub>50</sub> values of 4.53 and 3.07 μM, respectively. <b>1i</b> showed considerable potency against MCF-7 cells (4.51 μM) and HT-29 cells (3.52 μM); more importantly, it was less toxic to LO2 with an IC<sub>50</sub> value higher than 200 μM. In addition, <b>1m</b> showed a more potent activity against PC-3 cells, and the IC<sub>50</sub> value is 3.28 μM. However, compounds <b>1m</b>, <b>1p</b>, <b>1q</b>, <b>2f</b>, and <b>2g</b> with lower CK2 inhibitory activities than <b>CX-4945</b>, probably because of their steric hindrances or long methylene chains, had less antiproliferation activities against cancer cells than <b>CX-4945</b>. It was also worth noting that compounds <b>1j</b> and <b>1k</b> with moderate CK2 inhibitory activities also exhibited strong anticancer activity. When ester bonding served as the linker, the resulting compounds (<b>2a–e</b>) demonstrated much better cytotoxicity than <b>CX-4945</b>. In particular, <b>2c</b> not only displayed potent activity against CK2 but also showed strong inhibitory influence toward five different cancer cells. However, it was a little toxic to normal liver cells LO2. The possible reason is that functional groups varied from carboxylic acid to amide or ester in <b>CX-4945</b> might change the pharmacokinetic properties and the antitumor and CK2 inhibitory activity of the resulting compounds. Based on the above study, <b>1c</b> with high selectivity for CK2, potent inhibitory activity against the tested cancer cells, low toxicity to normal liver cells, and a suitable LLE value was chosen for further investigation.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. <i>In Vitro</i> Cytotoxicity Profiles of the Target Compounds against Several Human Cancer Cell Lines<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char="±">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cpd.</th><th class="colsep0 rowsep0" align="center" char="±">PC-3</th><th class="colsep0 rowsep0" align="center" char="±">HCT-116</th><th class="colsep0 rowsep0" align="center" char="±">MCF-7</th><th class="colsep0 rowsep0" align="center" char="±">HT-29</th><th class="colsep0 rowsep0" align="center" char="±">T24</th><th class="colsep0 rowsep0" align="center">LO2</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1a</b></td><td class="colsep0 rowsep0" align="char" char="±">15.09 ± 0.15</td><td class="colsep0 rowsep0" align="char" char="±">8.62 ± 0.25</td><td class="colsep0 rowsep0" align="char" char="±">7.66 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">9.98 ± 0.19</td><td class="colsep0 rowsep0" align="char" char="±">3.89 ± 0.10</td><td class="colsep0 rowsep0" align="left">21.42 ± 0.69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1b</b></td><td class="colsep0 rowsep0" align="char" char="±">4.16 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">13.25 ± 0.58</td><td class="colsep0 rowsep0" align="char" char="±">12.16 ± 0.45</td><td class="colsep0 rowsep0" align="char" char="±">17.81 ± 0.70</td><td class="colsep0 rowsep0" align="char" char="±">23.49 ± 0.70</td><td class="colsep0 rowsep0" align="left">28.43 ± 1.59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1c</b></td><td class="colsep0 rowsep0" align="char" char="±">4.53 ± 0.43</td><td class="colsep0 rowsep0" align="char" char="±">3.07 ± 0.67</td><td class="colsep0 rowsep0" align="char" char="±">7.50 ± 0.15</td><td class="colsep0 rowsep0" align="char" char="±">5.18 ± 0.12</td><td class="colsep0 rowsep0" align="char" char="±">6.10 ± 0.90</td><td class="colsep0 rowsep0" align="left">96.68 ± 1.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1d</b></td><td class="colsep0 rowsep0" align="char" char="±">5.48 ± 0.31</td><td class="colsep0 rowsep0" align="char" char="±">7.26 ± 0.49</td><td class="colsep0 rowsep0" align="char" char="±">4.88 ± 0.65</td><td class="colsep0 rowsep0" align="char" char="±">11.37 ± 0.38</td><td class="colsep0 rowsep0" align="char" char="±">14.42 ± 0.48</td><td class="colsep0 rowsep0" align="left">111.13 ± 2.46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1e</b></td><td class="colsep0 rowsep0" align="char" char="±">8.76 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">28.11 ± 1.42</td><td class="colsep0 rowsep0" align="char" char="±">14.86 ± 0.72</td><td class="colsep0 rowsep0" align="char" char="±">8.01 ± 0.12</td><td class="colsep0 rowsep0" align="char" char="±">8.95 ± 0.18</td><td class="colsep0 rowsep0" align="left">66.73 ± 3.53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1f</b></td><td class="colsep0 rowsep0" align="char" char="±">6.12 ± 0.56</td><td class="colsep0 rowsep0" align="char" char="±">16.54 ± 0.92</td><td class="colsep0 rowsep0" align="char" char="±">10.43 ± 018</td><td class="colsep0 rowsep0" align="char" char="±">13.95 ± 0.31</td><td class="colsep0 rowsep0" align="char" char="±">18.13 ± 0.35</td><td class="colsep0 rowsep0" align="left">18.37 ± 0.95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1g</b></td><td class="colsep0 rowsep0" align="char" char="±">11.08 ± 0.25</td><td class="colsep0 rowsep0" align="char" char="±">12.76 ± 0.78</td><td class="colsep0 rowsep0" align="char" char="±">6.01 ± 0.18</td><td class="colsep0 rowsep0" align="char" char="±">5.08 ± 0.10</td><td class="colsep0 rowsep0" align="char" char="±">5.93 ± 0.10</td><td class="colsep0 rowsep0" align="left">17.26 ± 0.67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1h</b></td><td class="colsep0 rowsep0" align="char" char="±">7.60 ± 0.18</td><td class="colsep0 rowsep0" align="char" char="±">21.21 ± 0.96</td><td class="colsep0 rowsep0" align="char" char="±">13.88 ± 0.69</td><td class="colsep0 rowsep0" align="char" char="±">16.43 ± 0.52</td><td class="colsep0 rowsep0" align="char" char="±">18.49 ± 0.26</td><td class="colsep0 rowsep0" align="left">28.41 ± 2.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1i</b></td><td class="colsep0 rowsep0" align="char" char="±">9.94 ± 0.24</td><td class="colsep0 rowsep0" align="char" char="±">8.13 ± 0.92</td><td class="colsep0 rowsep0" align="char" char="±">4.51 ± 0.52</td><td class="colsep0 rowsep0" align="char" char="±">3.52 ± 0.16</td><td class="colsep0 rowsep0" align="char" char="±">10.67 ± 0.29</td><td class="colsep0 rowsep0" align="left">>200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1j</b></td><td class="colsep0 rowsep0" align="char" char="±">10.07 ± 0.57</td><td class="colsep0 rowsep0" align="char" char="±">8.79 ± 0.36</td><td class="colsep0 rowsep0" align="char" char="±">8.60 ± 0.10</td><td class="colsep0 rowsep0" align="char" char="±">7.94 ± 0.15</td><td class="colsep0 rowsep0" align="char" char="±">3.23 ± 0.03</td><td class="colsep0 rowsep0" align="left">16.04 ± 0.93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1k</b></td><td class="colsep0 rowsep0" align="char" char="±">6.08 ± 0.39</td><td class="colsep0 rowsep0" align="char" char="±">8.60 ± 0.20</td><td class="colsep0 rowsep0" align="char" char="±">3.74 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">13.80 ± 0.17</td><td class="colsep0 rowsep0" align="char" char="±">3.24 ± 0.07</td><td class="colsep0 rowsep0" align="left">14.31 ± 0.70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1l</b></td><td class="colsep0 rowsep0" align="char" char="±">3.28 ± 0.10</td><td class="colsep0 rowsep0" align="char" char="±">7.98 ± 1.40</td><td class="colsep0 rowsep0" align="char" char="±">11.01 ± 0.15</td><td class="colsep0 rowsep0" align="char" char="±">13.37 ± 0.25</td><td class="colsep0 rowsep0" align="char" char="±">8.73 ± 0.55</td><td class="colsep0 rowsep0" align="left">37.81 ± 1.74</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1m</b></td><td class="colsep0 rowsep0" align="char" char="±">8.94 ± 0.12</td><td class="colsep0 rowsep0" align="char" char="±">13.68 ± 0.30</td><td class="colsep0 rowsep0" align="char" char="±">7.71 ± 0.13</td><td class="colsep0 rowsep0" align="char" char="±">11.75 ± 0.15</td><td class="colsep0 rowsep0" align="char" char="±">18.80 ± 0.53</td><td class="colsep0 rowsep0" align="left">74.16 ± 2.40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1n</b></td><td class="colsep0 rowsep0" align="char" char="±">14.10 ± 0.25</td><td class="colsep0 rowsep0" align="char" char="±">15.92 ± 0.85</td><td class="colsep0 rowsep0" align="char" char="±">19.71 ± 0.54</td><td class="colsep0 rowsep0" align="char" char="±">9.87 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">37.28 ± 0.90</td><td class="colsep0 rowsep0" align="left">84.97 ± 1.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1o</b></td><td class="colsep0 rowsep0" align="char" char="±">4.89 ± 0.10</td><td class="colsep0 rowsep0" align="char" char="±">5.91 ± 0.24</td><td class="colsep0 rowsep0" align="char" char="±">19.80 ± 0.70</td><td class="colsep0 rowsep0" align="char" char="±">20.60 ± 0.35</td><td class="colsep0 rowsep0" align="char" char="±">12.93 ± 0.15</td><td class="colsep0 rowsep0" align="left">89.12 ± 6.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1p</b></td><td class="colsep0 rowsep0" align="char" char="±">16.18 ± 0.36</td><td class="colsep0 rowsep0" align="char" char="±">4.60 ± 0.10</td><td class="colsep0 rowsep0" align="char" char="±">24.55 ± 0.96</td><td class="colsep0 rowsep0" align="char" char="±">19.90 ± 0.27</td><td class="colsep0 rowsep0" align="char" char="±">24.42 ± 0.50</td><td class="colsep0 rowsep0" align="left">72.84 ± 4.53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1q</b></td><td class="colsep0 rowsep0" align="char" char="±">4.20 ± 0.25</td><td class="colsep0 rowsep0" align="char" char="±">24.77 ± 1.57</td><td class="colsep0 rowsep0" align="char" char="±">19.63 ± 0.98</td><td class="colsep0 rowsep0" align="char" char="±">14.51 ± 0.64</td><td class="colsep0 rowsep0" align="char" char="±">21.14 ± 0.58</td><td class="colsep0 rowsep0" align="left">32.24 ± 0.82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2a</b></td><td class="colsep0 rowsep0" align="char" char="±">9.15 ± 0.69</td><td class="colsep0 rowsep0" align="char" char="±">10.91 ± 2.55</td><td class="colsep0 rowsep0" align="char" char="±">15.18 ± 0.28</td><td class="colsep0 rowsep0" align="char" char="±">10.90 ± 0.12</td><td class="colsep0 rowsep0" align="char" char="±">16.61 ± 0.56</td><td class="colsep0 rowsep0" align="left">45.13 ± 3.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2b</b></td><td class="colsep0 rowsep0" align="char" char="±">10.01 ± 0.37</td><td class="colsep0 rowsep0" align="char" char="±">17.73 ± 1.15</td><td class="colsep0 rowsep0" align="char" char="±">10.69 ± 0.39</td><td class="colsep0 rowsep0" align="char" char="±">17.13 ± 0.30</td><td class="colsep0 rowsep0" align="char" char="±">17.48 ± 0.62</td><td class="colsep0 rowsep0" align="left">43.46 ± 1.60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2c</b></td><td class="colsep0 rowsep0" align="char" char="±">6.40 ± 0.18</td><td class="colsep0 rowsep0" align="char" char="±">4.28 ± 0.27</td><td class="colsep0 rowsep0" align="char" char="±">5.98 ± 0.22</td><td class="colsep0 rowsep0" align="char" char="±">7.80 ± 0.21</td><td class="colsep0 rowsep0" align="char" char="±">5.91 ± 0.86</td><td class="colsep0 rowsep0" align="left">57.76 ± 3.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2d</b></td><td class="colsep0 rowsep0" align="char" char="±">11.00 ± 0.27</td><td class="colsep0 rowsep0" align="char" char="±">6.91 ± 0.18</td><td class="colsep0 rowsep0" align="char" char="±">10.10 ± 0.30</td><td class="colsep0 rowsep0" align="char" char="±">9.52 ± 0.25</td><td class="colsep0 rowsep0" align="char" char="±">22.53 ± 0.50</td><td class="colsep0 rowsep0" align="left">24.92 ± 1.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2e</b></td><td class="colsep0 rowsep0" align="char" char="±">22.09 ± 1.25</td><td class="colsep0 rowsep0" align="char" char="±">7.52 ± 1.60</td><td class="colsep0 rowsep0" align="char" char="±">9.85 ± 0.80</td><td class="colsep0 rowsep0" align="char" char="±">8.09 ± 0.13</td><td class="colsep0 rowsep0" align="char" char="±">22.73 ± 0.39</td><td class="colsep0 rowsep0" align="left">83.91 ± 1.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2f</b></td><td class="colsep0 rowsep0" align="char" char="±">13.53 ± 0.31</td><td class="colsep0 rowsep0" align="char" char="±">20.83 ± 1.20</td><td class="colsep0 rowsep0" align="char" char="±">14.23 ± 0.85</td><td class="colsep0 rowsep0" align="char" char="±">18.40 ± 0.80</td><td class="colsep0 rowsep0" align="char" char="±">20.62 ± 0.46</td><td class="colsep0 rowsep0" align="left">21.98 ± 1.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2g</b></td><td class="colsep0 rowsep0" align="char" char="±">19.18 ± 0.15</td><td class="colsep0 rowsep0" align="char" char="±">9.71 ± 0.19</td><td class="colsep0 rowsep0" align="char" char="±">13.58 ± 0.20</td><td class="colsep0 rowsep0" align="char" char="±">12.62 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">14.08 ± 0.38</td><td class="colsep0 rowsep0" align="left">30.70 ± 1.39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CX-4945</b></td><td class="colsep0 rowsep0" align="char" char="±">12.75 ± 0.21</td><td class="colsep0 rowsep0" align="char" char="±">13.21 ± 0.52</td><td class="colsep0 rowsep0" align="char" char="±">15.31 ± 0.45</td><td class="colsep0 rowsep0" align="char" char="±">16.00 ± 0.30</td><td class="colsep0 rowsep0" align="char" char="±">12.92 ± 0.25</td><td class="colsep0 rowsep0" align="left">22.98 ± 2.52</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values were given as the means ± SD of three independent experiments.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Investigation of the Representative Compound on Its CK2α Targeting</h3><div class="NLM_p">To confirm that <b>1c</b> can act directly on endogenous CK2α as well, the phosphorylation level of Akt1 serine 129 (p-Akt1<sup>S129</sup>) and Cdc37 serine 13 (p-Cdc37<sup>S13</sup>), the two specific phosphorylation targets of CK2, was also investigated by western blot in HCT-116 cells. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a,b, compound <b>1c</b> can obviously suppress the expression of p-Akt1<sup>S129</sup> and p-Cdc37<sup>S13</sup> in a dose-dependent manner, suggesting that <b>1c</b> can not only inhibit exogenous CK2α but also inhibit endogenous CK2α in HCT-116 cells.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Western blot analysis on the specific CK2 phosphorylation targets: (a) phosphorylation of the Akt1 serine 129 and (b) Cdc37 serine 13 in HCT-116 cells inoculated with varying levels of <b>1c</b> (5, 10, and 20 μM) for 24 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition, molecular docking simulations of <b>1c</b> with CK2α and Clk2 were also performed using AutoDock Vina. CK2α (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6isj">6isj</a>) and Clk2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6khe">6khe</a>) co-structures complexed with <b>CX-4945</b> were used as a template. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a, compound <b>1c</b> is bound tightly to the surface of the protein with good compatibility. The amide serving as both a hydrogen bond donor and a hydrogen bond acceptor forms two important hydrogen bonds with TRP-175 and THR-112 residues <i>via</i> its O and H atom, respectively. The N atom on the ring A of naphthyridine produces a hydrogen bond with the VAL-115 residue. Meanwhile, the hydroxyl group on the side chain of 2-aminoethanol also forms hydrogen bonding with ASP-174 and GLU-80 residues by its O and H atom, respectively. The five hydrogen bonds enable the entire <b>1c</b> skeleton to be firmly anchored deep in the CK2α active cavity. Compared with CK2α, <b>1c</b> is not inserted deep into the activity cavity of Clk2 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b). There are only three hydrogen bonds between <b>1c</b> and the amino acid residues in the active cavity of Clk2. The hydrogen atoms from the amide and the hydroxyl group generate hydrogen bonding with ASP-127 residues, respectively, while the N atom in ring A has hydrogen bonds with GLU-224 residues. The results illustrate that <b>1c</b> binds CK2α more tightly than Clk2.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Molecular docking. Docking of <b>1c</b> into (a) CK2α (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6isj">6isj</a>) and (b) Clk2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6khe">6khe</a>) kinase X-ray crystal structure. Potentially relevant residues to the docking are labeled. Interactions are illustrated by dashed lines (H bonds, yellow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Investigation on the Inhibition of ALDH1A1</h3><div class="NLM_p">It has been proven that CK2α positively modulates Notch1 transcriptional activity and the population of CD44<sup>+</sup>/CD24<sup>–</sup>, which participate in stem cell maintenance.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> With the inherent CK2 inhibitory activity, we hypothesize that <b>1c</b> may also inhibit cancer cell stemness by regulating stem-cell-related signaling pathways. As aldehyde dehydrogenase 1-A1 (ALDH1A1), one of the strongest CSC hallmarks, plays a core role in sustaining the stemness of HCT-116 cells,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> it was detected to quantify the proportion of ALDH<sup>+</sup> cells. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a (see also Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_001.pdf" class="ext-link">Figure S1</a>), the ratio of the ALDH<sup>+</sup> cell subpopulation was up to 63% in HCT-116 cells, indicating that <b>1c</b> could strongly inhibit the proportion of intracellular ALDH<sup>+</sup> cell subsets and present a concentration-dependent inhibitory manner. The inhibitory ratio of <b>1c</b> reached 96% at 20 μM and 77% even at 5 μM, significantly higher than that of <b>CX-4945</b> (61%) at the same concentration of 5 μM. This was further validated by the related western blotting analysis (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a). Moreover, the impact of <b>1c</b> on ALDH1A1 expression in HCT-116 cells was investigated. As expected, the transcriptional level of ALDH1A1 in HCT-116 cells decreased significantly after being treated with <b>1c</b> (20 μM) for 24 h, which was only half of that in the <b>CX-4945</b>-treated group (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>c). In addition, we also evaluated the inhibitory activity of <b>1c</b> against the exogenous ALDH1A1 enzyme. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>d, both <b>CX-4945</b> and <b>1c</b> can inhibit exogenous ALDH1A1 enzyme activity in a dose-dependent manner, especially <b>1c</b>, with an IC<sub>50</sub> value of 0.10 μM that is 8.8 times higher than that of <b>CX-4945</b>. To further elucidate the binding mechanism between <b>1c</b> and ALDH1A1, we performed a related molecular docking study. As shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_001.pdf" class="ext-link">Figure S2</a>, the N atom in ring A, O atom in amide, and OH group in 2-aminoethanol form hydrogen bonding with GLY-458, CYS-303, and ASN-170 residues, respectively. These hydrogen bonds hold <b>1c</b> firmly in the ALDH1A1 active cavity. These results demonstrate that <b>1c</b> can target ALDH1A1 protein and inhibit its activity, and regulate certain signaling pathways to inhibit the transcription and protein expression of ALDH1A1.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Investigation on the inhibition of <b>1c</b> on ALDH1A1. (a) A statistical analysis of the ALDH1A1 inhibitory ratio. (b) Western blotting assessment on expression of ALDH1A1 protein in HCT-116 cells treated with <b>CX-4945</b> (5 μM) and different quantities of <b>1c</b> (5, 10, and 20 μM) for 24 h, respectively. (c) mRNA transcription levels of ALDH1A1 after exposure to <b>CX-4945</b> and <b>1c</b> at 20 μM, respectively, in the HCT-116 cells for 24 h. (d) Inhibition rate of <b>1c</b> and <b>CX-4945</b> at different concentrations on the enzyme activity of ALDH1A1. Data were subjected to statistical analysis by using Student’s <i>t</i> test and given as the mean ± SD (<i>n</i> = 3). *<i>P</i> < 0.05 and **<i>P</i> < 0.01 vs <b>CX-4945</b> group or the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Investigation on the Inhibition of Cancer Cell Stemness</h3><div class="NLM_p">Based on the inhibitory effect of <b>1c</b> on ALDH1A1, we further explored the influence of <b>1c</b> on the stemness driven by ALDH in HCT-116 cells. ALDH<sup>+</sup> population cells in HCT-116 cells were sorted by flow cytometer and named HCT-116<sup>ALDH+</sup> cells. It is known that CSC surface antigens’ expression is cancer type-distinct or cancer subtype-distinct. Since they play a vital role in invasiveness and promoting cancer recurrence, it is pivotal to comprehend how CSCs are modulated and maintained at the molecular level.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> To examine the influence of <b>1c</b> on the cancer cell stemness, the expression of CD44<sup>+</sup> and CD133<sup>+</sup> in HCT-116<sup>ALDH+</sup> cells treated with <b>1c</b> was determined by flow cytometry using <b>CX-4945</b> and napabucasin (<b>BBI608</b>) as the positive controls. <b>BBI608</b>, currently in Phase II/III clinical trials, is a known STAT3 inhibitor that can potently block spherogenesis, kill stem cancer cells isolated from numerous kinds of cancer, and repress stemness gene expression.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>a and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_001.pdf" class="ext-link">Figure S3</a>, compound <b>1c</b> shows a potent inhibitory effect on CD44<sup>+</sup>/CD133<sup>+</sup>, with an inhibitory rate of about 84%, second only to <b>BBI608</b> (89%), which is 1.45 times higher than that of <b>CX-4945</b> (58%). SOX2, OCT4, and Nanog, essential transcription factors to maintain the characteristics of stem cells, are currently recognized as the signature genes of CSCs, which have an important role in maintaining self-renewal along with proliferation in malignant tumors.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The influence of <b>1c</b> on the transcription levels of the signature genes of CSCs in HCT-116<sup>ALDH+</sup> cells was quantitatively analyzed. As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>b, noticeable differences in mRNA expression were observed for the transcription factor. <b>CX-4945</b> had the weakest inhibitory activity, whose transcription levels of OCT4, SOX2, and Nanog were 2.27, 2.34, and 1.57 times as many as those of <b>1c</b>, respectively. It is noteworthy that the level of SOX2 transcription in HCT-116<sup>ALDH+</sup> cells treated with <b>BBI608</b> was 1.75 times higher than the <b>1c</b> group despite the transcription levels of OCT4 and Nanog being slightly lower than the <b>1c</b> group. It has been documented that the high expression level of SOX2 enhances the tumorigenic potential by regulating the expressions of genes that participate in proliferation, apoptosis, and cell cycle modulation.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> In addition, SOX2 overexpressed in human colon CSCs promotes chemotherapy resistance and tumor growth. The capability of tumorsphere formation was also tested. As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>c,d, obvious phenotypic alterations were observed in HCT-116<sup>ALDH+</sup>-derived tumorspheres in all the groups. HCT-116<sup>ALDH+</sup> cells treated with <b>1c</b> exhibited fewer sphere number and smaller size than those treated with either <b>CX-4945</b> or <b>BBI608</b>. This also proved that <b>1c</b> has a stronger inhibitory effect on the cancer cell stemness than <b>BBI608</b>.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Investigation on the inhibition of cancer cell stemness. (a) A statistical analysis of the CD44<sup>+</sup>/CD133<sup>+</sup> inhibitory ratio. (b) qRT-PCR of mRNA transcription levels of stemness genes after exposure to <b>BBI608</b>, <b>CX-4945</b>, and <b>1c</b>, respectively, at 20 μM in the HCT-116<sup>ALDH+</sup> cells for 24 h. (c) The number and (d) the morphological observation of the HCT-116<sup>AHDH+</sup> cell tumorspheres treated with vehicle (DMSO), <b>BBI608</b> (5 μM), <b>CX-4945</b> (5 μM), and <b>1c</b> (5 μM) for 24 h and then cultivated for 10 days. Comparison of gene expression level was performed using the 2<sup>–ΔΔCt</sup> approach. Data were subjected to statistical analysis by using Student’s <i>t</i> test and given as the mean ± SD (<i>n</i> = 3). *<i>P</i> < 0.05 and **<i>P</i> < 0.01 vs <b>BBI608</b> group or the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Investigation on the Signaling Pathway of Wnt/β-Catenin</h3><div class="NLM_p">The Wnt/β-catenin signaling pathway plays a core role in tumor invasion, especially in tumor metastasis and differentiation.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> β-Catenin binds to the TCF/LEF transcription factor family in the nucleus to activate the promoter of β-catenin target genes, thus activating the target genes of the Wnt signaling pathway like CD44, CD24, CD133, ABCG2, ALDH1A1, EpCAM, MMP7, Vimentin, and Slug. It has been confirmed that Wnt1 can enhance ALDH1A1 expression, hence enhancing the expression of Akt as well as β-catenin.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Phosphorylated Akt inactivates GSK-3β through phosphorylating GSK-3β at ser9, repressing its capacity to degrade β-catenin.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> Therefore, it is suggested that <b>1c</b> might regulate the expression of ALDH1A1 through the Akt-GSK-3β(ser9)-Wnt/β-catenin signaling pathway, thereby affecting tumor invasion and metastasis. As illustrated in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>a, compound <b>1c</b> significantly inhibited GSK-3β(ser9) protein phosphorylation in HCT-116 cells dose-dependently. In addition, the mRNA levels of Wnt target genes consisting of c-Myc, cyclin D1, MMP7, and S100A4 were remarkably reduced upon treatment of <b>1c</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>b). Meanwhile, the protein level of DKK1 was upregulated with the increasing concentrations of <b>1c</b>, while that of β-catenin was significantly downregulated (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>c). In addition, <b>1c</b> also exhibited a superior capacity to repress the invasion of HCT-116 cells (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>d). The above results indicated that <b>1c</b> decreased the activity of CK2 by specifically targeting CK2 and then reduced ALDH1A1 expression and inhibited the invasion of cancer cells by suppressing the Akt1(ser129)-GSK-3β(ser9)-Wnt/β-catenin signaling pathway.</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>1c</b> regulated the GSK-3β(ser9)-Wnt/β-catenin signaling pathway. Western blotting images of (a) p-GSK-3β(ser9), GSK-3β, (c) DKK1, and β-catenin proteins induced by different concentrations of <b>1c</b> for 24 h in HCT-116 cells. (b) Decreased mRNA levels of Wnt target genes in HCT-116 cells upon exposure to <b>1c</b> (20 μM) for 24 h. (d) Transwell invasion assays. The HCT-116 cells were inoculated with <b>1c</b> and <b>CX-4945</b>, respectively, at 5 μM for 24 h. Data were subjected to statistical analysis by using Student’s <i>t</i> test and given as the mean ± SD (<i>n</i> = 3). *<i>P</i> < 0.05 and **<i>P</i> < 0.01 vs the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Investigation on the Cell Apoptosis and Cell Cycle Arrest</h3><div class="NLM_p">Cell apoptosis was measured <i>via</i> flow cytometric assays. HCT-116 cells after being treated with <b>CX-4945</b> (5 μM) and varying levels of <b>1c</b> (5, 10, and 20 μM) for 24 h were analyzed. As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>a,b, at the same concentration (5 μM), the ratio of apoptosis triggered by <b>1c</b> was much higher in contrast with that of <b>CX-4945</b>. With the increasing concentration, the proportion of apoptosis induced by <b>1c</b> also increased gradually. At the concentration of 20 μM, the apoptotic ratio reached about 55%, exhibiting a dose-dependent behavior. The effect of <b>1c</b> on HCT-116 cell cycle progression was examined <i>via</i> flow cytometry, with <b>CX-4945</b> serving as the positive control. Due to the analogous structure, both <b>CX-4945</b> and <b>1c</b> arrested the cell cycle at the G0–G1 phase in HCT-116 cells as illustrated in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>c,d</a>.</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Cell apoptosis and cell cycle arrest analysis. (a) Cell apoptosis in HCT-116 cells treated with <b>CX-4945</b> (5 μM) and varying levels of <b>1c</b> (5, 10, and 20 μM) was assessed using flow cytometry (stained with Annexin V-FITC and PI). (b) A statistical analysis of apoptotic ratio. (c) Cell cycle arrest in HCT-116 cells inoculated with <b>CX-4945</b> (20 μM) and <b>1c</b> (20 μM), respectively, for 24 h; stained with PI; and explored with flow cytometry. (d) A statistical analysis of cell cycle arrest. The results were given as the mean ± SD (<i>n</i> = 3). **<i>P</i> < 0.01 vs the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Investigation on the Mechanism of Apoptotic Pathway</h3><div class="NLM_p">The mitochondrial linked apoptotic proteins including cytochrome c (Cyt c), Bax, Bcl-2, pro-caspase 9, cleaved caspase 9, pro-caspase 3, cleaved caspase 3, total PARP, and cleaved PARP were assessed in HCT-116 cells after inoculation with <b>1c</b> by western blotting, using <b>CX-4945</b> as the positive control. The results are indicated in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>a,b. In contrast with the control, <b>1c</b> induced an obvious decrease in the level of Bcl-2 and increased the Bax expression to a higher degree than <b>CX-4945</b>. Moreover, treatment of <b>1c</b> in HCT-116 cells released more Cyt c than that of <b>CX-4945</b>, resulting in the activation of the downstream caspase cascade. The activations of downstream caspases and PARP were observed, which were able to trigger the apoptosis of cancer cells. As expected, exposure of HCT-116 cells to <b>1c</b> caused more starkly downregulation in the levels of pro-caspase 9, pro-caspase 3, and total PARP and upregulation in the levels of cleaved caspase 9, cleaved caspase 3, and cleaved PARP relative to <b>CX-4945</b>. These results indicate that <b>1c</b> can induce HCT-116 cell apoptosis through a mitochondrial-mediated signaling pathway and caspase cascade.</div><figure id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Study on the mechanism of apoptotic pathway. (a) Western blotting assessment of Cyt c, Bcl-2, Bax, pro-caspase 9, cleaved caspase 9, pro-caspase 3, cleaved caspase 3, total PARP, cleaved PARP as well as β-actin after 24 h treatment of HCT-116 cells with <b>CX-4945</b> (20 μM) and <b>1c</b> (20 μM), respectively. (b) Expression levels of (a) acquired from western blotting and standardized with β-actin. The results are given as the mean ± SD (<i>n</i> = 3). **<i>P</i> < 0.01 and *<i>P</i> < 0.05 vs the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Pharmacokinetic Study</h3><div class="NLM_p">The pharmacokinetic profiles of <b>1c</b> and <b>CX-4945</b> were evaluated in Sprague–Dawley (SD) rats following a single 25 mg/kg dose administration by the oral route. To be consistent with previous reports,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a><b>CX-4945</b> was transformed into its sodium salt (<b>CX-4945·Na</b>). As summarized in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, the PK profile of <b>1c</b> is similar to that of <b>CX-4945·Na</b> with a slight improvement. The maximal drug concentration (<i>C</i><sub>max</sub>) reached 7017.8 ng/mL in plasma, elimination half-life (<i>t</i><sub>1/2</sub>) was approximately 6.67 h, and the plasma exposure AUC<sub>0–<i>t</i></sub> and AUC<sub>0–∞</sub> were above 4000 ng·h/mL, which were a little better than those of <b>CX-4945·Na</b> except for the clearance. These results reveal that <b>1c</b> presents a favorable pharmacokinetic behavior.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Pharmacokinetic Parameters of Compound <b>1c</b> in SD Rats<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center"><b>CX-4945·Na</b></th><th class="colsep0 rowsep0" align="center"><b>1c</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">2.00 ± 0.00</td><td class="colsep0 rowsep0" align="left">2.33 ± 0.58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng·mL<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">6786.32 ± 223.88</td><td class="colsep0 rowsep0" align="left">7017.81 ± 297.85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">5.82 ± 0.27</td><td class="colsep0 rowsep0" align="left">6.67 ± 1.59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (L·h<sup>–1</sup>·kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">0.63 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.60 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–<i>t</i></sub> (ng·h·mL<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">38,919.58 ± 90.48</td><td class="colsep0 rowsep0" align="left">40,460.61 ± 2353.48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–∞</sub> (ng·h·mL<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">39,994.05 ± 74.29</td><td class="colsep0 rowsep0" align="left">41,450.07 ± 2378.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>d</sub> (L·kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">2.39 ± 0.50</td><td class="colsep0 rowsep0" align="left">2.77 ± 0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT<sub>0–<i>t</i></sub> (h)</td><td class="colsep0 rowsep0" align="left">6.45 ± 0.55</td><td class="colsep0 rowsep0" align="left">6.21 ± 0.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT<sub>0–∞</sub> (h)</td><td class="colsep0 rowsep0" align="left">6.52 ± 0.61</td><td class="colsep0 rowsep0" align="left">6.26 ± 0.29</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last"><i>T</i><sub>max</sub>, time for peak concentration; <i>C</i><sub>max</sub>, peak value; <i>t</i><sub>1/2</sub>, elimination half-life period; CL, plasma clearance; AUC, area under the time concentration curve; <i>V</i><sub>d</sub>, apparent volume of distribution; and MRT, mean residue time.</p></div></div></div></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>In Vivo</i> Antitumor Activity</h3><div class="NLM_p">The antitumor activity of <b>1c</b> in HCT-116 xenograft models was tested, in which animals were grouped randomly into four groups as vehicle, <b>CX-4945·Na</b> (60 mg/kg), and <b>1c</b> at two doses (60 and 90 mg/kg) and administrated po twice a day for 4 weeks. The volume of tumors and body weight were assessed every 3 days. As illustrated in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>a–c, the inhibitory rate (59%) of <b>1c</b> at the low dose is 3.9 times higher than that (15%) of <b>CX-4945·Na</b>. In addition, it is noticed that <b>1c</b> obviously inhibits the tumor growth dose-dependently with a maximum inhibitory rate of 69% at a dose of 90 mg/kg. There is no conspicuous change in body weight of all the mice treated with <b>1c</b>. Furthermore, the HE staining of slices from the heart, liver, spleen, lung, and kidney of an animal randomly selected from each tested group in HCT-116 models demonstrates that <b>1c</b> at the used dosages has hardly toxic effects on organ tissues (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_001.pdf" class="ext-link">Figure S4</a>), revealing that <b>1c</b> has low systemic toxicity and good safety (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>d). These results indicate that <b>1c</b> exhibits potent antitumor activity with low toxicity in the HCT-116 xenograft mice model.</div><figure id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. <i>In vivo</i> HCT-116 xenograft model study of <b>1c</b>. Twenty nude mice inoculated with HCT-116 cells in the right armpit were divided into four groups as vehicle (equivalent volume of CMC-Na), <b>CX-4945·Na</b> (60 mg/kg), and <b>1c</b> (60 and 90 mg/kg). Animals were orally administrated twice a day for 4 weeks. (a) Excised tumor images from each group. (b) The relative volume of the tumors. (c) The relative tumor weight resected from all groups of sacrificed mice on the last day. (d) The body weights of each group mice in the period of 28 days. Data are given as the mean ± SD. *<i>P</i> < 0.05 and **<i>P</i> < 0.01 vs the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38676" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38676" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Herein, a series of 5-(3-chlorophenylamino)benzo[<i>c</i>][2,6]naphthyridine derivatives were synthesized with <b>CX-4945</b> as the lead compound. <b>1c</b> stands out for its excellent selectivity and inhibitory activity on CK2. Biological studies indicated that <b>1c</b> exhibited stronger CK2 inhibitory activity with much higher ClK2/CK2 selectivity than <b>CX-4945</b>, which greatly reduces the off-target toxicity of <b>CX-4945</b>. In addition, <b>1c</b> also exhibited a potent inhibitory effect on cancer cell stemness. Further research on the mechanism of action reveals that <b>1c</b> can inhibit the Akt1(ser129)-GSK-3β(ser9)-Wnt/β-catenin signaling pathway and inhibit the expression of the stemness markers ALDH1A1, CSCs surface antigens (CD44<sup>+</sup> and CD133<sup>+</sup>), and stem genes (SOX2, OCT4, and Nanog), thereby inhibiting the CSCs. Furthermore, <b>1c</b> displayed superior pharmacokinetics and antitumor activity compared with <b>CX-4945·Na</b> without obvious toxicity. The development of novel antitumor drugs and therapeutic strategies targeting the CK2 and CSCs in tumors is a still unmet need, but it may represent a definite advantage in cancer treatment. The identification of <b>1c</b> is a step forward in this direction. The favorable antiproliferative and antitumor activities of <b>1c</b> make it possible for <b>1c</b> to act as a multifunctional drug candidate to suppress CK2 protein and CSCs for the treatment of cancer.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81628" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81628" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Materials and Instruments</h3><div class="NLM_p last">All chemical reagents along with the solvents were commercially acquired from Energy Chemical, Acros, Alfa, Maybridge, or Adamas-beta and utilized without further purification. Flash column chromatography employed a silica gel (100–200 mesh). NMR spectra were obtained in DMSO-<i>d</i><sub>6</sub>, unless otherwise stated, on Bruker 600 (<sup>1</sup>H at 600 MHz, <sup>13</sup>C at 150 MHz) NMR spectrometers, and tetramethylsilane (TMS) was employed as reference. An Agilent 6224 ESI/TOF MS instrument was employed to measure the mass spectra. Purities of the tested compounds, determined by RP-HPLC analysis using a Waters e2965 HPLC with ODS column (5 μm, 250 × 4.6 mm column and methanol/water), were ≥ 95%. All cell lines utilized herein were purchased from Biorn Lifescience Co., Ltd. (Nanjiang, Jiangsu, China). p-Akt1<sup>S</sup><sup>129</sup>, Akt, p-Cdc37<sup>S13</sup>, Cdc37, p-GSK-3β(ser9), GSK-3β, DKK1, β-catenin, Cyt c, Bax, Bcl-2, pro-caspase 9, cleaved caspase 9, pro-caspase 3, cleaved caspase 3, total PARP, cleaved PARP, and β-actin antibodies were supplied by Beyotime Biotechnology. The HRP-conjugated secondary antibody (1: 2000) was provided by Santa Cruz Biotechnologies.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Synthesis and Characterization of the Compounds</h3><div class="NLM_p">Compound <b>BTE</b> and <b>CX-4945</b> were synthesized following the previously documented procedures<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and verified by <sup>1</sup>H NMR. Compound <b>BTE</b>: <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.09 (s, 1H), 9.91 (s, 1H), 8.94 (d, <i>J</i> = 5.6 Hz, 1H), 8.79 (d, <i>J</i> = 8.5 Hz, 1H), 8.77 (d, <i>J</i> = 5.6 Hz, 1H), 8.34 (t, <i>J</i> = 1.9 Hz, 1H), 8.17 (dd, <i>J</i> = 6.3, 1.4 Hz, 2H), 7.90 (dd, <i>J</i> = 8.4, 1.7 Hz, 1H), 7.42 (t, <i>J</i> = 8.1 Hz, 1H), 7.12 (dd, <i>J</i> = 7.9, 1.4 Hz, 1H), 3.92 (s, 3H) ppm; <b>CX-4945</b>: <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ12.04 (s, 1H), 10.30 (s, 1H), 10.16(s, 1H), 9.08 (d, <i>J</i> = 5.8 Hz, 1H), 9.00–8.97 (m, 1H), 8.94 (d, <i>J</i> = 8.5 Hz, 1H), 8.31–8.28 (m, 2H), 8.12 (d, <i>J</i> = 8.2 Hz, 1H), 8.03 (dd, <i>J</i> = 8.4, 1.5 Hz, 1H), 7.45 (t, <i>J</i> = 8.1 Hz, 1H), 7.17 (d, <i>J</i> = 7.9 Hz, 1H) ppm.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Synthesis of <b>1a</b></h4><div class="NLM_p last">KOH (1.12 g, 20 mmol) and NH<sub>2</sub>OH·HCl (0.695 g, 10 mmol) were dissolved in 5 and 8 mL MeOH, respectively, to get solutions A and B. Then, solution A was added dropwise to solution B at 0 °C. The temperature of the reaction system was slowly raised to room temperature, and the reaction was continued for 30 min.  At the end of the reaction, the precipitated solid was removed by suction filtration to obtain an alkaline hydroxylamine solution. <b>BTE</b> (0.36 g, 1 mmol) was dissolved in alkaline hydroxylamine solution (5 mL), stirred 1 h at room temperature, and monitored by TLC. After the substrate was completely consumed, the solvent was removed under vacuum, and the residue was acidified with 2 M HCl to pH = 5–6, filtering the precipitate; washed with H<sub>2</sub>O (3 × 15 mL); and dried to obtain the crude product of <b>1b</b>. The precipitate was recrystallized with MeOH (10 mL) to get a bright yellow solid (0.332 g). Yield: 91.2%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.52 (s, 1H), 10.16 (s, 1H), 9.65 (s, 1H), 9.19 (s, 1H), 8.97 (d, <i>J</i> = 5.4 Hz, 1H), 8.83 (d, <i>J</i> = 8.4 Hz, 1H), 8.57 (d, <i>J</i> = 5.2 Hz, 1H), 8.33 (s, 1H), 8.15 (d, <i>J</i> = 1.2 Hz, 1H), 8.07 (d, <i>J</i> = 8.0 Hz, 1H), 7.85 (d, <i>J</i> = 1.2 Hz, 1H), 7.43 (t, <i>J</i> = 8.0 Hz, 1H), 7.13 (dd, <i>J</i> = 7.8, 1.2 Hz, 1H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.19, 150.52, 148.13, 147.73, 143.74, 142.35, 134.16, 133.27, 130.53, 127.49, 126.08, 124.19, 122.95, 122.90, 122.64, 121.54, 120.60, 119.60, 116.81 ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>19</sub>H<sub>13</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 365.0805; found: 365.0800.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> General Procedure for Preparation of Compounds <b>1b</b>–<b>1o</b></h4><div id="sec4_2_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> 5-((3-Chlorophenyl)amino)-<i>N</i>-(methylsulfonyl)benzo[<i>c</i>][2,6]naphthyridine-8-carboxamide (<b>1b</b>)</h5><div class="NLM_p last">To a solution of <b>CX-4945</b> (0.210 g, 0.6 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (DMF) (5 mL) was added 2-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate (HATU) (0.273 g, 0.72 mmol) and stirred at room temperature for 10 min. Then, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA) (0.197 mL, 1.2 mmol) was added to the solution and stirred for 10 min at the same temperature, followed by addition of methanesulfonamide (0.048 g, 0.5 mmol), and the solution was stirred overnight in a nitrogen atmosphere. The progress of the reaction was monitored with TLC. After the substrate was completely consumed, the solvent was removed under vacuum, and the residue was treated with EtOAc (50 mL). The organic layers were washed with saturated salt water (3 × 20 mL) and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The organic layers were concentrated under vacuum to obtain the crude product and further purified with silica gel chromatography with the eluent of MeOH and DCM (1:100–1:50) to give a yellow solid <b>1b</b> (0.093 g). Yield: 43.5%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.26 (s, 1H), 10.19 (s, 1H), 9.69 (s, 1H), 9.01 (d, <i>J</i> = 5.5 Hz, 1H), 8.87 (d, <i>J</i> = 8.4 Hz, 1H), 8.60 (d, <i>J</i> = 5.6 Hz, 1H), 8.33 (s, 1H), 8.28 (s, 1H), 8.10 (d, <i>J</i> = 8.2 Hz, 1H), 7.99 (d, <i>J</i> = 8.1 Hz, 1H), 7.45 (t, <i>J</i> = 8.1 Hz, 1H), 7.16–7.13 (d, <i>J</i> = 7.8 Hz, 1H), 2.51 (s, 3H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 150.71, 150.60, 148.30, 148.09, 143.76, 142.33, 133.24, 130.62, 128.72, 127.42, 124.70, 124.47, 123.13, 123.08, 122.80, 122.67, 120.57, 119.61, 116.86, 63.26 ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>20</sub>H<sub>15</sub>ClN<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup>: 427.0631; found: 427.0643.</div></div><div id="sec4_2_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> 5-((3-Chlorophenyl)amino)-<i>N</i>-(2-hydroxyethyl)benzo[<i>c</i>][2,6]naphthyridine-8-carboxamide (<b>1c</b>)</h5><div class="NLM_p last">Yellow solid. Yield: 72.1%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.18 (s, 1H), 9.89 (s, 1H), 8.97 (d, <i>J</i> = 5.4 Hz, 1H), 8.84 (t, <i>J</i> = 6.0 Hz, 2H), 8.77 (d, <i>J</i> = 5.4 Hz, 1H), 8.35 (s, 1H), 8.27 (s, 1H), 8.21 (d, <i>J</i> = 8.2 Hz, 1H), 8.00 (d, <i>J</i> = 8.2 Hz, 1H), 7.45 (t, <i>J</i> = 8.0 Hz, 1H), 7.14 (d, <i>J</i> = 7.6 Hz, 1H), 4.91 (t, <i>J</i> = 5.6 Hz, 1H), 3.61 (q, <i>J</i> = 5.8 Hz, 2H), 3.43 (dd, <i>J</i> = 11.2, 5.4 Hz, 2H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.40, 150.61, 148.05, 147.64, 143.77, 142.51, 135.92, 133.19, 130.46, 127.52, 126.40, 124.25, 123.38, 122.71, 122.56, 121.46, 120.70, 119.73, 117.16, 60.20, 42.88 ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>21</sub>H<sub>17</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 393.1118; found: 393.1120.</div></div><div id="sec4_2_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> <i>N</i>-(2-Aminoethyl)-5-((3-chlorophenyl)amino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxamide (<b>1d</b>)</h5><div class="NLM_p last">Yellow solid. Yield: 81.6%. Compound <b>1d</b> may also be prepared by the method reported in the literature.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.12 (s, 1H), 9.60 (s, 1H), 8.95 (d, <i>J</i> = 5.4 Hz, 1H), 8.81–8.79 (m, 1H), 8.54 (s, 1H), 8.53 (d, <i>J</i> = 5.6 Hz, 1H), 8.24 (t, <i>J</i> = 1.8 Hz, 1H), 8.20 (d, <i>J</i> = 1.4 Hz, 1H), 8.09 (d, <i>J</i> = 8.2 Hz, 1H), 7.93 (dd, <i>J</i> = 8.2, 1.4 Hz, 1H), 7.42 (t, <i>J</i> = 8.2 Hz, 1H), 7.11 (d, <i>J</i> = 7.8 Hz, 1H), 3.45 (dd, <i>J</i> = 12.6, 6.4 Hz, 2H), 3.35 (m, 2H), 1.94–1.88 (m, 2H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.29, 150.46, 148.07, 147.66, 143.75, 142.37, 135.96, 133.26, 130.52, 127.48, 126.25, 124.13, 123.30, 122.74, 122.62, 121.45, 120.65, 119.65, 116.78, 37.98, 29.60 ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>21</sub>H<sub>18</sub>ClN<sub>5</sub>O [M + H]<sup>+</sup>: 393.1278; found: 393.1280.</div></div><div id="sec4_2_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> <i>N</i>-(2-Bromoethyl)-5-((3-chlorophenyl)amino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxamide (<b>1e</b>)</h5><div class="NLM_p last">Yellow solid. Yield: 61.4%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.20 (s, 1H), 9.67 (s, 1H), 9.12 (t, <i>J</i> = 5.0 Hz, 1H), 9.00 (d, <i>J</i> = 5.4 Hz, 1H), 8.82 (d, <i>J</i> = 3.8 Hz, 1H), 8.59 (d, <i>J</i> = 5.4 Hz, 1H), 8.29 (s, 1H), 8.28 (s, 1H), 8.13 (d, <i>J</i> = 8.0 Hz, 1H), 7.97 (d, <i>J</i> = 8.2 Hz, 1H), 7.45 (t, <i>J</i> = 8.0 Hz, 1H), 7.15 (d, <i>J</i> = 7.6 Hz, 1H), 4.85 (t, <i>J</i> = 5.2 Hz, 2H), 3.88–3.84 (m, 2H) ppm.<sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.69, 152.29, 150.61, 148.16, 147.77, 143.79, 142.37, 135.05, 133.28, 130.55, 127.50, 126.41, 124.25, 123.36, 122.87, 122.71, 120.76, 119.76, 116.84, 79.74, 38.61 ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>21</sub>H<sub>16</sub>BrClN<sub>4</sub>O [M + H]<sup>+</sup>: 455.0274; found: 455.0272.</div></div><div id="sec4_2_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 5-((3-Chlorophenyl)amino)-<i>N</i>-(2,2-difluoroethyl)benzo[<i>c</i>][2,6]naphthyridine-8-carboxamide (<b>1f</b>)</h5><div class="NLM_p last">Yellow solid. Yield: 61.8%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.18 (s, 1H), 9.99 (s, 1H), 9.28 (s, 1H), 8.96 (d, <i>J</i> = 4.6 Hz, 1H), 8.86 (d, <i>J</i> = 8.2 Hz, 1H), 8.83 (d, <i>J</i> = 4.6 Hz, 1H), 8.37 (s, 1H), 8.29 (s, 1H), 8.22 (d, <i>J</i> = 7.4 Hz, 1H), 8.01 (d, <i>J</i> = 7.8 Hz, 1H), 7.44 (t, <i>J</i> = 7.8 Hz, 1H), 7.14 (d, <i>J</i> = 7.2 Hz, 1H), 6.23 (t, <i>J</i> = 13.2 Hz, 1H), 3.77 (t, <i>J</i> = 14.8 Hz, 2H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.98, 150.76, 148.05, 147.77, 143.80, 142.50, 134.89, 133.17, 130.42, 127.44, 126.57, 124.37, 123.31, 122.90, 122.59, 121.87, 120.80, 119.82, 117.29, 115.09 (t, <i>J</i> = 240.2 Hz), 42.25 (t, <i>J</i> = 26.6 Hz) ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>21</sub>H<sub>15</sub>ClF<sub>2</sub>N<sub>4</sub>O [M + H]<sup>+</sup>: 413.0980; found: 413.0967.</div></div><div id="sec4_2_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> 5-((3-Chlorophenyl)amino)-<i>N</i>-(2-(dimethylamino)ethyl)benzo[<i>c</i>][2,6]naphthyridine-8-carboxamide (<b>1g</b>)</h5><div class="NLM_p last">Yellow solid. Yield: 69.8%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.18 (s, 1H), 9.67 (s, 1H), 8.98 (d, <i>J</i> = 5.6 Hz, 1H), 8.84 (d, <i>J</i> = 8.4 Hz, 1H), 8.72 (t, <i>J</i> = 5.4 Hz, 1H), 8.59 (d, <i>J</i> = 5.6 Hz, 1H), 8.28 (t, <i>J</i> = 1.8 Hz, 1H), 8.23 (d, <i>J</i> = 1.4 Hz, 1H), 8.11 (dd, <i>J</i> = 8.4, 1.0 Hz, 1H), 7.94 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 7.45 (t, <i>J</i> = 8.2 Hz, 1H), 7.15 (dd, <i>J</i> = 7.8, 1.4 Hz, 1H), 3.45 (dd, <i>J</i> = 12.8, 6.6 Hz, 2H), 2.53–2.51 (m, 2H), 2.25 (s, 6H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.19, 150.54, 148.13, 147.70, 143.77, 142.39, 135.94, 133.27, 130.54, 127.53, 126.29, 124.20, 123.35, 122.76, 122.66, 121.50, 120.71, 119.70, 116.83, 58.59, 45.64, 37.92 ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>23</sub>H<sub>22</sub>ClN<sub>5</sub>O [M + H]<sup>+</sup>: 420.1591; found: 420.1595.</div></div><div id="sec4_2_2_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 5-((3-Chlorophenyl)amino)-<i>N</i>-(prop-2-yn-1-yl)benzo[<i>c</i>][2,6]naphthyridine-8-carboxamide (<b>1h</b>)</h5><div class="NLM_p last">Yellow solid. Yield: 76.4%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.17 (s, 1H), 9.96 (s, 1H), 9.36 (t, <i>J</i> = 5.2 Hz, 1H), 8.96 (d, <i>J</i> = 5.4 Hz, 1H), 8.85 (d, <i>J</i> = 8.4 Hz, 1H), 8.82 (d, <i>J</i> = 5.5 Hz, 1H), 8.40 (s, 1H), 8.28 (s, 1H), 8.23 (d, <i>J</i> = 8.2 Hz, 1H), 8.00 (d, <i>J</i> = 8.3 Hz, 1H), 7.45 (t, <i>J</i> = 8.1 Hz, 1H), 7.15 (d, <i>J</i> = 7.8 Hz, 1H), 4.18 (d, <i>J</i> = 3.2 Hz, 2H), 3.21 (s, 1H) ppm. <sup>13</sup>C NMR (1500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.06, 150.67, 147.69, 143.78, 142.50, 135.11, 133.17, 130.40, 128.23, 127.42, 126.52, 124.31, 123.26, 122.83, 122.54, 121.73, 120.71, 119.74, 117.23, 81.83, 73.37, 29.12 ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>22</sub>H<sub>15</sub>ClN<sub>4</sub>O [M + H]<sup>+</sup>: 387.1012; found: 387.1011.</div></div><div id="sec4_2_2_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> Methyl 3-(5-((3-Chlorophenyl)amino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxamido)propanoate (<b>1i</b>)</h5><div class="NLM_p last">Yellow solid. Yield: 65.4%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.18 (s, 1H), 9.66 (s, 1H), 8.99 (d, <i>J</i> = 5.6 Hz, 1H), 8.88 (t, <i>J</i> = 5.4 Hz, 1H), 8.85 (d, <i>J</i> = 8.4 Hz, 1H), 8.58 (d, <i>J</i> = 5.6 Hz, 1H), 8.28 (t, <i>J</i> = 1.8 Hz, 1H), 8.22 (d, <i>J</i> = 1.4 Hz, 1H), 8.10 (dd, <i>J</i> = 8.2, 1.2 Hz, 1H), 7.93 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 7.45 (t, <i>J</i> = 8.2 Hz, 1H), 7.15 (dd, <i>J</i> = 7.8, 1.2 Hz, 1H), 3.65 (s, 3H), 3.58 (dd, <i>J</i> = 12.6, 6.8 Hz, 2H), 2.68 (t, <i>J</i> = 7.0 Hz, 2H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.28, 166.39, 150.55, 148.15, 147.73, 143.76, 142.37, 135.72, 133.27, 130.55, 127.51, 126.31, 124.21, 123.33, 122.81, 122.68, 121.58, 120.71, 119.71, 116.82, 51.89, 36.13, 34.02 ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>23</sub>H<sub>19</sub>ClN<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 435.1224; found: 435.1220.</div></div><div id="sec4_2_2_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 5-((3-Chlorophenyl)amino)-<i>N</i>-(2-(pyrrolidin-1-yl)ethyl)benzo[<i>c</i>][2,6]naphthyridine-8-carboxamide (<b>1j</b>)</h5><div class="NLM_p last">Yellow solid. Yield: 72.8%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.19 (s, 1H), 9.69 (s, 1H), 9.00 (d, <i>J</i> = 5.6 Hz, 1H), 8.97 (d, <i>J</i> = 5.2 Hz, 1H), 8.88 (d, <i>J</i> = 8.4 Hz, 1H), 8.58 (d, <i>J</i> = 5.6 Hz, 1H), 8.26 (d, <i>J</i> = 4.2 Hz, 2H), 8.05 (d, <i>J</i> = 8.0 Hz, 1H), 7.96 (d, <i>J</i> = 8.2 Hz, 1H), 7.44 (t, <i>J</i> = 8.2 Hz, 1H), 7.16 (d, <i>J</i> = 7.8 Hz, 1H), 3.66 (dd, <i>J</i> = 10.8, 4.8 Hz, 2H), 3.37 (m, 6H), 1.96 (m, 4H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.99, 150.73, 148.20, 147.90, 143.79, 142.32, 135.29, 133.29, 130.59, 127.49, 126.43, 124.32, 123.43, 122.92, 122.83, 121.85, 120.90, 119.89, 116.88, 54.06, 53.91, 36.50, 23.00 ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>24</sub>ClN<sub>5</sub>O [M + H]<sup>+</sup>: 446.1747; found: 446.1750.</div></div><div id="sec4_2_2_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 5-((3-Chlorophenyl)amino)-<i>N</i>-(2-(piperidin-1-yl)ethyl)benzo[<i>c</i>][2,6]naphthyridine-8-carboxamide (<b>1k</b>)</h5><div class="NLM_p last">Yellow solid. Yield: 77.1%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.19 (s, 1H), 9.69 (s, 1H), 9.00 (d, <i>J</i> = 5.4 Hz, 2H), 8.88 (d, <i>J</i> = 8.4 Hz, 1H), 8.59 (d, <i>J</i> = 5.6 Hz, 1H), 8.27 (s, 1H), 8.25 (d, <i>J</i> = 0.8 Hz, 1H), 8.05 (d, <i>J</i> = 8.2 Hz, 1H), 7.96 (dd, <i>J</i> = 8.4, 1.0 Hz, 1H), 7.45 (t, <i>J</i> = 8.2 Hz, 1H), 7.16 (dd, <i>J</i> = 7.8, 1.2 Hz, 1H), 3.70 (dd, <i>J</i> = 11.8, 5.8 Hz, 2H), 3.59 (t, <i>J</i> = 5.8 Hz, 2H), 3.30 (t, <i>J</i> = 6.2 Hz, 2H), 2.97 (t, <i>J</i> = 6.4 Hz, 2H), 1.91–1.61 (m, 6H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.00, 151.59, 148.20, 147.90, 143.79, 142.31, 135.24, 133.28, 130.59, 129.32, 126.43, 124.32, 123.39, 122.96, 122.83, 121.19, 120.89, 119.88, 116.88, 55.62, 52.81, 34.77, 22.99, 21.68 ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>26</sub>ClN<sub>5</sub>O [M + H]<sup>+</sup>: 460.1904; found: 460.1900.</div></div><div id="sec4_2_2_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 5-((3-Chlorophenyl)amino)-<i>N</i>-(2-morpholinoethyl)benzo[<i>c</i>][2,6]naphthyridine-8-carboxamide (<b>1l</b>)</h5><div class="NLM_p last">Yellow solid. Yield: 68.7%. Compound <b>1l</b> may also be prepared by the method reported in the literature.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.16 (s, 1H), 9.98 (s, 1H), 8.94 (d, <i>J</i> = 5.6 Hz, 1H), 8.84 (d, <i>J</i> = 5.2 Hz, 2H), 8.82 (s, 1H), 8.38 (s, 1H), 8.22 (s, 1H), 8.19 (d, <i>J</i> = 8.3 Hz, 1H), 7.96 (d, <i>J</i> = 8.2 Hz, 1H), 7.42 (t, <i>J</i> = 8.1 Hz, 1H), 7.12 (dd, <i>J</i> = 7.8, 0.9 Hz, 1H), 3.62 (m, 4H), 3.49 (m, 2H), 3.38 (m, 4H), 2.61 (m, 2H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.30, 150.71, 148.04, 147.67, 143.80, 142.56, 135.89, 133.16, 130.42, 127.53, 126.36, 124.31, 123.32, 122.79, 122.55, 121.53, 120.79, 119.81, 117.37, 66.36, 63.29, 57.60, 53.54 ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>24</sub>ClN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 462.1697; found: 462.1695.</div></div><div id="sec4_2_2_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 5-((3-Chlorophenyl)amino)-<i>N</i>-(3-hydroxypropyl)benzo[<i>c</i>][2,6]naphthyridine-8-carboxamide (<b>1m</b>)</h5><div class="NLM_p last">Yellow solid. Yield: 79.8%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.19 (s, 1H), 9.67 (s, 1H), 8.99 (d, <i>J</i> = 5.6 Hz, 1H), 8.85 (d, <i>J</i> = 8.4 Hz, 1H), 8.77 (t, <i>J</i> = 5.6 Hz, 1H), 8.59 (d, <i>J</i> = 5.6 Hz, 1H), 8.28 (s, 1H), 8.23 (s, 1H), 8.12 (dd, <i>J</i> = 8.2, 1.0 Hz, 1H), 7.95 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 7.45 (t, <i>J</i> = 8.2 Hz, 1H), 7.15 (dd, <i>J</i> = 7.8, 1.2 Hz, 1H), 4.54 (t, <i>J</i> = 5.2 Hz, 1H), 3.52 (q, <i>J</i> = 6.2 Hz, 2H), 3.40 (dd, <i>J</i> = 12.8, 7.0 Hz, 2H), 1.75 (p, <i>J</i> = 6.6 Hz, 2H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.27, 150.53, 148.15, 147.70, 143.78, 142.39, 136.06, 133.27, 130.56, 127.54, 126.27, 124.19, 123.35, 122.77, 122.66, 121.46, 120.68, 119.69, 116.84, 59.13, 37.22, 32.92 ppm.HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>22</sub>H<sub>19</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 407.1269; found: 407.1264.</div></div><div id="sec4_2_2_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> <i>N</i>-(3-Aminopropyl)-5-((3-chlorophenyl)amino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxamide (<b>1n</b>)</h5><div class="NLM_p last">Yellow solid. Yield: 57.3%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.19 (s, 1H), 10.01 (s, 1H), 8.96 (d, <i>J</i> = 5.6 Hz, 1H), 8.91 (t, <i>J</i> = 5.4 Hz, 1H), 8.87 (d, <i>J</i> = 3.8 Hz, 1H), 8.38 (s, 1H), 8.25–8.21 (m, 2H), 8.04 (s, 1H), 7.99 (d, <i>J</i> = 8.4 Hz, 1H), 7.44 (t, <i>J</i> = 8.2 Hz, 1H), 7.14 (d, <i>J</i> = 7.8 Hz, 1H), 3.36 (dd, <i>J</i> = 12.6, 6.4 Hz, 2H), 3.18 (dd, <i>J</i> = 12.8, 6.2 Hz, 2H), 1.76–1.70 (m, 2H), 1.22 (s, 2H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.25, 161.58, 150.71, 148.07, 147.68, 143.82, 142.56, 135.91, 133.16, 130.46, 127.55, 126.34, 124.30, 123.21, 122.79, 122.56, 120.77, 119.82, 117.38, 37.53, 35.51, 29.61 ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>22</sub>H<sub>20</sub>ClN<sub>5</sub>O [M + H]<sup>+</sup>: 406.1434; found: 406.1431.</div></div><div id="sec4_2_2_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> Methyl 4-(5-((3-Chlorophenyl)amino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxamido)butanoate (<b>1o</b>)</h5><div class="NLM_p last">Orange solid. Yield: 65.8%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.17 (s, 1H), 9.94 (s, 1H), 8.95 (d, <i>J</i> = 6.0 Hz, 1H), 8.87–8.83 (m, 2H), 8.81 (d, <i>J</i> = 5.0 Hz, 1H), 8.34 (s, 1H), 8.22 (s, 1H), 8.19 (d, <i>J</i> = 8.0 Hz, 1H), 7.95 (d, <i>J</i> = 7.8 Hz, 1H), 7.43 (t, <i>J</i> = 7.8 Hz, 1H), 7.13 (d, <i>J</i> = 7.4 Hz, 1H), 3.59 (s, 3H), 3.35 (dd, <i>J</i> = 12.6, 6.8 Hz, 2H), 2.41 (t, <i>J</i> = 6.8 Hz, 2H), 1.87–1.81 (m, 2H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.68, 166.36, 150.69, 148.03, 147.66, 143.79, 142.52, 135.91, 133.17, 130.46, 127.54, 126.30, 124.29, 123.35, 122.76, 122.59, 121.49, 120.78, 119.81, 117.30, 51.75, 39.15, 31.36, 24.94 ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>24</sub>H<sub>2<b>1c</b></sub>lN<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 449.1380; found: 449.1386.</div></div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> General Procedure for Preparation of Compounds <b>1p</b>–<b>1q</b></h4><div id="sec4_2_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 3-(5-((3-Chlorophenyl)amino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxamido)propanoic Acid (<b>1p</b>)</h5><div class="NLM_p last">General procedure B: To a solution of <b>1i</b> (0.434 g, 1 mmol) in MeOH (10 mL) were added H<sub>2</sub>O (5 mL) and LiOH·H<sub>2</sub>O (0.105 g, 2.5 mmol) and stirred at 60 °C overnight. The progress of the reaction was monitored with TLC. After the substrate was completely consumed, the solvent was removed under vacuum, and the residue was acidified with 1 M HCl to pH = 5, filtering the precipitate; washed with water (3 × 10 mL); and dried to obtain the crude product of <b>1p</b>. The crude product was recrystallized with MeOH (15 mL) to get a yellow solid (0.370 g). Yield: 88.1%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.37 (s, 1H), 10.15 (s, 1H), 9.63 (s, 1H), 8.96 (s, 1H), 8.84 (s, 1H), 8.81 (d, <i>J</i> = 7.4 Hz, 1H), 8.55 (s, 1H), 8.24 (t, <i>J</i> = 1.8 Hz, 1H), 8.21 (d, <i>J</i> = 1.2 Hz, 1H), 8.09 (d, <i>J</i> = 6.8 Hz, 1H), 7.92 (dd, <i>J</i> = 7.2, 1.8 Hz, 1H), 7.42 (d, <i>J</i> = 6.8 Hz, 1H), 7.13 (d, <i>J</i> = 6.4 Hz, 1H), 3.54 (dd, <i>J</i> = 10.6, 5.8 Hz, 2H), 2.58 (t, <i>J</i> = 6.4 Hz, 2H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.63, 166.29, 150.52, 148.12, 147.69, 143.75, 142.37, 135.77, 133.27, 130.54, 127.50, 126.30, 124.18, 123.32, 122.76, 122.65, 121.53, 120.68, 119.68, 116.80, 36.31, 34.40 ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>22</sub>H<sub>17</sub>ClN<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 421.1067; found: 421.1060.</div></div><div id="sec4_2_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 4-(5-((3-Chlorophenyl)amino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxamido)butanoic Acid (<b>1q</b>)</h5><div class="NLM_p last">Yellow solid. Yield: 83.6%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.43 (s, 1H), 10.18 (s, 1H), 9.66 (d, <i>J</i> = 5.3 Hz, 1H), 8.99 (d, <i>J</i> = 5.4 Hz, 1H), 8.84 (d, <i>J</i> = 8.4 Hz, 1H), 8.81 (t, <i>J</i> = 6.4 Hz, 1H), 8.58 (d, <i>J</i> = 5.4 Hz, 1H), 8.27 (s, 1H), 8.24 (s, 1H), 8.13 (d, <i>J</i> = 8.5 Hz, 1H), 7.96 (d, <i>J</i> = 8.3 Hz, 1H), 7.46 (t, <i>J</i> = 8.1 Hz, 1H), 7.15 (d, <i>J</i> = 7.5 Hz, 1H), 3.38 (dd, <i>J</i> = 12.6, 6.5 Hz, 2H), 2.35 (t, <i>J</i> = 7.3 Hz, 2H), 1.87–1.81 (m, 2H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 174.80, 166.28, 150.50, 148.13, 147.68, 143.76, 142.38, 135.96, 133.27, 130.55, 127.52, 126.30, 124.17, 123.37, 122.74, 122.64, 121.47, 120.67, 119.67, 116.81, 39.29, 31.72, 25.05 ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>23</sub>H<sub>19</sub>ClN<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 435.1224; found: 435.1221.</div></div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> General Procedure for Preparation of Compounds <b>2a</b>–<b>2g</b></h4><div id="sec4_2_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 2-Hydroxyethyl 5-((3-Chlorophenyl)amino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylate (<b>2a</b>)</h5><div class="NLM_p last">General procedure C: To a solution of <b>CX-4945</b> (0.210 g, 0.6 mmol) in DMF (5 mL) was added <i>O</i>-(benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium tetrafluoroborate (TBTU) (0.231 g, 0.72 mmol) and stirred at 45 °C for 10 min. Then, triethylamine (TEA) (0.167 mL, 1.2 mmol) was added to the solution and stirred for 10 min at the same temperature, followed by the addition of ethylene glycol (0.062 g, 1 mmol), and the solution was stirred for 24 h in a nitrogen atmosphere. The progress of the reaction was monitored with TLC. After the substrate was completely consumed, the solvent was removed under vacuum, and the residue was treated with EtOAc (25 mL). The organic layers were washed with saturated salt water (3 × 20 mL) and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The organic layers were concentrated under vacuum to obtain the crude product and further purified with silica gel chromatography with the eluent of MeOH and DCM (1:100–1:50) to give a yellow solid (0.204 g). Yield: 86.5%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>)δ 10.17 (s, 1H), 9.95 (s, 1H), 8.99 (d, <i>J</i> = 5.6 Hz, 1H), 8.88 (d, <i>J</i> = 8.5 Hz, 1H), 8.79 (d, <i>J</i> = 5.6 Hz, 1H), 8.32 (t, <i>J</i> = 2.0 Hz, 1H), 8.27 (d, <i>J</i> = 1.6 Hz, 1H), 8.18 (dd, <i>J</i> = 8.2, 1.3 Hz, 1H), 8.01 (dd, <i>J</i> = 8.4, 1.7 Hz, 1H), 7.45 (t, <i>J</i> = 8.1 Hz, 1H), 7.15 (dd, <i>J</i> = 7.9, 1.4 Hz, 1H), 5.12 (t, <i>J</i> = 5.4 Hz, 1H), 4.39–4.35 (m, 2H), 3.78 (dd, <i>J</i> = 9.4, 4.8 Hz, 2H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) <sup>13</sup>C NMR (151 MHz, DMSO) δ 166.18, 150.85, 148.21, 148.16, 143.76, 142.34, 133.15, 131.11, 130.52, 128.59, 127.27, 124.62, 124.41, 123.23, 123.15, 122.71, 120.79, 119.85, 117.26, 67.36, 59.52 ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>21</sub>H<sub>16</sub>ClN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 394.0958; found: 394.0961.</div></div><div id="sec4_2_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> 2-Iodoethyl 5-((3-Chlorophenyl)amino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylate (<b>2b</b>)</h5><div class="NLM_p last">Yellow solid. Yield: 77.3%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.16 (s, 1H), 10.04 (s, 1H), 8.98 (d, <i>J</i> = 5.6 Hz, 1H), 8.82 (d, <i>J</i> = 8.5 Hz, 1H), 8.52 (dd, <i>J</i> = 8.3, 1.0 Hz, 1H), 8.34 (s, 1H), 8.26 (d, <i>J</i> = 8.2 Hz, 1H), 8.02 (d, <i>J</i> = 1.4 Hz, 1H), 7.73 (dd, <i>J</i> = 8.4, 1.5 Hz, 1H), 7.48 (t, <i>J</i> = 8.1 Hz, 1H), 7.16 (dd, <i>J</i> = 7.9, 1.2 Hz, 1H), 5.11–5.08 (t, <i>J</i> = 8.2 Hz, 2H), 4.78 (t, <i>J</i> = 7.8 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.62, 152.34, 150.89, 148.19, 143.68, 142.39, 133.15, 130.50, 130.26, 128.49, 127.20, 124.66, 124.04, 123.26, 123.17, 122.71, 120.89, 119.95, 117.39, 79.06, 63.61. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>21</sub>H<sub>15</sub>ClF<sub>2</sub>N<sub>4</sub>O [M + H]<sup>+</sup>: 503.9975; found: 503.9980.</div></div><div id="sec4_2_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> 2-Fluoroethyl 5-((3-Chlorophenyl)amino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylate (<b>2c</b>)</h5><div class="NLM_p last">Yellow solid. Yield: 82.8%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.11 (s, 1H), 9.64 (s, 1H), 8.97 (d, <i>J</i> = 5.4 Hz, 1H), 8.82 (d, <i>J</i> = 8.2 Hz, 1H), 8.54 (d, <i>J</i> = 5.2 Hz, 1H), 8.22 (s, 1H), 8.20 (s, 1H), 8.07 (d, <i>J</i> = 8.0 Hz, 1H), 7.94 (d, <i>J</i> = 8.2 Hz, 1H), 7.44 (t, <i>J</i> = 8.0 Hz, 1H), 7.14 (dd, <i>J</i> = 7.8, 1.2 Hz, 1H), 4.88–4.86 (m, 1H), 4.80–4.77 (m, 1H), 4.65–4.62 (m, 1H), 4.59–4.57 (m, 1H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.79, 150.59, 148.15, 148.11, 143.62, 142.15, 133.19, 130.51, 130.46, 128.53, 127.08, 124.44, 124.18, 123.20, 123.18, 122.70, 120.64, 119.64, 116.72, 82.22 (d, <i>J</i> = 166.2 Hz), 64.72 (d, <i>J</i> = 18.2 Hz) ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>21</sub>H<sub>15</sub>ClFN<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 396.0915; found: 396.0911.</div></div><div id="sec4_2_4_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> 2-(Pyridin-2-yl)ethyl 5-((3-Chlorophenyl)amino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylate (<b>2d</b>)</h5><div class="NLM_p last">Yellow solid. Yield: 77.2%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.15 (s, 1H), 10.02 (s, 1H), 8.97 (s, 1H), 8.87 (d, <i>J</i> = 7.0 Hz, 1H), 8.83 (s, 1H), 8.61 (s, 1H), 8.36 (s, 1H), 8.27 (s, 1H), 8.18 (d, <i>J</i> = 6.1 Hz, 1H), 8.00 (d, <i>J</i> = 6.7 Hz, 1H), 7.88 (s, 1H), 7.57 (d, <i>J</i> = 5.3 Hz, 1H), 7.43 (s, 1H), 7.39 (s, 1H), 7.13 (d, <i>J</i> = 5.9 Hz, 1H), 5.50 (s, 2H), 3.40 (s, 1H), 3.18 (s, 1H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.78, 156.03, 150.96, 149.74, 148.25, 143.82, 142.36, 137.58, 133.11, 130.64, 130.47, 128.69, 127.23, 124.71, 124.32, 123.63, 123.44, 122.68, 122.50, 122.10, 120.83, 119.88, 118.27, 117.41, 67.41, 49.03 ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>19</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 455.1275; found: 455.1269.</div></div><div id="sec4_2_4_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> 2,2-Difluoroethyl 5-((3-Chlorophenyl)amino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylate (<b>2e</b>)</h5><div class="NLM_p last">Earth-yellow solid. Yield: 65.7%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.10 (s, 1H), 9.90 (s, 1H), 8.96 (d, <i>J</i> = 5.6 Hz, 1H), 8.83 (d, <i>J</i> = 8.5 Hz, 1H), 8.76 (d, <i>J</i> = 5.4 Hz, 1H), 8.31 (d, <i>J</i> = 1.7 Hz, 1H), 8.19 (d, <i>J</i> = 1.7 Hz, 1H), 8.16–8.14 (m, 1H), 7.93 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 7.44 (t, <i>J</i> = 8.2 Hz, 1H), 7.14 (dd, <i>J</i> = 7.8, 1.2 Hz, 1H), 6.51 (tt, <i>J</i> = 54.2, 3.2 Hz, 1H), 4.68 (td, <i>J</i> = 15.2, 3.2 Hz, 2H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO<i>-d</i><sub>6</sub>) δ 165.21, 150.86, 148.21, 148.12, 143.70, 142.25, 133.12, 130.41, 129.78, 128.69, 127.07, 124.63, 124.17, 123.51, 123.37, 122.69, 120.82, 119.82, 117.19, 114.12 (t, <i>J</i> = 238.9 Hz), 63.04 (t, <i>J</i> = 26.4 Hz).HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>21</sub>H<sub>14</sub>ClF<sub>2</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 414.0821; found: 414.0820.</div></div><div id="sec4_2_4_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> 3,3-Dichloropropyl 5-((3-Chlorophenyl)amino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylate (<b>2f</b>)</h5><div class="NLM_p last">Yellow solid (0.141 g). Yield: 61.5%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.14 (s, 1H), 10.02 (s, 1H), 8.97 (d, <i>J</i> = 5.6 Hz, 1H), 8.87 (d, <i>J</i> = 3.6 Hz, 1H), 8.86 (s, 1H), 8.39 (t, <i>J</i> = 1.8 Hz, 1H), 8.24 (d, <i>J</i> = 1.4 Hz, 1H), 8.17 (dd, <i>J</i> = 8.2, 1.2 Hz, 1H), 7.98 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 7.43 (t, <i>J</i> = 8.2 Hz, 1H), 7.14 (dd, <i>J</i> = 7.8, 1.2 Hz, 1H), 4.84–4.80 (m, 1H), 4.70 (dd, <i>J</i> = 11.8, 4.6 Hz, 1H), 4.65 (dd, <i>J</i> = 11.8, 6.2 Hz, 1H), 4.14 (t, <i>J</i> = 5.2 Hz, 2H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.47, 150.91, 148.21, 148.17, 143.75, 142.34, 133.12, 130.40, 130.23, 128.72, 127.17, 124.67, 124.27, 123.44, 123.36, 122.67, 120.86, 119.87, 117.38, 65.77, 58.78, 46.48 ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>22</sub>H<sub>16</sub>Cl<sub>3</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 460.0386; found: 460.0380.</div></div><div id="sec4_2_4_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> 2-(2-(2-Hydroxyethoxy)ethoxy)ethyl 5-((3-Chlorophenyl)amino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylate (<b>2g</b>)</h5><div class="NLM_p last">Yellow solid. Yield: 72.6%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.12 (s,1H), 9.63 (s, 1H), 8.98 (d, <i>J</i> = 6.0 Hz, 1H), 8.82 (d, <i>J</i> = 6.0 Hz, 1H), 8.54 (d, <i>J</i> = 6.0 Hz, 1H), 8.27 (t, <i>J</i> = 2.0 Hz, 1H), 8.20 (d, <i>J</i> = 1.6 Hz, 1H), 8.07 (dd, <i>J</i> = 8.2, 1.4 Hz, 1H), 7.94 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 7.45 (t, J = 8.1 Hz, 1H), 7.15 (dd, J = 6.0, 1.4 Hz, 1H), 4.57 (t, <i>J</i> = 6.0 Hz, 1H), 4.47 (t, <i>J</i> = 6.0 Hz, 2H), 3.83 (t, <i>J</i> = 6.0 Hz, 2H), 3.66 (dd, <i>J</i> = 5.8, 3.8 Hz, 2H), 3.58 (dd, <i>J</i> = 5.8, 3.8 Hz, 2H), 3.48 (dd, <i>J</i> = 10.4, 4.8 Hz,2H), 3.44 (dd, <i>J</i> = 7.8, 3.0 Hz, 2H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.97, 150.65, 148.22, 148.16, 143.67, 142.19, 133.22, 130.88, 130.54, 128.53, 127.19, 124.49, 124.25, 123.21, 123.15, 122.73, 120.67, 119.67, 116.78, 72.86, 70.41, 70.27, 68.84, 64.79, 60.69 ppm. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>24</sub>ClN<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 482.1482; found: 482.1483.</div></div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> CK2, ClK2, and ALDH1A1 Assay</h3><div class="NLM_p last">CK2, Clk2, and the ALDH1A1 Kinase (Human) Assay/Inhibitor Screening Assay Kit as well as CK2, Clk2, and ALDH1A1 enzymes were supplied by Shanghai Fusheng Industrial Co., Ltd. (Shanghai, China). The inhibitory activity of tested compounds on CK2, ClK2, and ALDH1A1 was detected according to manufacturer’s instruction by commercial CK2, ClK2, and ALDH1A1 assay kits with <b>CX-4945</b> as the positive control. As shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_001.pdf" class="ext-link">Figure S7</a>, we take CK2 enzyme activity detection as an example to briefly introduce the experimental process. 50 μL, 60 U/L of CK2 enzyme reaction solution was added to each well of 96-well plates after thawing, and then five gradient concentrations (500.0, 100.0, 20.0, 4.0, and 0.8 nM) of fresh compound solutions were added to each well, respectively. In addition, the same solution without the inhibitor was added to each well in the control group. The 96 well plate was sealed with sealing film and incubated in 37 °C incubator for 2 h. After that, the conjugate reagent (50 μL) was introduced to every well, except for the control group, and incubated at 37 °C for another 30 min. The color developing reagents A (50 μL) and B (50 μL) were successively added to each hole, the mixture was shaken gently and mixed well, light was avoided for 15 min, and then the stop buffer (50 μL) was added to each hole. The reaction mixtures were incubated at room temperature for 10 min, and the value of O.D. was measured <i>via</i> an enzyme-labeling instrument at 450 nm. The IC<sub>50</sub> value of each compound is given as the mean ± SD and was obtained by three parallel experiments.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Cell Line Culture</h3><div class="NLM_p last">The CK2-overexpressed cell lines PC-3 (prostate cancer cell line), HCT-116 (colorectal cancer cell line), MCF-7 ( breast cancer cell line), HT-29 ( colorectal cancer cell line), and T24 (bladder Cancer Cell line) and the normal human liver cell line LO2 were grown under 5% CO<sub>2</sub> and 95% air at 37 °C conditions. All these cells were grown in monolayer in DMEM or RPMI-1640 medium enriched with 10% FBS, 100 μg/mL streptomycin, and 100 μg/mL penicillin solutions.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Antiproliferative Assay</h3><div class="NLM_p last">MTT assay was used to detect the antiproliferative effect of all the target compounds against several cancer cell lines. About 5 × 10<sup>3</sup> cells per well were planted in a 96-well plate and incubated at 37 °C in 5% CO<sub>2</sub> overnight. Compounds were dissolved with DMSO and diluted with medium to various concentrations, and added to these different cells culture medium, respectively, for 72 h. After that, 10 μL of 5 mg/mL MTT was introduced to all the wells, and incubation of the cells was continued for 4 h. The medium was discarded, and 150 μL of DMSO was added to dissolve the dark blue crystals on the bottom. The value of O.D. was determined with an enzyme-labeling instrument at 490 nm. The IC<sub>50</sub> value of each compound presented as the mean ± SD was obtained by three parallel experiments.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Kinase Inhibition Assays</h3><div class="NLM_p last">The potential of compound <b>1c</b> as a CK2 inhibitor was determined at 1 μmol/L concentration against a panel of 208 kinases through the commercially available service provided by ICE Bioscience Inc. (Beijing, China).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Molecular Docking</h3><div class="NLM_p last">Molecular docking of <b>1c</b> to CK2α (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6isj">6isj</a>), Clk2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6khe">6khe</a>), and ALDH1A1 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4x4l">4x4l</a>) was conducted <i>via</i> AutoDock Vina, where the Iterated Local Search Globule Optimizer was employed as the optimization algorithm. Ligand <b>1c</b> was prepared in ChemBioDraw Ultra 14.0 and minimized with ChemBio3D Ultra 14.0. Before the docking process, the natural ligand along with the water molecules was deleted from the crystal structure. Subsequently, all hydrogen atoms were added to the each protein and ligand to be docked, and every coordinate file of the protein, as well as the ligand was generated as a PDBQT file <i>via</i> AutoDockTools-1.5.6. A grid box for binding site covered the protein’s catalytic site. The box possessed a 1.0 Å grid spacing and was centered at the geometric center of the protein. In every docking experiment, we selected the best binding mode on the basis of the binding affinity determined by the scoring function in AutoDock Vina. Docking results were analyzed and visualized with PyMOL (Schroedinger LLC, NY).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> ALDH Activity Assay</h3><div class="NLM_p last">The HCT-116 cells were inoculated on six-well plates at 2 × 10<sup>5</sup> cells per well; grown at 37 °C in 5% CO<sub>2</sub> overnight; and then treated with <b>CX-4945</b> (5 μM), different concentrations of <b>1c</b> (5, 10, and 20 μM), and vehicle (DMSO), respectively, for 24 h, to explore ALDH1A1 expression in HCT-116 cells. Aldefluor (Stem Cell Technologies, Vancouver, BC, Canada) staining was assayed with the FITC channel of fluorescent activated cell sorting as described by the manufacturer. To mark the base fluorescence, pretreatment with the DEAB ALDH inhibitor was employed as a negative control to mark the base fluorescence.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Quantitative Real-Time PCR Assay</h3><div class="NLM_p last">TRIZOL was employed to isolate total cellular RNA from HCT-116 or HCT-116<sup>AHDH+</sup> cells treated for 24 h with the tested compounds. RNA was reverse-transcribed with the Luna universal one-step RT-qPCR (GeneAmp 9600, PERKIN ELMER), and the resulting cDNA was subsequently run on a thermal cycler (ABI StepOnePlus, ABI). Thermal profile was as follows: reverse transcription for 10 min at 55 °C and initial denaturation for 1 min at 95 °C followed by 39 thermal cycles of denaturation for 10 s at 95 °C and extension for 30 s at 60 °C. Primer sequences are listed in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_001.pdf" class="ext-link">Table S1</a>. All PCRs included melting curve analysis and template-free negative technical controls to verify specific single-product amplification. β-Actin mRNA was employed as an internal standard. The relative expression of mRNA is represented as fold increase (2<sup>–ΔΔCt</sup>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> CD44 and CD133 Expression Assay</h3><div class="NLM_p last">The HCT-116<sup>ALDH+</sup> cells were planted in six-well plates at 2 × 10<sup>5</sup> cells per well; cultured overnight under 37 °C and 5% CO<sub>2</sub> conditions; and then treated with vehicle (DMSO), <b>BBI608</b> (20 μM), <b>CX-4945</b> (20 μM), and <b>1c</b> (20 μM), respectively. After co-incubation for 24 h, we collected the cells and stained them with PE-labeled anti-CD133 and FITC-labeled anti-CD44 for 30 min as described by the manufacturer. The expression of CD44<sup>+</sup> along with CD133<sup>+</sup> was detected with flow cytometry by the Cell Quest software.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Cancer Stem-like Spheroid Formation Assay</h3><div class="NLM_p last">A spheroid formation assay was used to explore the stemness of HCT-116<sup>ALDH+</sup> cells. Concisely, 800 cells/well were planted in the 24-well plates (3473, Corning) in serum-free DMEM enriched with B27 (17504044, Invitrogen, 1: 50), EGF (20 ng/mL, AF-100-15, Peprotech), and β-FGF (10 ng/mL, 100-18B, Peprotech). Vehicle (DMSO), <b>BBI608</b> (5 μM), <b>CX-4945</b> (5 μm) along with 1C (5 μm) were added into each well of the 24-well plate, respectively, and co-incubated with cells for 10 days. After that, the numbers and diameter of the tumorsphere were measured in the microscopy images.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Transwell Invasion Assays</h3><div class="NLM_p last">Transwell chambers with 8 mm pores were employed to detect the invasion ability of cells. In the assay, 1 × 10<sup>5</sup> HCT-116 cells in 200 μL of serum-free medium were introduced into the upper compartment, and 500 μL of DMEM enriched with 10% FBS as a chemoattractant was introduced into the lower compartment. After inoculation with vehicle (DMSO), <b>CX-4945</b> (5 μM), and <b>1c</b> (5 μM) for 24 h, a cotton swab was employed to remove the HCT-116 cells on the upper surface of the inserted membrane. Crystal violet staining was performed on the HCT-116 cells on the lower surface of the inserted membrane for 30 min. Lastly, an inverted microscope was employed to image the number of cells on the lower surface of the membrane.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Cell Apoptotic Assay</h3><div class="NLM_p last">An Annexin V-FITC apoptotic detection kit was employed to explore the apoptosis of HCT-116 cells induced by vehicle (DMSO), <b>CX-4945</b> (5 μM), and <b>1c</b> (5, 10 and 20 μM). We collected the HCT-116 cells in the log growth phase and suspended them in DMEM enriched with 10% FBS. A total of 2 × 10<sup>5</sup> cells/well were inoculated in a six-well plate and left to adhere overnight. Then, the original growth medium was discarded, and fresh medium was added and treated with the compounds under study, respectively, for 24 h at 37 °C. The cells were inoculated with Annexin V-FITC followed by PI in the dark for 10 min at room temperature. Afterward, the cells were assessed by flow cytometry, and the apoptotic value was obtained by the Cell-Quest software (BD Biosciences).</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Cell Cycle Arrest Assay</h3><div class="NLM_p last">The HCT-116 cells were diluted into 2 × 10<sup>5</sup> cells/mL mixed liquid with DMEM with 10% FBS, inoculated in a six-well plate, and grown at 37 °C for 12 h. Then, the cancer cells were treated with vehicle (DMSO), <b>CX-4945</b> (20 μM), and <b>1c</b> (20 μM) for 24 h. The cells in each group were collected into a 5 mL centrifuge tube, about 500 μL of 70% ethanol was added, and the cells were placed in a refrigerator at −20 °C for 12 h. Subsequently, the supernatant was removed, treated with RnaseA (100 μg/mL) at 37 °C for 20 min, and stained with 1 mg/mL PI for 30 min in the dark at 4 °C. The sample was assayed by flow cytometry, and the data were analyzed with the FlowJo software (TreeStar, Inc.).</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Western Blot Assay</h3><div class="NLM_p last">The HCT-116 cells were diluted into 2 × 10<sup>5</sup> cells/mL mixed liquid with DMEM with 10% FBS, planted in a six-well plate, and grown at 37 °C for 12 h. The cells were treated with <b>CX-4945</b> (20 μM), <b>1c</b> (20 μM), and vehicle (DMSO) for 24 h; collected; centrifuged; and rinsed twice in PBS. Thereafter, the lysis buffer was employed to lyse the cells for 30 min on ice. The cells were then spun at 15,000 rpm for 15 min at 4 °C. The BCA protein assay reagents (Imgenex, USA) were employed to quantify the proteins as described by the manufacturer. Next, the proteins were fractionated on 10% SDS-PAGE gels and blotted onto a PVDF membrane (GE Healthcare). After that, 5% nonfat milk in the TBST buffer was employed to block the membrane, which was subsequently co-inoculated with primary antibodies (p-Akt1<sup>S</sup><sup>129</sup>, Akt, p-Cdc37<sup>S13</sup>, Cdc37, p-GSK-3β(ser9), GSK-3β, DKK1, β-catenin, Cyt c, Bax, Bcl-2, pro-caspase 9, cleaved caspase 9, pro-caspase 3, cleaved caspase 3, total PARP, cleaved PARP, and β-actin) at 4 °C overnight. Thereafter, the membranes were incubated with the HRP-labeled secondary antibodies for 2 h and rinsed thrice in the TBST buffer for 15 min, and a chemiluminescence reagent (Thermo Fisher Scientifics Ltd.) was employed to visualize the protein bands.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Thermodynamic Solubility (Shake Flask Method)</h3><div class="NLM_p last"><b>1c</b> was added into 2 mL glass vials prior to the addition of pH 6.8 phosphate buffer to obtain a nominal concentration of 2 mg/mL. The samples were sonicated for 10 min and shaken overnight at 800 rpm (Titrimax 1000, Heidolph) at room temperature. A first phase separation of supernatant and undissolved solid was performed by centrifugation at 5000 rpm for 20 min (Eppendorf Centrifuge 5804). The supernatant was then transferred into a conical glass vial for a second centrifugation. An adequate dilution was made using the particle-free supernatant, and the concentration was quantified by LC-HRMS using a six-point calibration curve (Vanquish coupled to an Exactive-Plus, Thermo Scientific). The final determination of the solubility of <b>1c</b> in phosphate buffer solution with pH = 6.8 was 0.89 mg/mL.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Pharmacokinetic Assay</h3><div class="NLM_p">The pharmacokinetic profile of <b>1c</b> was assessed in overnight-fasted male SD rats after a single oral dose (po). <b>1c</b> was dissolved in 5% CMC-Na, and the positive control of <b>CX-4945·Na</b> was a sodium salt formulated in phosphate buffer for the rats. Six male SD rats (three for each leg) weighing about 250–270 g were clustered randomly into two groups and administered with <b>1c</b> (25 mg/kg) and <b>CX-4945·Na</b> (25 mg/kg), respectively. We collected blood samples from all the rats at 0.25, 0.50, 0.75, 1, 2, 3, 4, 6, 8, 12, 24, and 48 h post oral dosing. The blood samples were centrifuged at 4000 rpm for 10 min, and the plasma was collected and stored at −40 °C. LC–MS/MS was employed to analyze the sample. The data of blood concentration (<i>c</i>)–time (<i>T</i>) measured after oral administration were processed by the Das 2.0 software. The appropriate mathematical model was selected to fit, and the pharmacokinetic parameters were calculated.</div><div class="NLM_p last">Preparation of standard curves: 10 μL of blank plasma was added to the standard solution of <b>1c</b> or <b>CX-4945·Na</b> at different concentrations (30, 60, 150, 300, 600, 1500, 3000, 6000, 15,000, and 30,000 ng/mL), respectively, to prepare plasma samples equivalent to ropivacaine with plasma mass concentrations of 3, 6, 15, 30, 60, 150, 300, 600, 1500, and 3000 ng/mL. The LC–MS/MS technique was used to analyze the samples with different concentrations (5 μL), the ratio <i>Y</i> of the peak area of each component to the internal standard peak area was used to perform linear regression operation on the plasma mass concentration <i>X</i>, and the regression equation obtained was the standard curve. The regression equations of <b>1c</b> and <b>CX-4945·Na</b> are <i>Y</i> = 0.116<i>X</i> – 0.00140 (<i>r</i> = 0.9986) and <i>Y</i> = 0.704<i>X</i> + 0.000548 (r = 0.9968), respectively, and the minimum quantitative limit is 3 ng/mL.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Antitumor Activity Assay</h3><div class="NLM_p last">Animal studies were performed as per the relevant laws and institutional guidelines set by the Jiangsu Province Committee of Use and Care of Laboratory Animals, and all protocols were approved by the Institutional Animal Care and Use Committee of Southeast University. The antitumor efficacy of <b>1c</b> was investigated in HCT-116 xenograft tumor models in nude mice. A total of 0.2 mL of 5 × 10<sup>7</sup> cell/mL cell suspension was taken and injected into the right armpit of 5-week-old male BALB/c athymic nude mice weighing about 16–18 g (purchased from Shanghai Sipo-Bikai Laboratory Animal Co. Ltd. (Shanghai, China)). When the tumors reached a volume of about 100 mm<sup>3</sup> in all mice, they were grouped randomly into four groups of five mice and treated <i>via</i> intragastric administration with 0.1 mL 5% glucose injection (twice a day for 4 weeks), <b>CX-4945·Na</b> (60 mg/kg, twice a day for 4 weeks), and <b>1c</b> (60 and 90 mg/kg, twice a day for 4 weeks). <b>CX-4945·Na</b> was dissolved in 25 mM NaH<sub>2</sub>PO<sub><span class="strike">4</span></sub> solution, and <b>1c</b> was dissolved in 5% CMC-Na. Tumor volumes along with body weights were recorded twice a week. The calculation formula of tumor volume (TV, mm<sup>3</sup>) is TV = 0.5 × length × width<sup>2</sup>. The average tumor volume within each experimental group at the set time points was employed to plot growth curves <i>via</i> Origin 9.0. We sacrificed 20 mice after the last treatment, and then the tumor weight was determined as the antitumor activity of the respective groups. The heart, liver, spleen, lung, kidney, and tumor tissues were excised for HE staining. The body weight along with physical state of the mice was determined simultaneously as an indicator of systemic toxicity.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Statistical Analysis</h3><div class="NLM_p last">The data are given as means ± SD from at least three independent experiments, each in triplicate samples for individual treatment or dosage. Statistical analyses were conducted using an unpaired, two-tailed Student’s <i>t</i> test. <i>*P</i> < 0.05 and <i>**P</i> < 0.01 signified statistical significance.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i68"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00131" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05546" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05546" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00131?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00131</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthetic route of <b>BTE</b> and <b>CX-4945</b>, representative flow cytometry figures from the Aldefluor assays, docking of <b>1c</b> into ALDH1A1 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4x4l">4x4l</a>) kinase X-ray crystal structure, Annexin CD44-FITC and CD133-PI staining results of <b>1c</b> in the HCT-116<sup>ALDH+</sup> cells, HE staining internal organs and tumor tissues in the animal xenograft model of HCT-116, the inhibitory rate of the synthesized compounds on PC-3, HCT-116, MCF-7, HT-29, T24, and LO2 cells at different concentrations, the inhibitory rate of the synthesized compounds on CK2 and Clk2 at different concentrations, schematic diagram of the inhibition activity detection of compounds against CK2 and Clk2, table of the percent inhibition of compound <b>1c</b> against 208 kinases, table of the primer sequences used for qRT-PCR, table of the <i>in vivo</i> blood concentration results of <b>CX-4945·Na</b> and <b>1c</b>, table of the inhibitory effects of the measured samples on the HCT-116 cancer cell xenograft mice model, figures of <sup>1</sup>H and <sup>13</sup>C NMR, HR-MS spectra, and RP-HPLC chromatograms (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">PDB file of <b>1c</b>-CK2α (PDB ID: 6isj) (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">PDB file of <b>1c</b>-Clk2 (PDB ID: 6khe) (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">PDB file of <b>1c</b>-ALDH1A1 (PDB ID: 4x4l) (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_005.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_001.pdf">jm1c00131_si_001.pdf (12.3 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_002.csv">jm1c00131_si_002.csv (4.08 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_003.pdb">jm1c00131_si_003.pdb (264.92 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_004.pdb">jm1c00131_si_004.pdb (279.79 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_005.pdb">jm1c00131_si_005.pdb (618.86 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00131" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02763" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02763" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shaohua Gou</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, PR China</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0284-5480" title="Orcid link">http://orcid.org/0000-0003-0284-5480</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f6c4c4c7cfc4c0c3cec6c6b68787d895999b"><span class="__cf_email__" data-cfemail="447676757d7672717c74740435356a272b29">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuanjiang Wang</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, PR China</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhaodan Lv</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feihong Chen</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, PR China</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xing Wang</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i69">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50022" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50022" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank the National Natural Science Foundation of China (Project No. 22077015); Graduate Research and Innovation Fund of Jiangsu Province, China (Project No. KYCX19_0102); and Fundamental Research Funds for the Central Universities (Project 2242020 K30059) for financial aid to this work. The authors are thankful to ICE Bioscience Inc. (Beijing) for undertaking the detection experiment of kinase spectrum. Nanjing Biorn Life Science Co. Ltd. is acknowledged for the <i>in vivo</i> tests.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">ABBREVIATIONS</td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase</p></td></tr><tr><td class="NLM_term">ALDH1A1</td><td class="NLM_def"><p class="first last">aldehyde dehydrogenase 1A1</p></td></tr><tr><td class="NLM_term">Bcl-2</td><td class="NLM_def"><p class="first last">B-cell lymphoma-2 protein</p></td></tr><tr><td class="NLM_term">Bax</td><td class="NLM_def"><p class="first last">Bcl-2 associated X protein</p></td></tr><tr><td class="NLM_term">CSC</td><td class="NLM_def"><p class="first last">cancer stem cell</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco’s modified Eagle’s medium</p></td></tr><tr><td class="NLM_term">CMC-Na</td><td class="NLM_def"><p class="first last">sodium carboxymethyl cellulose</p></td></tr><tr><td class="NLM_term">Cyt c</td><td class="NLM_def"><p class="first last">cytochrome C</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">FACS</td><td class="NLM_def"><p class="first last">fluorescence-activated cell sorting</p></td></tr><tr><td class="NLM_term">FBA</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr><tr><td class="NLM_term">FITC</td><td class="NLM_def"><p class="first last">fluorescein isothiocyanate isomer</p></td></tr><tr><td class="NLM_term">GSK-3β</td><td class="NLM_def"><p class="first last">glycogen synthase kinase-3β</p></td></tr><tr><td class="NLM_term">HCT-116</td><td class="NLM_def"><p class="first last">human colon cancer cell line</p></td></tr><tr><td class="NLM_term">HT-29</td><td class="NLM_def"><p class="first last">human colon cancer cell line</p></td></tr><tr><td class="NLM_term">HR-MS</td><td class="NLM_def"><p class="first last">high-resolution mass spectrometry</p></td></tr><tr><td class="NLM_term">PC-3</td><td class="NLM_def"><p class="first last">human prostate cancer cell line</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">propidium iodide</p></td></tr><tr><td class="NLM_term">PLK1</td><td class="NLM_def"><p class="first last">polo-like kinase 1</p></td></tr><tr><td class="NLM_term">LO2</td><td class="NLM_def"><p class="first last">human normal hepatocytes cell line</p></td></tr><tr><td class="NLM_term">MCF-7</td><td class="NLM_def"><p class="first last">human breast cancer cell line</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly ADP-ribose polymerase</p></td></tr><tr><td class="NLM_term">qRT-PCR</td><td class="NLM_def"><p class="first last">quantitative real-time PCR</p></td></tr><tr><td class="NLM_term">RBITC</td><td class="NLM_def"><p class="first last">rhodamine B isothiocyanate</p></td></tr><tr><td class="NLM_term">RPMI-1640</td><td class="NLM_def"><p class="first last">Roswell Park Memorial Institute-1640</p></td></tr><tr><td class="NLM_term">SDSPAGE</td><td class="NLM_def"><p class="first last">sodium dodecyl sulfate polyacrylamide gel electrophoresis</p></td></tr><tr><td class="NLM_term">S100A4</td><td class="NLM_def"><p class="first last">S100 calcium binding protein A4</p></td></tr><tr><td class="NLM_term">TMS</td><td class="NLM_def"><p class="first last">tetramethylsilane</p></td></tr><tr><td class="NLM_term">T24</td><td class="NLM_def"><p class="first last">human bladder cancer cell line</p></td></tr><tr><td class="NLM_term">ZAP70</td><td class="NLM_def"><p class="first last">70-kDa zeta-associated protein.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i71">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30105" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30105" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 42 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kossenkov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purandare, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desilva, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jure-Kunkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrilovich, D. I.</span></span> <span> </span><span class="NLM_article-title">Inhibition of casein kinase 2 disrupts differentiation of myeloid cells in cancer and enhances the efficacy of immunotherapy in mice</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">5644</span>– <span class="NLM_lpage">5655</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-1229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1158%2F0008-5472.CAN-18-1229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=30139814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlSju7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=5644-5655&author=A.+Hashimotoauthor=C.+Gaoauthor=J.+Mastioauthor=A.+Kossenkovauthor=S.+I.+Abramsauthor=A.+V.+Purandareauthor=H.+Desilvaauthor=S.+Weeauthor=J.+Huntauthor=M.+Jure-Kunkelauthor=D.+I.+Gabrilovich&title=Inhibition+of+casein+kinase+2+disrupts+differentiation+of+myeloid+cells+in+cancer+and+enhances+the+efficacy+of+immunotherapy+in+mice&doi=10.1158%2F0008-5472.CAN-18-1229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of casein kinase 2 disrupts differentiation of myeloid cells in cancer and enhances the efficacy of immunotherapy in mice</span></div><div class="casAuthors">Hashimoto, Ayumi; Gao, Chan; Mastio, Jerome; Kossenkov, Andrew; Abrams, Scott I.; Purandare, Ashok V.; Desilva, Heshani; Wee, Susan; Hunt, John; Jure-Kunkel, Maria; Gabrilovich, Dmitry I.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5644-5655</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The role of myeloid cells as regulators of tumor progression that significantly impact the efficacy of cancer immunotherapies makes them an attractive target for inhibition.  Here we explore the effect of a novel, potent, and selective inhibitor of serine/threonine protein kinase casein kinase 2 (CK2) on modulating myeloid cells in the tumor microenvironment.  Although inhibition of CK2 caused only a modest effect on dendritic cells in tumor-bearing mice, it substantially reduced the amt. of polymorphonuclear myeloid-derived suppressor cells and tumor-assocd. macrophages.  This effect was not caused by the induction of apoptosis, but rather by a block of differentiation.  Our results implicated downregulation of CCAAT-enhancer binding protein-α in this effect.  Although CK2 inhibition did not directly affect tumor cells, it dramatically enhanced the antitumor activity of immune checkpoint receptor blockade using anti-CTLA-4 antibody.  These results suggest a potential role of CK2 inhibitors in combination therapies against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBY1mwFqvLhLVg90H21EOLACvtfcHk0lhXHAtLa23rzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlSju7rO&md5=bc9ead05597f71437fbf55e6832cc2b8</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-1229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-1229%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DMastio%26aufirst%3DJ.%26aulast%3DKossenkov%26aufirst%3DA.%26aulast%3DAbrams%26aufirst%3DS.%2BI.%26aulast%3DPurandare%26aufirst%3DA.%2BV.%26aulast%3DDesilva%26aufirst%3DH.%26aulast%3DWee%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DJ.%26aulast%3DJure-Kunkel%26aufirst%3DM.%26aulast%3DGabrilovich%26aufirst%3DD.%2BI.%26atitle%3DInhibition%2520of%2520casein%2520kinase%25202%2520disrupts%2520differentiation%2520of%2520myeloid%2520cells%2520in%2520cancer%2520and%2520enhances%2520the%2520efficacy%2520of%2520immunotherapy%2520in%2520mice%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D5644%26epage%3D5655%26doi%3D10.1158%2F0008-5472.CAN-18-1229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issinger, O.-G.</span></span> <span> </span><span class="NLM_article-title">Protein kinase CK2 in human diseases</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1870</span>– <span class="NLM_lpage">1886</span>, <span class="refDoi"> DOI: 10.2174/092986708785132933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.2174%2F092986708785132933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=18691045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVSrsL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1870-1886&author=B.+Guerraauthor=O.-G.+Issinger&title=Protein+kinase+CK2+in+human+diseases&doi=10.2174%2F092986708785132933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase CK2 in human diseases</span></div><div class="casAuthors">Guerra, Barbara; Issinger, Olaf-Georg</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1870-1886</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinase CK2 (formerly referred to as casein kinase II) is an evolutionary conserved, ubiquitous protein kinase.  There are two paralog catalytic subunits, i.e. alpha (A1) and alpha' (A2).  The alpha and alpha' subunits are linked to two beta subunits to produce a heterotetrameric structure.  The catalytic alpha subunits are distantly related to the CMGC subfamily of kinases, such as the Cdk kinases.  There are some peculiarities assocd. with protein kinase CK2, which are not found with most other protein kinases: (1) the enzyme is constitutively active, (2) it can use ATP and GTP and (3) it is found elevated in most tumors investigated and rapidly proliferating tissues.  With the elucidation of the structure of the catalytic subunit, it was possible to explain why the enzyme is constitutively active and why it can bind GTP.  Considerable information on the potential roles of CK2 in various disease processes including cancer has been gained in recent years, and the present review may help to further elucidate its aberrant role in many disease states.  Its peculiar structural features may be advantageous in designing tailor-made compds. with the possibility to specifically target this protein kinase.  Since not all the aspects of what has been published on CK2 can be covered in this review, we would like to recommend the following reviews; (1) for general information on CK2 and (2) with a focus on aberrant CK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHAjFIdLj5brVg90H21EOLACvtfcHk0lhXHAtLa23rzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVSrsL7N&md5=af6ef98b360211abbb0ce5adcfe439e3</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2174%2F092986708785132933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708785132933%26sid%3Dliteratum%253Aachs%26aulast%3DGuerra%26aufirst%3DB.%26aulast%3DIssinger%26aufirst%3DO.-G.%26atitle%3DProtein%2520kinase%2520CK2%2520in%2520human%2520diseases%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D1870%26epage%3D1886%26doi%3D10.2174%2F092986708785132933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nitta, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gholamin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feroze, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheshier, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span> <span> </span><span class="NLM_article-title">Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathway</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">3688</span>– <span class="NLM_lpage">3699</span>, <span class="refDoi"> DOI: 10.1038/onc.2014.299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1038%2Fonc.2014.299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=25241897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyhtL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=3688-3699&author=R.+T.+Nittaauthor=S.+Gholaminauthor=A.+H.+Ferozeauthor=M.+Agarwalauthor=S.+H.+Cheshierauthor=S.+S.+Mitraauthor=G.+Li&title=Casein+kinase+2%CE%B1+regulates+glioblastoma+brain+tumor-initiating+cell+growth+through+the+%CE%B2-catenin+pathway&doi=10.1038%2Fonc.2014.299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathway</span></div><div class="casAuthors">Nitta, R. T.; Gholamin, S.; Feroze, A. H.; Agarwal, M.; Cheshier, S. H.; Mitra, S. S.; Li, G.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3688-3699</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glioblastoma (GBM) is the most common and fatal primary brain tumor in humans, and it is essential that new and better therapies are developed to treat this disease.  Previous research suggests that casein kinase 2 (CK2) may be a promising therapeutic target for GBMs.  CK2 has enhanced expression or activity in numerous cancers, including GBM, and it has been demonstrated that inhibitors of CK2 regressed tumor growth in GBM xenograft mouse models.  Our studies demonstrate that the CK2 subunit, CK2α, is overexpressed in and has an important role in regulating brain tumor-initiating cells (BTIC) in GBM.  Initial studies showed that two GBM cell lines (U87-MG and U138) transduced with CK2α had enhanced proliferation and anchorage-independent growth.  Inhibition of CKα using siRNA or small-mol. inhibitors (TBBz, CX-4945) reduced cell growth, decreased tumor size, and increased survival rates in GBM xenograft mouse models.  We also verified that inhibition of CK2α decreased the activity of a well-known GBM-initiating cell regulator, β-catenin.  Loss of CK2α decreased two β-catenin-regulated genes that are involved in GBM-initiating cell growth, OCT4 and NANOG.  To det. the importance of CK2α in GBM stem cell maintenance, we reduced CK2α activity in primary GBM samples and tumor spheres derived from GBM patients.  We discovered that loss of CK2α activity reduced the sphere-forming capacity of BTIC and decreased numerous GBM stem cell markers, including CD133, CD90, CD49f and A2B5.  Our study suggests that CK2α is involved in GBM tumorigenesis by maintaining BTIC through the regulation of β-catenin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcrw3mE50HGLVg90H21EOLACvtfcHk0lhXHAtLa23rzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyhtL7L&md5=892bcf619d64a1a0752beb8cd720814a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fonc.2014.299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2014.299%26sid%3Dliteratum%253Aachs%26aulast%3DNitta%26aufirst%3DR.%2BT.%26aulast%3DGholamin%26aufirst%3DS.%26aulast%3DFeroze%26aufirst%3DA.%2BH.%26aulast%3DAgarwal%26aufirst%3DM.%26aulast%3DCheshier%26aufirst%3DS.%2BH.%26aulast%3DMitra%26aufirst%3DS.%2BS.%26aulast%3DLi%26aufirst%3DG.%26atitle%3DCasein%2520kinase%25202%25CE%25B1%2520regulates%2520glioblastoma%2520brain%2520tumor-initiating%2520cell%2520growth%2520through%2520the%2520%25CE%25B2-catenin%2520pathway%26jtitle%3DOncogene%26date%3D2015%26volume%3D34%26spage%3D3688%26epage%3D3699%26doi%3D10.1038%2Fonc.2014.299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donella-Deana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzzene, M.</span></span> <span> </span><span class="NLM_article-title">Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e49193</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0049193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1371%2Fjournal.pone.0049193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=23145120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCju7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=S.+Zaninauthor=C.+Borgoauthor=C.+Girardiauthor=S.+E.+O%E2%80%99Brienauthor=Y.+Miyataauthor=L.+A.+Pinnaauthor=A.+Donella-Deanaauthor=M.+Ruzzene&title=Effects+of+the+CK2+inhibitors+CX-4945+and+CX-5011+on+drug-resistant+cells&doi=10.1371%2Fjournal.pone.0049193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells</span></div><div class="casAuthors">Zanin, Sofia; Borgo, Christian; Girardi, Cristina; O'Brien, Sean E.; Miyata, Yoshihiko; Pinna, Lorenzo A.; Donella-Deana, Arianna; Ruzzene, Maria</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e49193</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">CK2 is a pleiotropic protein kinase, which regulates many survival pathways and plays a global anti-apoptotic function.  It is highly expressed in tumor cells, and is presently considered a promising therapeutic target.  Among the many inhibitors available for this kinase, the recently developed CX-4945 and CX-5011 have proved to be very potent, selective and effective in inducing cell death in tumor cells; CX-4945 has recently entered clin. trials.  However, no data are available on the efficacy of these compds. to overcome drug resistance, a major reasons of cancer therapy failure.  Here we address this point, by studying their effects in several tumor cell lines, each available as variant R resistant to drug-induced apoptosis, and normal-sensitive variant S.  We found that the inhibition of endogenous CK2 was very similar in S and R treated cells, with more than 50% CK2 activity redn. at sub-micromolar concns. of CX-4945 and CX-5011.  A consequent apoptotic response was induced both in S and R variants of each pairs.  Moreover, the combined treatment of CX-4945 plus vinblastine was able to sensitize to vinblastine R cells that are otherwise almost insensitive to this conventional antitumor drug.  Consistently, doxorubicin accumulation in multidrug resistant (MDR) cells was greatly increased by CX-4945.  In summary, we demonstrated that all the R variants are sensitive to CX-4945 and CX-5011; since some of the treated R lines express the extrusion pump Pgp, often responsible of the MDR phenotype, we can also conclude that the two inhibitors can successfully overcome the MDR phenomenon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMN0ukrWreobVg90H21EOLACvtfcHk0lgRT1VX_O-OoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCju7fK&md5=7586f90184c89ce05f94a83ed126b93a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0049193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0049193%26sid%3Dliteratum%253Aachs%26aulast%3DZanin%26aufirst%3DS.%26aulast%3DBorgo%26aufirst%3DC.%26aulast%3DGirardi%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BE.%26aulast%3DMiyata%26aufirst%3DY.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26aulast%3DDonella-Deana%26aufirst%3DA.%26aulast%3DRuzzene%26aufirst%3DM.%26atitle%3DEffects%2520of%2520the%2520CK2%2520inhibitors%2520CX-4945%2520and%2520CX-5011%2520on%2520drug-resistant%2520cells%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0049193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litchfield, D. W.</span></span> <span> </span><span class="NLM_article-title">Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1784</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2007.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2Fj.bbapap.2007.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=17931986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlCjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1784&publication_year=2008&pages=33-47&author=J.+S.+Duncanauthor=D.+W.+Litchfield&title=Too+much+of+a+good+thing%3A+the+role+of+protein+kinase+CK2+in+tumorigenesis+and+prospects+for+therapeutic+inhibition+of+CK2&doi=10.1016%2Fj.bbapap.2007.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Too much of a good thing: The role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2</span></div><div class="casAuthors">Duncan, James S.; Litchfield, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1784</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-47</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  CK2 is a highly conserved protein serine/threonine kinase that is ubiquitously distributed in eukaryotes, constitutively active and has been implicated in multiple cellular functions, as well as in tumorigenesis and transformation.  Elevated CK2 activity has been assocd. with the malignant transformation of several tissues and is assocd. with aggressive tumor behavior.  While the precise roles of CK2 in tumorigenesis remain incompletely understood, mounting evidence suggests a role for CK2 in the protection of cells from apoptosis via the regulation of tumor suppressor and oncogene activity.  Consequently, CK2 has emerged as a potential therapeutic target, and strategies to inhibit CK2 have been ongoing in pre-clin. trials.  This review will focus on published evidence highlighting the mol. mechanisms by which CK2 functions in the promotion of tumorigenesis, as well as review current strategies being used to inhibit CK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1OxaWc4qFxrVg90H21EOLACvtfcHk0lgRT1VX_O-OoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlCjsg%253D%253D&md5=eb3e72e4aeb2e192122002e902ee9d7b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2007.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2007.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DDuncan%26aufirst%3DJ.%2BS.%26aulast%3DLitchfield%26aufirst%3DD.%2BW.%26atitle%3DToo%2520much%2520of%2520a%2520good%2520thing%253A%2520the%2520role%2520of%2520protein%2520kinase%2520CK2%2520in%2520tumorigenesis%2520and%2520prospects%2520for%2520therapeutic%2520inhibition%2520of%2520CK2%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2008%26volume%3D1784%26spage%3D33%26epage%3D47%26doi%3D10.1016%2Fj.bbapap.2007.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Small molecule modulators targeting protein kinase CK1 and CK2</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">111581</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2Fj.ejmech.2019.111581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=31400711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFKjt7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2019&pages=111581&author=Y.+Qiaoauthor=T.+Chenauthor=H.+Yangauthor=Y.+Chenauthor=H.+Linauthor=W.+Quauthor=F.+Fengauthor=W.+Liuauthor=Q.+Guoauthor=Z.+Liuauthor=H.+Sun&title=Small+molecule+modulators+targeting+protein+kinase+CK1+and+CK2&doi=10.1016%2Fj.ejmech.2019.111581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule modulators targeting protein kinase CK1 and CK2</span></div><div class="casAuthors">Qiao, Yuting; Chen, Tingkai; Yang, Hongyu; Chen, Yao; Lin, Hongzhi; Qu, Wei; Feng, Feng; Liu, Wenyuan; Guo, Qinglong; Liu, Zongliang; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111581</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Casein kinase (CK) is a type of conserved serine/threonine protein kinase that phosphorylates many important proteins in body.  Researchers found that CK is involved in a variety of signaling pathways, and also plays an important role in inflammation, cancer, and nervous system diseases.  Thus, it is considered to be a promising target for the treatment of related diseases.  Many CK small mol. inhibitors have been reported so far, and most are ATP competitive inhibitors.  However, these CK inhibitors lack the basic properties required for in vivo use, such as selectivity, cell permeability, metabolic stability, correct pharmacokinetic characteristics, and cellular environment.  But small mol. inhibitors still have an advantage in drug research due to their controllable pharmacol. and pharmacokinetic properties.  CX-4945 discovered by Cylene Pharmaceutical is the only one CK2 inhibitor entering into Phase II clin. trials till now.  In recent years, significant advances have been made in the design of non-competitive inhibitors of CK and in the application of multi-target inhibition strategies.  Here, we review the published CK inhibitors and analyze their structure-activity relationships (SAR).  We also summarized the eutectic structure with identified hot spots to provide a ref. for future drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIgjpzLBZU1rVg90H21EOLACvtfcHk0lgRT1VX_O-OoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFKjt7%252FN&md5=95b54cedad246ee9c0784e997194b4ea</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111581%26sid%3Dliteratum%253Aachs%26aulast%3DQiao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DQu%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DSmall%2520molecule%2520modulators%2520targeting%2520protein%2520kinase%2520CK1%2520and%2520CK2%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D181%26spage%3D111581%26doi%3D10.1016%2Fj.ejmech.2019.111581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trembley, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, K.</span></span> <span> </span><span class="NLM_article-title">Protein kinase CK2 in health and disease: CK2: a key player in cancer biology</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1858</span>– <span class="NLM_lpage">1867</span>, <span class="refDoi"> DOI: 10.1007/s00018-009-9154-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1007%2Fs00018-009-9154-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=19387548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsVGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2009&pages=1858-1867&author=J.+H.+Trembleyauthor=G.+Wangauthor=G.+Ungerauthor=J.+Slatonauthor=K.+Ahmed&title=Protein+kinase+CK2+in+health+and+disease%3A+CK2%3A+a+key+player+in+cancer+biology&doi=10.1007%2Fs00018-009-9154-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">CK2: a key player in cancer biology</span></div><div class="casAuthors">Trembley, J. H.; Wang, G.; Unger, G.; Slaton, J.; Ahmed, K.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">11-12</span>),
    <span class="NLM_cas:pages">1858-1867</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  Elevated levels of protein kinase CK2 (formerly casein kinase 2 or II) have long been assocd. with increased cell growth and proliferation both in normal and cancer cells.  The ability of CK2 to also act as a potent suppressor of apoptosis offers an important link to its involvement in cancer since deregulation of both cell proliferation and apoptosis are among the key features of cancer cell biol.  Dysregulated CK2 may impact both of these processes in cancer cells.  All cancers that were examd. show increased CK2 expression, which may also relate to prognosis.  The extensive involvement of CK2 in cancer derives from its impact on diverse mol. pathways controlling cell proliferation and cell death.  Downregulation of CK2 by various approaches results in induction of apoptosis in cultured cell and xenograft cancer models suggesting its potential as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5aEwY88dKgLVg90H21EOLACvtfcHk0ljluhIYiuPUFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsVGjs7g%253D&md5=2b39fc769c570871f2769d3668c53253</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs00018-009-9154-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-009-9154-y%26sid%3Dliteratum%253Aachs%26aulast%3DTrembley%26aufirst%3DJ.%2BH.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DUnger%26aufirst%3DG.%26aulast%3DSlaton%26aufirst%3DJ.%26aulast%3DAhmed%26aufirst%3DK.%26atitle%3DProtein%2520kinase%2520CK2%2520in%2520health%2520and%2520disease%253A%2520CK2%253A%2520a%2520key%2520player%2520in%2520cancer%2520biology%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2009%26volume%3D66%26spage%3D1858%26epage%3D1867%26doi%3D10.1007%2Fs00018-009-9154-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruzzene, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, L. A.</span></span> <span> </span><span class="NLM_article-title">Addiction to protein kinase CK2: a common denominator of diverse cancer cells?</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1804</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">504</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2009.07.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2Fj.bbapap.2009.07.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=19665589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1ynu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1804&publication_year=2010&pages=499-504&author=M.+Ruzzeneauthor=L.+A.+Pinna&title=Addiction+to+protein+kinase+CK2%3A+a+common+denominator+of+diverse+cancer+cells%3F&doi=10.1016%2Fj.bbapap.2009.07.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Addiction to protein kinase CK2: A common denominator of diverse cancer cells?</span></div><div class="casAuthors">Ruzzene, Maria; Pinna, Lorenzo A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1804</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">499-504</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  At variance with most oncogenic protein kinases whose malignancy is generally due to genetic alterations conferring constitutive activity, CK2 is a highly pleiotropic Ser/Thr protein kinase naturally endowed with constitutive activity and lacking gain-of-function mutants.  Nonetheless CK2 is abnormally elevated in a wide variety of tumors and there is strong evidence that it operates as a cancer driver by creating a cellular environment favorable to neoplasia: notably, CK2 plays a global role as an anti-apoptotic and pro-survival agent, it enhances the multi-drug resistance (MDR) phenotype, it assists the chaperone machinery which protects the "onco-kinome" and it promotes neo-angiogenesis.  Based on this scenario we propose that the implication of CK2 in neoplasia is an example of "non oncogene addiction", i.e. over reliance of the perturbed cellular signaling network on high CK2 level for its own maintenance.  Consistent with this, an ample spectrum of diverse types of cancer cells have been already shown to rely on high CK2 level for their survival, as judged from their response to specific CK2 inhibitors and silencing of endogenous CK2 catalytic subunits.  Remarkably, among these are cells whose cancer phenotype arises from the genetic alteration of onco-kinases (e.g. Abl and Alk) different from CK2 and insensitive to the CK2 inhibitors used in those expts.  Based on these premises, CK2 could represent a "multi-purpose" target for the treatment of different kinds of tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryaRBb7mWsWrVg90H21EOLACvtfcHk0ljluhIYiuPUFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1ynu7k%253D&md5=a8088e387d13469774ce9aef315d0ae5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2009.07.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2009.07.018%26sid%3Dliteratum%253Aachs%26aulast%3DRuzzene%26aufirst%3DM.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26atitle%3DAddiction%2520to%2520protein%2520kinase%2520CK2%253A%2520a%2520common%2520denominator%2520of%2520diverse%2520cancer%2520cells%253F%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2010%26volume%3D1804%26spage%3D499%26epage%3D504%26doi%3D10.1016%2Fj.bbapap.2009.07.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perea, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baladrón, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzuela, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, Y.</span></span> <span> </span><span class="NLM_article-title">CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation</span>. <i>Semin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1053/j.seminoncol.2018.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1053%2Fj.seminoncol.2018.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=30318085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtV2ltr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2018&pages=58-67&author=S.+E.+Pereaauthor=I.+Baladr%C3%B3nauthor=C.+Valenzuelaauthor=Y.+Perera&title=CIGB-300%3A+A+peptide-based+drug+that+impairs+the+Protein+Kinase+CK2-mediated+phosphorylation&doi=10.1053%2Fj.seminoncol.2018.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation</span></div><div class="casAuthors">Perea, Silvio E.; Baladron, Idania; Valenzuela, Carmen; Perera, Yasser</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">58-67</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Protein kinase CK2, formerly referred to as casein kinase II, is a serine/threonine kinase often found overexpressed in solid tumors and hematol. malignancies that phosphorylates many substrates integral to the hallmarks of cancer.  CK2 has emerged as a viable oncol. target having been exptl. validated with different kinase inhibitors, including small mol. ATP-competitors, synthetic peptides, and antisense oligonucleotides.  To date only two CK2 inhibitors, CIGB-300 and CX-4945, have entered the clinic in phase 1-2 trials.  This review provides information on CIGB-300, a cell-permeable cyclic peptide that inhibits CK2-mediated phosphorylation by targeting the substrate phosphoacceptor domain.  We review data that support the concept of CK2 as an anticancer target, address the mechanism of action, and summarize preclin. studies showing antiangiogenic and antimetastatic effects as well as synergism with anticancer drugs in preclin. models.  We also summarize early clin. research (phase 1/2 trials) of CIGB-300 in cervical cancer, including data in combination with chemoradiotherapy.  The clin. data demonstrate the safety, tolerability, and clin. effects of intratumoral injections of CIGB-300 and provide the foundation for future phase 3 clin. trials in locally advanced cervical cancer in combination with std. chemoradiotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI8SBguqIb-7Vg90H21EOLACvtfcHk0ljrlLgwaWTzAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtV2ltr3F&md5=ce3365d0035b44b315497a0f1ec57e8c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2018.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2018.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DPerea%26aufirst%3DS.%2BE.%26aulast%3DBaladr%25C3%25B3n%26aufirst%3DI.%26aulast%3DValenzuela%26aufirst%3DC.%26aulast%3DPerera%26aufirst%3DY.%26atitle%3DCIGB-300%253A%2520A%2520peptide-based%2520drug%2520that%2520impairs%2520the%2520Protein%2520Kinase%2520CK2-mediated%2520phosphorylation%26jtitle%3DSemin.%2520Oncol.%26date%3D2018%26volume%3D45%26spage%3D58%26epage%3D67%26doi%3D10.1053%2Fj.seminoncol.2018.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Fusco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brear, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iegre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiou, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sore, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyvönen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3471</span>– <span class="NLM_lpage">3482</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.04.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2Fj.bmc.2017.04.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=28495381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntlWktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=3471-3482&author=C.+de%0AFuscoauthor=P.+Brearauthor=J.+Iegreauthor=K.+H.+Georgiouauthor=H.+F.+Soreauthor=M.+Hyv%C3%B6nenauthor=D.+R.+Spring&title=A+fragment-based+approach+leading+to+the+discovery+of+a+novel+binding+site+and+the+selective+CK2+inhibitor+CAM4066&doi=10.1016%2Fj.bmc.2017.04.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066</span></div><div class="casAuthors">De Fusco, Claudia; Brear, Paul; Iegre, Jessica; Georgiou, Kathy Hadje; Sore, Hannah F.; Hyvonen, Marko; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3471-3482</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recently the authors reported the discovery of a potent and selective CK2α inhibitor CAM4066.  This compd. inhibits CK2 activity by exploiting a pocket located outside the ATP binding site (αD pocket).  Here the authors describe in detail the journey that led to the discovery of CAM4066 using the challenging fragment linking strategy.  Specifically, the authors aimed to develop inhibitors by linking a high-affinity fragment anchored in the αD site to a weakly binding warhead fragment occupying the ATP site.  Moreover, the authors describe the remarkable impact that mol. modeling had on the development of this novel chem. tool.  The work described herein shows potential for the development of a novel class of CK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-es_MXrRt5bVg90H21EOLACvtfcHk0ljrlLgwaWTzAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntlWktbc%253D&md5=2c4bf2e6b0528149dc09d04badfdeab3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.04.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.04.037%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BFusco%26aufirst%3DC.%26aulast%3DBrear%26aufirst%3DP.%26aulast%3DIegre%26aufirst%3DJ.%26aulast%3DGeorgiou%26aufirst%3DK.%2BH.%26aulast%3DSore%26aufirst%3DH.%2BF.%26aulast%3DHyv%25C3%25B6nen%26aufirst%3DM.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DA%2520fragment-based%2520approach%2520leading%2520to%2520the%2520discovery%2520of%2520a%2520novel%2520binding%2520site%2520and%2520the%2520selective%2520CK2%2520inhibitor%2520CAM4066%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D3471%26epage%3D3482%26doi%3D10.1016%2Fj.bmc.2017.04.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic studies unveiled the drug-drug interaction between trans-2,3,5,4′-tetrahydroxystilbene-2-O-β-d-glucopyranoside and emodin that may contribute to the idiosyncratic hepatotoxicity of polygoni multiflori radix</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">672</span>– <span class="NLM_lpage">680</span>, <span class="refDoi"> DOI: 10.1016/j.jpba.2018.11.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2Fj.jpba.2018.11.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=30472586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ylsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2019&pages=672-680&author=Y.+Xingauthor=L.+Wangauthor=C.+Wangauthor=Y.+Zhangauthor=Y.+Zhangauthor=L.+Huauthor=X.+Gaoauthor=L.+Hanauthor=W.+Yang&title=Pharmacokinetic+studies+unveiled+the+drug-drug+interaction+between+trans-2%2C3%2C5%2C4%E2%80%B2-tetrahydroxystilbene-2-O-%CE%B2-d-glucopyranoside+and+emodin+that+may+contribute+to+the+idiosyncratic+hepatotoxicity+of+polygoni+multiflori+radix&doi=10.1016%2Fj.jpba.2018.11.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic studies unveiled the drug-drug interaction between trans-2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucopyranoside and emodin that may contribute to the idiosyncratic hepatotoxicity of Polygoni Multiflori Radix</span></div><div class="casAuthors">Xing, Yanchao; Wang, Linlin; Wang, Chenxi; Zhang, Youcai; Zhang, Yi; Hu, Limin; Gao, Xiumei; Han, Lifeng; Yang, Wenzhi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">672-680</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Polygoni Multiflori Radix (PMR) has been a reputable tonifying traditional Chinese medicine for a long history.  However, clin. side effects regarding its idiosyncratic hepatotoxicity are occasionally reported.  The contg. anthraquinones, particularly emodin, could cause liver injury in both in vitro and in vivo expts.  It is well-known that some compds. could influence other compds.' pharmacokinetic parameters significantly.  In this work, the influence of trans-2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucopyranoside (TSG) on the pharmacokinetic behavior of emodin in rats was evaluated by an ultra-high performance liq. chromatog./triple quadrupole mass spectrometry (UHPLC/MS-MS) approach.  Pharmacokinetic parameters of emodin, PMR ext., and TSG-free PMR ext. (prepd. by a component "knock-out" strategy with TSG eliminated), in rats after one-day and seven-day administration were detd. and compared.  We found that, after seven-day administration of the whole PMR ext. (rather than TSG-free ext.), emodin in rats was accumulated.  And accordingly, the exposure of emodin in rats pre-treated with single TSG for seven days could be significantly enhanced.  The results indicate that TSG was able to accelerate the exposure and metab. of emodin.  The effect of TSG on the metabolic activities of cytochrome P 450 enzymes was further assessed by an LC-MS cocktail method.  The accelerated exposure and metab. of emodin could result from the up-regulation activity of CYP450s, in particular CYP1A2 isoenzyme.  The findings obtained in this work firstly unveiled DDI between TSG and emodin in the administration of PMR, thus may provide a basis for unveiling the underlying mechanism of PMR-induced liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC4F4HUD-t87Vg90H21EOLACvtfcHk0ljrlLgwaWTzAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ylsbrN&md5=3ec3f487fac3c68b09a227d7d3d177a9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2018.11.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2018.11.034%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DW.%26atitle%3DPharmacokinetic%2520studies%2520unveiled%2520the%2520drug-drug%2520interaction%2520between%2520trans-2%252C3%252C5%252C4%25E2%2580%25B2-tetrahydroxystilbene-2-O-%25CE%25B2-d-glucopyranoside%2520and%2520emodin%2520that%2520may%2520contribute%2520to%2520the%2520idiosyncratic%2520hepatotoxicity%2520of%2520polygoni%2520multiflori%2520radix%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2019%26volume%3D164%26spage%3D672%26epage%3D680%26doi%3D10.1016%2Fj.jpba.2018.11.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buontempo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCubrey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzzene, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappellini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelisti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelisti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barata, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A. M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targeting of CK2 in acute and chronic leukemias</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1038%2Fleu.2017.301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=28951560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtlShsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=1-10&author=F.+Buontempoauthor=J.+A.+McCubreyauthor=E.+Orsiniauthor=M.+Ruzzeneauthor=A.+Cappelliniauthor=A.+Lonettiauthor=C.+Evangelistiauthor=F.+Chiariniauthor=C.+Evangelistiauthor=J.+T.+Barataauthor=A.+M.+Martelli&title=Therapeutic+targeting+of+CK2+in+acute+and+chronic+leukemias&doi=10.1038%2Fleu.2017.301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of CK2 in acute and chronic leukemias</span></div><div class="casAuthors">Buontempo, F.; McCubrey, J. A.; Orsini, E.; Ruzzene, M.; Cappellini, A.; Lonetti, A.; Evangelisti, C.; Chiarini, F.; Evangelisti, C.; Barata, J. T.; Martelli, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">CK2 is a ubiquitously expressed, constitutively active Ser/Thr protein kinase, which is considered the most pleiotropic protein kinase in the human kinome.  Such a pleiotropy explains the involvement of CK2 in many cellular events.  However, its predominant roles are stimulation of cell growth and prevention of apoptosis.  High levels of CK2 mRNA and protein are assocd. with CK2 pathol. functions in human cancers.  Over the last decade, basic and translational studies have provided evidence of CK2 as a pivotal mol. driving the growth of different blood malignancies.  CK2 overexpression has been demonstrated in nearly all the types of hematol. cancers, including acute and chronic leukemias, where CK2 is a key regulator of signaling networks crit. for cell proliferation, survival and drug resistance.  The findings that emerged from these studies suggest that CK2 could be a valuable therapeutic target in leukemias and supported the initiation of clin. trials using CK2 antagonists.  In this review, we summarize the recent advances on the understanding of the signaling pathways involved in CK2 inhibition-mediated effects with a particular emphasis on the combinatorial use of CK2 inhibitors as novel therapeutic strategies for treating both acute and chronic leukemia patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1J7PM7mhdwLVg90H21EOLACvtfcHk0ljk2NFtMmQt-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtlShsw%253D%253D&md5=072c052cf8a42b610a533ae0048510fb</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.301%26sid%3Dliteratum%253Aachs%26aulast%3DBuontempo%26aufirst%3DF.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26aulast%3DOrsini%26aufirst%3DE.%26aulast%3DRuzzene%26aufirst%3DM.%26aulast%3DCappellini%26aufirst%3DA.%26aulast%3DLonetti%26aufirst%3DA.%26aulast%3DEvangelisti%26aufirst%3DC.%26aulast%3DChiarini%26aufirst%3DF.%26aulast%3DEvangelisti%26aufirst%3DC.%26aulast%3DBarata%26aufirst%3DJ.%2BT.%26aulast%3DMartelli%26aufirst%3DA.%2BM.%26atitle%3DTherapeutic%2520targeting%2520of%2520CK2%2520in%2520acute%2520and%2520chronic%2520leukemias%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D1%26epage%3D10%26doi%3D10.1038%2Fleu.2017.301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erdreich-Epstein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groshen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garlich, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durden, D. L.</span></span> <span> </span><span class="NLM_article-title">Association of high microvessel αvβ3 and low PTEN with poor outcome in Stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">52193</span>– <span class="NLM_lpage">52210</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.13386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.18632%2Foncotarget.13386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=28881723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A280%3ADC%252BC1cbls1ylsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=52193-52210&author=A.+Erdreich-Epsteinauthor=L.+R.+Singhauthor=S.+Joshiauthor=F.+M.+Vegaauthor=P.+Guoauthor=J.+Xuauthor=S.+Groshenauthor=W.+Yeauthor=M.+Millardauthor=M.+Campanauthor=G.+Moralesauthor=J.+R.+Garlichauthor=P.+W.+Lairdauthor=R.+C.+Seegerauthor=H.+Shimadaauthor=D.+L.+Durden&title=Association+of+high+microvessel+%CE%B1v%CE%B23+and+low+PTEN+with+poor+outcome+in+Stage+3+neuroblastoma%3A+rationale+for+using+first+in+class+dual+PI3K%2FBRD4+inhibitor%2C+SF1126&doi=10.18632%2Foncotarget.13386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126</span></div><div class="casAuthors">Erdreich-Epstein Anat; Guo Pinzheng; Xu Jingying; Millard Melissa; Seeger Robert C; Erdreich-Epstein Anat; Shimada Hiroyuki; Singh Alok R; Joshi Shweta; Vega Francisco M; Durden Donald L; Vega Francisco M; Groshen Susan; Ye Wei; Campan Mihaela; Laird Peter W; Morales Guillermo; Garlich Joseph R; Durden Donald L; Laird Peter W; Laird Peter W; Durden Donald L</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">52193-52210</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Neuroblastoma (NB) is the most common extracranial solid tumor in children.  Our previous studies showed that the angiogenic integrin αvβ3 was increased in high-risk metastatic (stage 4) NB compared with localized neuroblastomas.  Herein, we show that integrin αvβ3 was expressed on 68% of microvessels in MYCN-amplified stage 3 neuroblastomas, but only on 34% (means) in MYCN-non-amplified tumors (p < 0.001; n = 54).  PTEN, a tumor suppressor involved in αvβ3 signaling, was expressed in neuroblastomas either diffusely, focally or not at all (immunohistochemistry).  Integrin αvβ3 was expressed on 60% of tumor microvessels when PTEN was negative or focal, as compared to 32% of microvessels in tumors with diffuse PTEN expression (p < 0.001).  In a MYCN transgenic mouse model, loss of one allele of PTEN promoted tumor growth, illustrating the potential role of PTEN in neuroblastoma pathogenesis.  Interestingly, we report the novel dual PI-3K/BRD4 activity of SF1126 (originally developed as an RGD-conjugated pan PI3K inhibitor).  SF1126 inhibits BRD4 bromodomain binding to acetylated lysine residues with histone H3 as well as PI3K activity in the MYCN amplified neuroblastoma cell line IMR-32.  Moreover, SF1126 suppressed MYCN expression and MYCN associated transcriptional activity in IMR-32 and CHLA136, resulting in overall decrease in neuroblastoma cell viability.  Finally, treatment of neuroblastoma tumors with SF1126 inhibited neuroblastoma growth in vivo.  These data suggest integrin αvβ3, MYCN/BRD4 and PTEN/PI3K/AKT signaling as biomarkers and hence therapeutic targets in neuroblastoma and support testing of the RGD integrin αvβ3-targeted PI-3K/BRD4 inhibitor, SF1126 as a therapeutic strategy in this specific subgroup of high risk neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQyuSQS7mkcmkBuFdjgVNKSfW6udTcc2ebL8blRITkVB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbls1ylsg%253D%253D&md5=87ecbd21fda42aa68e2061a405ede51c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13386%26sid%3Dliteratum%253Aachs%26aulast%3DErdreich-Epstein%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DL.%2BR.%26aulast%3DJoshi%26aufirst%3DS.%26aulast%3DVega%26aufirst%3DF.%2BM.%26aulast%3DGuo%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DGroshen%26aufirst%3DS.%26aulast%3DYe%26aufirst%3DW.%26aulast%3DMillard%26aufirst%3DM.%26aulast%3DCampan%26aufirst%3DM.%26aulast%3DMorales%26aufirst%3DG.%26aulast%3DGarlich%26aufirst%3DJ.%2BR.%26aulast%3DLaird%26aufirst%3DP.%2BW.%26aulast%3DSeeger%26aufirst%3DR.%2BC.%26aulast%3DShimada%26aufirst%3DH.%26aulast%3DDurden%26aufirst%3DD.%2BL.%26atitle%3DAssociation%2520of%2520high%2520microvessel%2520%25CE%25B1v%25CE%25B23%2520and%2520low%2520PTEN%2520with%2520poor%2520outcome%2520in%2520Stage%25203%2520neuroblastoma%253A%2520rationale%2520for%2520using%2520first%2520in%2520class%2520dual%2520PI3K%252FBRD4%2520inhibitor%252C%2520SF1126%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D52193%26epage%3D52210%26doi%3D10.18632%2Foncotarget.13386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zakharia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borad, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, L. R.</span></span> <span> </span><span class="NLM_article-title">Preclinical in vitro and in vivo evidence of an antitumor effect of CX-4945, a casein kinase II inhibitor, in cholangiocarcinoma</span>. <i>Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1016/j.tranon.2018.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2Fj.tranon.2018.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=30316146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A280%3ADC%252BB3czovVChsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=143-153&author=K.+Zakhariaauthor=K.+Miyabeauthor=Y.+Wangauthor=D.+Wuauthor=C.+D.+Moserauthor=M.+J.+Boradauthor=L.+R.+Roberts&title=Preclinical+in+vitro+and+in+vivo+evidence+of+an+antitumor+effect+of+CX-4945%2C+a+casein+kinase+II+inhibitor%2C+in+cholangiocarcinoma&doi=10.1016%2Fj.tranon.2018.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma</span></div><div class="casAuthors">Zakharia Kais; Miyabe Katsuyuki; Wu Dehai; Moser Catherine D; Wang Yu; Borad Mitesh J; Roberts Lewis R</div><div class="citationInfo"><span class="NLM_cas:title">Translational oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">143-153</span>
        ISSN:<span class="NLM_cas:issn">1936-5233</span>.
    </div><div class="casAbstract">PURPOSE:  We investigated the antitumor effect of the casein kinase II (CK2) inhibitor CX-4945 on cholangiocarcinoma (CCA).  METHODS:  We assessed the effect of CX-4945 alone and/or in combination with gemcitabine and cisplatin on cell viability, colony formation, and apoptosis of CCA cell lines and on in vivo growth of HuCCT1 xenografts.  RESULTS:  CX-4945 dose-dependently decreased viability of HuCCT1, EGI-1, and Liv27 and decreased phospho-AKT/total AKT and phospho-PTEN/total PTEN ratios.  CX-4945 significantly increased caspase 3/7 activity in a dose- and time-dependent manner.  CX-4945 significantly enhanced the effect of gemcitabine or cisplatin on HuCCT1, EGI-1, and Liv27 cells and inhibited the phosphorylation of DNA repairing enzymes XRCC1 and MDC1.  Further, CX-4945 alone significantly inhibited growth of HuCCT1 mouse xenograft tumors.  Combining CX-4945 with gemcitabine and cisplatin was more potent than CX-4945 alone or gemcitabine/cisplatin.  The effect of CX-4945 on cell proliferation, apoptosis, the PI3K/AKT pathway, and DNA repair was confirmed in the mouse xenografts.  CONCLUSION:  CX-4945 has an antiproliferative effect on CCA and enhances the effect of gemcitabine and cisplatin through its inhibitory effect on the PI3K/AKT pathway and DNA repair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThvXSGZdJlpxKDYG3bNImrfW6udTcc2eaodqa8BFtBMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czovVChsQ%253D%253D&md5=88f383f2a3aced740607c4b76bf6fd11</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.tranon.2018.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tranon.2018.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DZakharia%26aufirst%3DK.%26aulast%3DMiyabe%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DMoser%26aufirst%3DC.%2BD.%26aulast%3DBorad%26aufirst%3DM.%2BJ.%26aulast%3DRoberts%26aufirst%3DL.%2BR.%26atitle%3DPreclinical%2520in%2520vitro%2520and%2520in%2520vivo%2520evidence%2520of%2520an%2520antitumor%2520effect%2520of%2520CX-4945%252C%2520a%2520casein%2520kinase%2520II%2520inhibitor%252C%2520in%2520cholangiocarcinoma%26jtitle%3DTransl.%2520Oncol.%26date%3D2019%26volume%3D12%26spage%3D143%26epage%3D153%26doi%3D10.1016%2Fj.tranon.2018.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iegre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brear, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Fusco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sore, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyvönen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">Second-generation CK2α inhibitors targeting the αD pocket</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3041</span>– <span class="NLM_lpage">3049</span>, <span class="refDoi"> DOI: 10.1039/C7SC05122K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1039%2FC7SC05122K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=29732088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFGls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=3041-3049&author=J.+Iegreauthor=P.+Brearauthor=C.+de+Fuscoauthor=M.+Yoshidaauthor=S.+L.+Mitchellauthor=M.+Rossmannauthor=L.+Carroauthor=H.+F.+Soreauthor=M.+Hyv%C3%B6nenauthor=D.+R.+Spring&title=Second-generation+CK2%CE%B1+inhibitors+targeting+the+%CE%B1D+pocket&doi=10.1039%2FC7SC05122K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation CK2α inhibitors targeting the αD pocket</span></div><div class="casAuthors">Iegre, Jessica; Brear, Paul; De Fusco, Claudia; Yoshida, Masao; Mitchell, Sophie L.; Rossmann, Maxim; Carro, Laura; Sore, Hannah F.; Hyvonen, Marko; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3041-3049</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">CK2 is a crit. cell cycle regulator that also promotes various anti-apoptotic mechanisms.  Development of ATP-non-competitive inhibitors of CK2 is a very attractive strategy considering that the ATP binding site is highly conserved among other kinases.  We have previously utilized a pocket outside the active site to develop a novel CK2 inhibitor, CAM4066.  While CAM4066 bound to this new pocket it was also interacting with the ATP site: herein, we describe an example of a CK2α inhibitor that binds completely outside the active site.  This second generation αD-site binding inhibitor, compd. CAM4712 (IC50 = 7μM, GI50 = 10.0 ± 3.6μM), has numerous advantages over the previously reported CAM4066, including a redn. in the no. of rotatable bonds, the absence of amide groups susceptible to the action of proteases and improved cellular permeability.  Unlike with CAM4066, there was no need to facilitate cellular uptake by making a prodrug.  Moreover, CAM4712 displayed no drop off between its ability to inhibit the kinase in vitro (IC50) and the ability to inhibit cell proliferation (GI50).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprPLu-nG6dLLVg90H21EOLACvtfcHk0lhwrpZXDkp_Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFGls7w%253D&md5=4d57e89546e1c7bcac4868e3a02ba2f8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1039%2FC7SC05122K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7SC05122K%26sid%3Dliteratum%253Aachs%26aulast%3DIegre%26aufirst%3DJ.%26aulast%3DBrear%26aufirst%3DP.%26aulast%3Dde%2BFusco%26aufirst%3DC.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DMitchell%26aufirst%3DS.%2BL.%26aulast%3DRossmann%26aufirst%3DM.%26aulast%3DCarro%26aufirst%3DL.%26aulast%3DSore%26aufirst%3DH.%2BF.%26aulast%3DHyv%25C3%25B6nen%26aufirst%3DM.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DSecond-generation%2520CK2%25CE%25B1%2520inhibitors%2520targeting%2520the%2520%25CE%25B1D%2520pocket%26jtitle%3DChem.%2520Sci.%26date%3D2018%26volume%3D9%26spage%3D3041%26epage%3D3049%26doi%3D10.1039%2FC7SC05122K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel function of CX-4945 as a splicing regulator</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e94978</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0094978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1371%2Fjournal.pone.0094978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=24743259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFemurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=H.+Kimauthor=K.+Choiauthor=H.+Kangauthor=S.-Y.+Leeauthor=S.-W.+Chiauthor=M.-S.+Leeauthor=J.+Songauthor=D.+Imauthor=Y.+Choiauthor=S.+Cho&title=Identification+of+a+novel+function+of+CX-4945+as+a+splicing+regulator&doi=10.1371%2Fjournal.pone.0094978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel function of CX-4945 as a splicing regulator</span></div><div class="casAuthors">Kim, Hyeongki; Choi, Kwangman; Kang, Hyunju; Lee, So-Young; Chi, Seung-wook; Lee, Min-sung; Song, Jaehyoung; Im, Donghwa; Choi, Yura; Cho, Sungchan</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e94978/1-e94978/8, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Alternative splicing is a nearly ubiquitous versatile process that controls gene expression and creates numerous protein isoforms with different functions from a single gene.  The significance of alternative splicing has been confirmed by the increasing no. of human diseases that are caused by misregulation of splicing events.  Very few compds., however, have been reported to act as inhibitors of alternative splicing, and their potential clin. use needs to be evaluated.  Here, we report that CX-4945, a previously well-characterized inhibitor of casein kinase 2 (CK2) and a mol. currently in clin. trials (Phase II) for cancer treatment, regulates splicing in mammalian cells in a CK2-independent manner.  Transcriptome-wide anal. using exon array also showed a widespread alteration in alternative splicing of numerous genes.  We found that CX-4945 potently inhibits the Cdc2-like kinases (Clks) in vitro and in turn, leads to suppression of the phosphorylation of serine/arginine-rich (SR) proteins in mammalian cells.  Surprisingly, the overall efficacy of CX-4945 on Clks (IC50 = 3-90 nM) was stronger than that of TG-003, the strongest inhibitor reported to date.  Of the Clks, Clk2 was most strongly inhibited by CX-4945 in an ATP-competitive manner.  Our research revealed an unexpected activity of the drug candidate CX-4945 as a potent splicing modulator and also suggested a potential application for therapy of diseases caused by abnormal splicing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEmZdGtUZUe7Vg90H21EOLACvtfcHk0lhwrpZXDkp_Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFemurzL&md5=5edb2338401d950cddbcba7d35e57c04</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0094978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0094978%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%26aulast%3DChoi%26aufirst%3DK.%26aulast%3DKang%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DS.-Y.%26aulast%3DChi%26aufirst%3DS.-W.%26aulast%3DLee%26aufirst%3DM.-S.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DIm%26aufirst%3DD.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520a%2520novel%2520function%2520of%2520CX-4945%2520as%2520a%2520splicing%2520regulator%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0094978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui-Jain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drygin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streiner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliesath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huser, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proffitt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaebe, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderes, K.</span></span> <span> </span><span class="NLM_article-title">CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">10288</span>– <span class="NLM_lpage">10298</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-1893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1158%2F0008-5472.CAN-10-1893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=21159648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGrt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=10288-10298&author=A.+Siddiqui-Jainauthor=D.+Dryginauthor=N.+Streinerauthor=P.+Chuaauthor=F.+Pierreauthor=S.+E.+O%E2%80%99Brienauthor=J.+Bliesathauthor=M.+Omoriauthor=N.+Huserauthor=C.+Hoauthor=C.+Proffittauthor=M.+K.+Schwaebeauthor=D.+M.+Ryckmanauthor=W.+G.+Riceauthor=K.+Anderes&title=CX-4945%2C+an+orally+bioavailable+selective+inhibitor+of+protein+kinase+CK2%2C+inhibits+prosurvival+and+angiogenic+signaling+and+exhibits+antitumor+efficacy&doi=10.1158%2F0008-5472.CAN-10-1893"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy</span></div><div class="casAuthors">Siddiqui-Jain, Adam; Drygin, Denis; Streiner, Nicole; Chua, Peter; Pierre, Fabrice; O'Brien, Sean E.; Bliesath, Josh; Omori, Mayuko; Huser, Nanni; Ho, Caroline; Proffitt, Chris; Schwaebe, Michael K.; Ryckman, David M.; Rice, William G.; Anderes, Kenna</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10288-10298</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Malignant transformation and maintenance of the malignant phenotype depends on oncogenic and non-oncogenic proteins that are essential to mediate oncogene signaling and to support the altered physiol. demands induced by transformation.  Protein kinase CK2 supports key prosurvival signaling pathways and represents a prototypical non-oncogene.  In this study, we describe CX-4945, a potent and selective orally bioavailable small mol. inhibitor of CK2.  The antiproliferative activity of CX-4945 against cancer cells correlated with expression levels of the CK2α catalytic subunit.  Attenuation of PI3K/Akt signaling by CX-4945 was evidenced by dephosphorylation of Akt on the CK2-specific S129 site and the canonical S473 and T308 regulatory sites.  CX-4945 caused cell-cycle arrest and selectively induced apoptosis in cancer cells relative to normal cells.  In models of angiogenesis, CX-4945 inhibited human umbilical vein endothelial cell migration, tube formation, and blocked CK2-dependent hypoxia-induced factor 1 alpha (HIF-1α) transcription in cancer cells.  When administered orally in murine xenograft models, CX-4945 was well tolerated and demonstrated robust antitumor activity with concomitant redns. of the mechanism-based biomarker phospho-p21 (T145).  The obsd. antiproliferative and anti-angiogenic responses to CX-4945 in tumor cells and endothelial cells collectively illustrate that this compd. exerts its antitumor effects through inhibition of CK2-dependent signaling in multiple pathways.  Finally, CX-4945 is the first orally bioavailable small mol. inhibitor of CK2 to advance into human clin. trials, thereby paving the way for an entirely new class of targeted treatment for cancer.  Cancer Res; 70(24); 10288-98.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8s0Sa3hOwtbVg90H21EOLACvtfcHk0lgso-10LqnYSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGrt7fK&md5=bfcfe06730e099719e752574a6636dfb</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1893%26sid%3Dliteratum%253Aachs%26aulast%3DSiddiqui-Jain%26aufirst%3DA.%26aulast%3DDrygin%26aufirst%3DD.%26aulast%3DStreiner%26aufirst%3DN.%26aulast%3DChua%26aufirst%3DP.%26aulast%3DPierre%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BE.%26aulast%3DBliesath%26aufirst%3DJ.%26aulast%3DOmori%26aufirst%3DM.%26aulast%3DHuser%26aufirst%3DN.%26aulast%3DHo%26aufirst%3DC.%26aulast%3DProffitt%26aufirst%3DC.%26aulast%3DSchwaebe%26aufirst%3DM.%2BK.%26aulast%3DRyckman%26aufirst%3DD.%2BM.%26aulast%3DRice%26aufirst%3DW.%2BG.%26aulast%3DAnderes%26aufirst%3DK.%26atitle%3DCX-4945%252C%2520an%2520orally%2520bioavailable%2520selective%2520inhibitor%2520of%2520protein%2520kinase%2520CK2%252C%2520inhibits%2520prosurvival%2520and%2520angiogenic%2520signaling%2520and%2520exhibits%2520antitumor%2520efficacy%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D10288%26epage%3D10298%26doi%3D10.1158%2F0008-5472.CAN-10-1893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruise, E.</span></span> <span> </span><span class="NLM_article-title">An investigation of the CK2-dependent phosphoproteome using inhibitor refractory CK2-alpha</span>.  <i>Electronic Thesis and Dissertation Repository</i> <span class="NLM_year" style="font-weight: bold;">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=E.+Cruise&title=An+investigation+of+the+CK2-dependent+phosphoproteome+using+inhibitor+refractory+CK2-alpha"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCruise%26aufirst%3DE.%26atitle%3DAn%2520investigation%2520of%2520the%2520CK2-dependent%2520phosphoproteome%2520using%2520inhibitor%2520refractory%2520CK2-alpha%26jtitle%3DElectronic%2520Thesis%2520and%2520Dissertation%2520Repository%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0liHeQkv5XdoEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">The development and therapeutic potential of protein kinase inhibitors</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.1016/S1367-5931(99)80067-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2FS1367-5931%2899%2980067-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10419844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADyaK1MXlt1ejurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1999&pages=459-465&author=P.+Cohen&title=The+development+and+therapeutic+potential+of+protein+kinase+inhibitors&doi=10.1016%2FS1367-5931%2899%2980067-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The development and therapeutic potential of protein kinase inhibitors</span></div><div class="casAuthors">Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">459-465</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Publications</span>)
        </div><div class="casAbstract">A review with 46 refs.  A no. of low-mol.-wt. cell-permeant protein kinase inhibitors have been developed that have the potential for treating a variety of diseases.  The specificity and mechanism of action of several of these drugs has been elucidated and some are undergoing clin. trials in humans.  The role of reversible protein phosphorylation in human diseases (cancer, hypertension, chronic inflammations) and pharmacol. possibilities of its regulation are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgKohAlW0XOrVg90H21EOLACvtfcHk0liHeQkv5XdoEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlt1ejurw%253D&md5=5929d7d26e30df19a3e49f1dd145a1c8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS1367-5931%2899%2980067-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1367-5931%252899%252980067-2%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DThe%2520development%2520and%2520therapeutic%2520potential%2520of%2520protein%2520kinase%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D1999%26volume%3D3%26spage%3D459%26epage%3D465%26doi%3D10.1016%2FS1367-5931%2899%2980067-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asadzadeh, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansoori, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haji-Asgarzadeh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safarzadeh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokhtarzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duijf, P. H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baradaran, B.</span></span> <span> </span><span class="NLM_article-title">microRNAs in cancer stem cells: biology, pathways, and therapeutic opportunities</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">10002</span>– <span class="NLM_lpage">10017</span>, <span class="refDoi"> DOI: 10.1002/jcp.27885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1002%2Fjcp.27885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=30537109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVGmsbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2019&pages=10002-10017&author=Z.+Asadzadehauthor=B.+Mansooriauthor=A.+Mohammadiauthor=M.+Aghajaniauthor=K.+Haji-Asgarzadehauthor=E.+Safarzadehauthor=A.+Mokhtarzadehauthor=P.+H.+G.+Duijfauthor=B.+Baradaran&title=microRNAs+in+cancer+stem+cells%3A+biology%2C+pathways%2C+and+therapeutic+opportunities&doi=10.1002%2Fjcp.27885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">microRNAs in cancer stem cells: Biology, pathways, and therapeutic opportunities</span></div><div class="casAuthors">Asadzadeh, Zahra; Mansoori, Behzad; Mohammadi, Ali; Aghajani, Marjan; Haji-Asgarzadeh, Khalil; Safarzadeh, Elham; Mokhtarzadeh, Ahad; Duijf, Pascal H. G.; Baradaran, Behzad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">10002-10017</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) are a small subpopulation of tumor cells that have been identified in most types of cancer.  Features that distinguish them from the bulk of tumor cells include their pluripotency, self-renewal capacity, low proliferation rate, and tumor-initiating ability.  CSCs are highly malignant, as they confer drug resistance and facilitate tumor progression, relapse, and metastasis.  The mol. mechanisms underlying CSC biol. are now beginning to be understood.  In this context, microRNAs (miRNAs) occupy a prominent place.  These endogenous, small noncoding RNA mols. control gene expression at the posttranscriptional level.  This study reviews our current understanding of how the misexpression of tumor suppressor and oncogenic miRNAs in CSCs sustain their abundance and malignant properties.  We discuss how they partly do so by acting on major CSC signaling pathways, including the Wnt, Notch, Hedgehog, and BMI-1 pathways.  Our current knowledge of miRNA functions in CSCs may now be used for cancer diagnostic and prognostic purposes.  In addn., when combined with recent tech. advances in the in vivo delivery of miRNAs, we are now in an excellent position to develop strategies that harness miRNA interference and replacement technologies for the therapeutic targeting of CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsTNiKoa2uTrVg90H21EOLACvtfcHk0lhUCSU18sBPNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVGmsbrL&md5=efbc05e5989b766a310155f1d39cc763</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fjcp.27885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.27885%26sid%3Dliteratum%253Aachs%26aulast%3DAsadzadeh%26aufirst%3DZ.%26aulast%3DMansoori%26aufirst%3DB.%26aulast%3DMohammadi%26aufirst%3DA.%26aulast%3DAghajani%26aufirst%3DM.%26aulast%3DHaji-Asgarzadeh%26aufirst%3DK.%26aulast%3DSafarzadeh%26aufirst%3DE.%26aulast%3DMokhtarzadeh%26aufirst%3DA.%26aulast%3DDuijf%26aufirst%3DP.%2BH.%2BG.%26aulast%3DBaradaran%26aufirst%3DB.%26atitle%3DmicroRNAs%2520in%2520cancer%2520stem%2520cells%253A%2520biology%252C%2520pathways%252C%2520and%2520therapeutic%2520opportunities%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26volume%3D234%26spage%3D10002%26epage%3D10017%26doi%3D10.1002%2Fjcp.27885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pattabiraman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Tackling the cancer stem cells — what challenges do they pose?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">512</span>, <span class="refDoi"> DOI: 10.1038/nrd4253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1038%2Fnrd4253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=24981363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOisbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=497-512&author=D.+R.+Pattabiramanauthor=R.+A.+Weinberg&title=Tackling+the+cancer+stem+cells+%E2%80%94+what+challenges+do+they+pose%3F&doi=10.1038%2Fnrd4253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Tackling the cancer stem cells - what challenges do they pose?</span></div><div class="casAuthors">Pattabiraman, Diwakar R.; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">497-512</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since their identification in 1994, cancer stem cells (CSCs) have been objects of intensive study.  Their properties and mechanisms of formation have become a major focus of current cancer research, in part because of their enhanced ability to initiate and drive tumor growth and their intrinsic resistance to conventional therapeutics.  The discovery that activation of the epithelial-to-mesenchymal transition (EMT) program in carcinoma cells can give rise to cells with stem-like properties has provided one possible mechanism explaining how CSCs arise and presents a possible avenue for their therapeutic manipulation.  Here we address recent developments in CSC research, focusing on carcinomas that are able to undergo EMT.  We discuss the signalling pathways that create these cells, cell-intrinsic mechanisms that could be exploited for selective elimination or induction of their differentiation, and the role of the tumor microenvironment in sustaining them.  Finally, we propose ways to use our current knowledge of the complex biol. of CSCs to design novel therapies to eliminate them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHXcwOZJN_67Vg90H21EOLACvtfcHk0lhUCSU18sBPNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOisbzI&md5=db211f41b19198981cb37487b7a9abc3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrd4253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4253%26sid%3Dliteratum%253Aachs%26aulast%3DPattabiraman%26aufirst%3DD.%2BR.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DTackling%2520the%2520cancer%2520stem%2520cells%2520%25E2%2580%2594%2520what%2520challenges%2520do%2520they%2520pose%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D497%26epage%3D512%26doi%3D10.1038%2Fnrd4253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martins-Neves, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleton-Jansen, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, C. M. F.</span></span> <span> </span><span class="NLM_article-title">Therapy-induced enrichment of cancer stem-like cells in solid human tumors: where do we stand?</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2018.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2Fj.phrs.2018.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=30316903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKksLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2018&pages=193-204&author=S.+R.+Martins-Nevesauthor=A.-M.+Cleton-Jansenauthor=C.+M.+F.+Gomes&title=Therapy-induced+enrichment+of+cancer+stem-like+cells+in+solid+human+tumors%3A+where+do+we+stand%3F&doi=10.1016%2Fj.phrs.2018.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Therapy-induced enrichment of cancer stem-like cells in solid human tumors: Where do we stand</span></div><div class="casAuthors">Martins-Neves, Sara R.; Cleton-Jansen, Anne-Marie; Gomes, Celia M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">193-204</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of local recurrence and metastatic disease, most probably attributable to the intrinsic or acquired resistance of tumor cells to std. therapy, still constitute the major clin. problem preventing the cure of cancer patients.  Despite progress in the research of new therapeutic targets and compds., resistant cells displaying stem-like properties seem to play a leading role in therapeutic failures and to be the culprit cells responsible for assocd. tumor recurrence.  A whole new plethora of research studies suggest that drug-tolerant cancer stem cells may be induced by conventional cancer chemotherapeutics such as doxorubicin, cisplatinum and ionizing radiation.  This phenotypic plasticity and transition from a differentiated to stem-like cell state assocs. with the activation of diverse stem cell self-renewal (e.g. Notch, Hedgehog, Wnt), drug efflux (e.g. ABC transporters) and survival-related pathways (e.g. TGF-β, ERK, AKT), which may confer resistance and treatment failures in solid tumors.  Therefore, combined therapeutic strategies aiming to simultaneously target drug-sensitive tumor cells and their capacity of phenotypic switching may lead to survival benefits and meaningful disease remissions.  This knowledge can be applicable to the clinic and contribute to better therapeutic outcomes and prevent tumor recurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDE6ThuyN1AbVg90H21EOLACvtfcHk0lgqhW21aB-uhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKksLfJ&md5=f68fae306b461bdd2c3b4496dc89cfe1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2018.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2018.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DMartins-Neves%26aufirst%3DS.%2BR.%26aulast%3DCleton-Jansen%26aufirst%3DA.-M.%26aulast%3DGomes%26aufirst%3DC.%2BM.%2BF.%26atitle%3DTherapy-induced%2520enrichment%2520of%2520cancer%2520stem-like%2520cells%2520in%2520solid%2520human%2520tumors%253A%2520where%2520do%2520we%2520stand%253F%26jtitle%3DPharmacol.%2520Res.%26date%3D2018%26volume%3D137%26spage%3D193%26epage%3D204%26doi%3D10.1016%2Fj.phrs.2018.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tirino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desiderio, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rosa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaccio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Noce, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Francesco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaccio, G.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1096/fj.12-218222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1096%2Ffj.12-218222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=23024375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Gqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=13-24&author=V.+Tirinoauthor=V.+Desiderioauthor=F.+Painoauthor=A.+De+Rosaauthor=F.+Papaccioauthor=M.+La+Noceauthor=L.+Lainoauthor=F.+De+Francescoauthor=G.+Papaccio&title=Cancer+stem+cells+in+solid+tumors%3A+an+overview+and+new+approaches+for+their+isolation+and+characterization&doi=10.1096%2Ffj.12-218222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization</span></div><div class="casAuthors">Tirino, Virginia; Desiderio, Vincenzo; Paino, Francesca; De Rosa, Alfredo; Papaccio, Federica; La Noce, Marcella; Laino, Luigi; De Francesco, Francesco; Papaccio, Gianpaolo</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-24, 10.1096/fj.12-218222</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review.  Primary tumors are responsible for 10% of cancer deaths.  In most cases, the main cause of mortality is the formation of metastases.  Accumulating evidence suggests that a subpopulation of tumor cells with distinct stem-like properties is responsible for tumor initiation, invasive growth, and metastasis formation.  This population is defined as cancer stem cells (CSCs).  Existing therapies have enhanced the length of survival after diagnosis of cancer but have completely failed in terms of recovery.  CSCs appear to be resistant to chemotherapy, may remain quiescent for extended periods, and have affinity for hypoxic environments.  The CSCs can be identified and isolated by different methodologies, including isolation by CSC-specific cell surface marker expression, detection of side population phenotype by Hoechst 33342 exclusion, assessment of their ability to grow as floating spheres, and aldehyde dehydrogenase (ALDH) activity assay.  None of the methods mentioned are exclusively used to isolate the solid tumor CSCs, highlighting the imperative to delineate more specific markers or to use combinatorial markers and methodologies.  This review provides an overview of the main characteristics and approaches used to identify, isolate, and characterize CSCs from solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKHEZT73U6-bVg90H21EOLACvtfcHk0lgqhW21aB-uhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Gqtw%253D%253D&md5=de33a9ff83242808595b3772fac12f5d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1096%2Ffj.12-218222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.12-218222%26sid%3Dliteratum%253Aachs%26aulast%3DTirino%26aufirst%3DV.%26aulast%3DDesiderio%26aufirst%3DV.%26aulast%3DPaino%26aufirst%3DF.%26aulast%3DDe%2BRosa%26aufirst%3DA.%26aulast%3DPapaccio%26aufirst%3DF.%26aulast%3DLa%2BNoce%26aufirst%3DM.%26aulast%3DLaino%26aufirst%3DL.%26aulast%3DDe%2BFrancesco%26aufirst%3DF.%26aulast%3DPapaccio%26aufirst%3DG.%26atitle%3DCancer%2520stem%2520cells%2520in%2520solid%2520tumors%253A%2520an%2520overview%2520and%2520new%2520approaches%2520for%2520their%2520isolation%2520and%2520characterization%26jtitle%3DFASEB%2520J.%26date%3D2013%26volume%3D27%26spage%3D13%26epage%3D24%26doi%3D10.1096%2Ffj.12-218222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanahan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Hallmarks of cancer: The next generation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+cancer%3A+The+next+generation&doi=10.1016%2Fj.cell.2011.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0lhdTsnvnDXpLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520cancer%253A%2520The%2520next%2520generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D646%26epage%3D674%26doi%3D10.1016%2Fj.cell.2011.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michael, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M. D.</span></span> <span> </span><span class="NLM_article-title">Clinical and therapeutic implications of cancer stem cells</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">2237</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1804280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1056%2FNEJMra1804280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=31167052" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=2237-2245&author=F.+Michaelauthor=M.+D.+Clarke&title=Clinical+and+therapeutic+implications+of+cancer+stem+cells&doi=10.1056%2FNEJMra1804280"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1804280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1804280%26sid%3Dliteratum%253Aachs%26aulast%3DMichael%26aufirst%3DF.%26aulast%3DClarke%26aufirst%3DM.%2BD.%26atitle%3DClinical%2520and%2520therapeutic%2520implications%2520of%2520cancer%2520stem%2520cells%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26spage%3D2237%26epage%3D2245%26doi%3D10.1056%2FNEJMra1804280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poh, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span> <span> </span><span class="NLM_article-title">Soft fibrin gels promote selection and growth of tumorigenic cells</span>. <i>Nat. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">734</span>– <span class="NLM_lpage">741</span>, <span class="refDoi"> DOI: 10.1038/nmat3361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1038%2Fnmat3361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=22751180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVSrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=734-741&author=J.+Liuauthor=Y.+Tanauthor=H.+Zhangauthor=Y.+Zhangauthor=P.+Xuauthor=J.+Chenauthor=Y.-C.+Pohauthor=K.+Tangauthor=N.+Wangauthor=B.+Huang&title=Soft+fibrin+gels+promote+selection+and+growth+of+tumorigenic+cells&doi=10.1038%2Fnmat3361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Soft fibrin gels promote selection and growth of tumorigenic cells</span></div><div class="casAuthors">Liu, Jing; Tan, Youhua; Zhang, Huafeng; Zhang, Yi; Xu, Pingwei; Chen, Junwei; Poh, Yeh-Chuin; Tang, Ke; Wang, Ning; Huang, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Materials</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">734-741</span>CODEN:
                <span class="NLM_cas:coden">NMAACR</span>;
        ISSN:<span class="NLM_cas:issn">1476-1122</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The identification of stem-cell-like cancer cells through conventional methods that depend on stem cell markers is often unreliable.  We developed a mech. method for selecting tumorigenic cells by culturing single cancer cells in fibrin matrixes of ∼100 Pa in stiffness.  When cultured within these gels, primary human cancer cells or single cancer cells from mouse or human cancer cell lines grew within a few days into individual round colonies that resembled embryonic stem cell colonies.  S.c. or i.v. injection of 10 or 100 fibrin-cultured cells in syngeneic or severe combined immunodeficiency mice led to the formation of solid tumors at the site of injection or at the distant lung organ much more efficiently than control cancer cells selected using conventional surface marker methods or cultured on conventional rigid dishes or on soft gels.  Remarkably, as few as ten such cells were able to survive and form tumors in the lungs of wild-type non-syngeneic mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFB9tpBQLzGrVg90H21EOLACvtfcHk0lhdTsnvnDXpLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVSrt70%253D&md5=f64f95bdb9acdc0ac162efe6aeee2c39</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnmat3361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmat3361%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DPoh%26aufirst%3DY.-C.%26aulast%3DTang%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DB.%26atitle%3DSoft%2520fibrin%2520gels%2520promote%2520selection%2520and%2520growth%2520of%2520tumorigenic%2520cells%26jtitle%3DNat.%2520Mater.%26date%3D2012%26volume%3D11%26spage%3D734%26epage%3D741%26doi%3D10.1038%2Fnmat3361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaipio, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roering, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huhtinen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkonen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Östling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehtinen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansuri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korpela, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potdar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynninen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auranen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grénman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hautaniemi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpén, O.</span></span> <span> </span><span class="NLM_article-title">ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>250</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1002/path.5356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1002%2Fpath.5356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=31595974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsF2lsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=250&publication_year=2020&pages=159-169&author=K.+Kaipioauthor=P.+Chenauthor=P.+Roeringauthor=K.+Huhtinenauthor=P.+Mikkonenauthor=P.+%C3%96stlingauthor=L.+Lehtinenauthor=N.+Mansuriauthor=T.+Korpelaauthor=S.+Potdarauthor=J.+Hynninenauthor=A.+Auranenauthor=S.+Gr%C3%A9nmanauthor=K.+Wennerbergauthor=S.+Hautaniemiauthor=O.+Carp%C3%A9n&title=ALDH1A1-related+stemness+in+high-grade+serous+ovarian+cancer+is+a+negative+prognostic+indicator+but+potentially+targetable+by+EGFR%2FmTOR-PI3K%2Faurora+kinase+inhibitors&doi=10.1002%2Fpath.5356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors</span></div><div class="casAuthors">Kaipio, Katja; Chen, Ping; Roering, Pia; Huhtinen, Kaisa; Mikkonen, Piia; Oestling, Paeivi; Lehtinen, Laura; Mansuri, Naziha; Korpela, Taina; Potdar, Swapnil; Hynninen, Johanna; Auranen, Annika; Grenman, Seija; Wennerberg, Krister; Hautaniemi, Sampsa; Carpen, Olli</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">250</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-169</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Poor chemotherapy response remains a major treatment challenge for high-grade serous ovarian cancer (HGSC).  Cancer stem cells are the major contributors to relapse and treatment failure as they can survive conventional therapy.  Our objectives were to characterize stemness features in primary patient-derived cell lines, correlate stemness markers with clin. outcome and test the response of our cells to both conventional and exploratory drugs.  Tissue and ascites samples, treatment-naive and/or after neoadjuvant chemotherapy, were prospectively collected.  Primary cancer cells, cultured under conditions favoring either adherent or spheroid growth, were tested for stemness markers; the same markers were analyzed in tissue and correlated with chemotherapy response and survival.  Drug sensitivity and resistance testing was performed with 306 oncol. compds.  Spheroid growth condition HGSC cells showed increased stemness marker expression (including aldehyde dehydrogenase isoform I; ALDH1A1) as compared with adherent growth condition cells, and increased resistance to platinum and taxane.  A set of eight stemness markers sepd. treatment-naive tumors into two clusters and identified a distinct subgroup of HGSC with enriched stemness features.  Expression of ALDH1A1, but not most other stemness markers, was increased after neoadjuvant chemotherapy and its expression in treatment-naive tumors correlated with chemoresistance and reduced survival.  In drug sensitivity and resistance testing, five compds., including two PI3K-mTOR inhibitors, demonstrated significant activity in both cell culture conditions.  Thirteen compds., including EGFR, PI3K-mTOR and aurora kinase inhibitors, were more toxic to spheroid cells than adherent cells.  Our results identify stemness markers in HGSC that are assocd. with a decreased response to conventional chemotherapy and reduced survival if expressed by treatment-naive tumors.  EGFR, mTOR-PI3K and aurora kinase inhibitors are candidates for targeting this cell population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpyFDLnreWCbVg90H21EOLACvtfcHk0lgo01IMee8CuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsF2lsbk%253D&md5=df803ac48a19ddb99a7bbdab45c15c19</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fpath.5356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.5356%26sid%3Dliteratum%253Aachs%26aulast%3DKaipio%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DRoering%26aufirst%3DP.%26aulast%3DHuhtinen%26aufirst%3DK.%26aulast%3DMikkonen%26aufirst%3DP.%26aulast%3D%25C3%2596stling%26aufirst%3DP.%26aulast%3DLehtinen%26aufirst%3DL.%26aulast%3DMansuri%26aufirst%3DN.%26aulast%3DKorpela%26aufirst%3DT.%26aulast%3DPotdar%26aufirst%3DS.%26aulast%3DHynninen%26aufirst%3DJ.%26aulast%3DAuranen%26aufirst%3DA.%26aulast%3DGr%25C3%25A9nman%26aufirst%3DS.%26aulast%3DWennerberg%26aufirst%3DK.%26aulast%3DHautaniemi%26aufirst%3DS.%26aulast%3DCarp%25C3%25A9n%26aufirst%3DO.%26atitle%3DALDH1A1-related%2520stemness%2520in%2520high-grade%2520serous%2520ovarian%2520cancer%2520is%2520a%2520negative%2520prognostic%2520indicator%2520but%2520potentially%2520targetable%2520by%2520EGFR%252FmTOR-PI3K%252Faurora%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Pathol.%26date%3D2020%26volume%3D250%26spage%3D159%26epage%3D169%26doi%3D10.1002%2Fpath.5356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui-Jain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourbon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaebe, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vialettes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darjania, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stansfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliesath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drygin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proffitt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streiner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trent, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckman, D. M.</span></span> <span> </span><span class="NLM_article-title">Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">635</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1021/jm101251q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101251q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2kurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=635-654&author=F.+Pierreauthor=P.+C.+Chuaauthor=S.+E.+O%E2%80%99Brienauthor=A.+Siddiqui-Jainauthor=P.+Bourbonauthor=M.+Haddachauthor=J.+Michauxauthor=J.+Nagasawaauthor=M.+K.+Schwaebeauthor=E.+Stefanauthor=A.+Vialettesauthor=J.+P.+Whittenauthor=T.+K.+Chenauthor=L.+Darjaniaauthor=R.+Stansfieldauthor=K.+Anderesauthor=J.+Bliesathauthor=D.+Dryginauthor=C.+Hoauthor=M.+Omoriauthor=C.+Proffittauthor=N.+Streinerauthor=K.+Trentauthor=W.+G.+Riceauthor=D.+M.+Ryckman&title=Discovery+and+SAR+of+5-%283-chlorophenylamino%29benzo%5Bc%5D%5B2%2C6%5Dnaphthyridine-8-carboxylic+acid+%28CX-4945%29%2C+the+first+clinical+stage+inhibitor+of+protein+kinase+CK2+for+the+treatment+of+cancer&doi=10.1021%2Fjm101251q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer</span></div><div class="casAuthors">Pierre, Fabrice; Chua, Peter C.; O'Brien, Sean E.; Siddiqui-Jain, Adam; Bourbon, Pauline; Haddach, Mustapha; Michaux, Jerome; Nagasawa, Johnny; Schwaebe, Michael K.; Stefan, Eric; Vialettes, Anne; Whitten, Jeffrey P.; Chen, Ta Kung; Darjania, Levan; Stansfield, Ryan; Anderes, Kenna; Bliesath, Josh; Drygin, Denis; Ho, Caroline; Omori, May; Proffitt, Chris; Streiner, Nicole; Trent, Katy; Rice, William G.; Ryckman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">635-654</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we chronicle the discovery of CX-4945 (I), a first-in-class, orally bioavailable ATP-competitive inhibitor of protein kinase CK2 in clin. trials for cancer.  CK2 has long been considered a prime cancer drug target because of the roles of deregulated and overexpressed CK2 in cancer-promoting pro-survival and antiapoptotic pathways.  These biol. properties as well as the suitability of CK2's small ATP binding site for the design of selective inhibitors, led us to fashion novel therapeutic agents for cancer.  The optimization leading to I (Ki = 0.38 nM) was guided by mol. modeling, suggesting a strong binding of I resulting from a combination of hydrophobic interactions, an ionic bridge with Lys68, and hydrogen bonding with the hinge region. I was highly selective, orally bioavailable across species (20-51%) and efficacious in xenograft models.  The discovery of I will allow the therapeutic targeting of CK2 in humans for the first time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoONQeRuenlPrVg90H21EOLACvtfcHk0lgo01IMee8CuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2kurjL&md5=9b0f371ee1a2182b84877743c42dfda1</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm101251q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101251q%26sid%3Dliteratum%253Aachs%26aulast%3DPierre%26aufirst%3DF.%26aulast%3DChua%26aufirst%3DP.%2BC.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BE.%26aulast%3DSiddiqui-Jain%26aufirst%3DA.%26aulast%3DBourbon%26aufirst%3DP.%26aulast%3DHaddach%26aufirst%3DM.%26aulast%3DMichaux%26aufirst%3DJ.%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DSchwaebe%26aufirst%3DM.%2BK.%26aulast%3DStefan%26aufirst%3DE.%26aulast%3DVialettes%26aufirst%3DA.%26aulast%3DWhitten%26aufirst%3DJ.%2BP.%26aulast%3DChen%26aufirst%3DT.%2BK.%26aulast%3DDarjania%26aufirst%3DL.%26aulast%3DStansfield%26aufirst%3DR.%26aulast%3DAnderes%26aufirst%3DK.%26aulast%3DBliesath%26aufirst%3DJ.%26aulast%3DDrygin%26aufirst%3DD.%26aulast%3DHo%26aufirst%3DC.%26aulast%3DOmori%26aufirst%3DM.%26aulast%3DProffitt%26aufirst%3DC.%26aulast%3DStreiner%26aufirst%3DN.%26aulast%3DTrent%26aufirst%3DK.%26aulast%3DRice%26aufirst%3DW.%2BG.%26aulast%3DRyckman%26aufirst%3DD.%2BM.%26atitle%3DDiscovery%2520and%2520SAR%2520of%25205-%25283-chlorophenylamino%2529benzo%255Bc%255D%255B2%252C6%255Dnaphthyridine-8-carboxylic%2520acid%2520%2528CX-4945%2529%252C%2520the%2520first%2520clinical%2520stage%2520inhibitor%2520of%2520protein%2520kinase%2520CK2%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D635%26epage%3D654%26doi%3D10.1021%2Fjm101251q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserü, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. H.</span></span> <span> </span><span class="NLM_article-title">The role of ligand efficiency metrics in drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1038/nrd4163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105-121&author=A.+L.+Hopkinsauthor=G.+M.+Keser%C3%BCauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+role+of+ligand+efficiency+metrics+in+drug+discovery&doi=10.1038%2Fnrd4163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0lgJ_kGYZzckmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeser%25C3%25BC%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520role%2520of%2520ligand%2520efficiency%2520metrics%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D105%26epage%3D121%26doi%3D10.1038%2Fnrd4163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Au, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoppler, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jablons, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">854</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1111/jcmm.12068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1111%2Fjcmm.12068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=23651443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlCrt77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=854-862&author=S.+Zhangauthor=H.+Longauthor=Y.-L.+Yangauthor=Y.+Wangauthor=D.+Hsiehauthor=W.+Liauthor=A.+Auauthor=H.+J.+Stopplerauthor=Z.+Xuauthor=D.+M.+Jablonsauthor=L.+You&title=Inhibition+of+CK2%CE%B1+down-regulates+Notch1+signalling+in+lung+cancer+cells&doi=10.1111%2Fjcmm.12068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells</span></div><div class="casAuthors">Zhang, Shulin; Long, Hao; Yang, Yi-Lin; Wang, Yucheng; Hsieh, David; Li, Weiming; Au, Alfred; Stoppler, Hubert J.; Xu, Zhidong; Jablons, David M.; You, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">854-862</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Protein kinase CK2 is frequently elevated in a variety of human cancers.  The Notch1 signalling pathway has been implicated in stem cell maintenance and its aberrant activation has been shown in several types of cancer including lung cancer.  Here, we show, for the first time, that CK2α is a pos. regulator of Notch1 signalling in lung cancer cell lines A549 and H1299.  We found that Notch1 protein level was reduced after CK2α silencing.  Down-regulation of Notch1 transcriptional activity was demonstrated after the silencing of CK2α in lung cancer cells.  Furthermore, small-mol. CK2α inhibitor CX-4945 led to a dose-dependent inhibition of Notch1 transcriptional activity.  Conversely, forced overexpression of CK2α resulted in an increase in Notch1 transcriptional activity.  Finally, the inhibition of CK2α led to a reduced proportion of stem-like CD44+ /CD24- cell population.  Thus, we report that the inhibition of CK2α down-regulates Notch1 signalling and subsequently reduces a cancer stem-like cell population in human lung cancer cells.  Our data suggest that CK2α inhibitors may be beneficial to the lung cancer patients with activated Notch1 signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS2z_d0QXEmrVg90H21EOLACvtfcHk0lgJ_kGYZzckmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlCrt77P&md5=64b28baced76a2a254fc4d99ed30bb4d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.12068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.12068%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.-L.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHsieh%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DAu%26aufirst%3DA.%26aulast%3DStoppler%26aufirst%3DH.%2BJ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DJablons%26aufirst%3DD.%2BM.%26aulast%3DYou%26aufirst%3DL.%26atitle%3DInhibition%2520of%2520CK2%25CE%25B1%2520down-regulates%2520Notch1%2520signalling%2520in%2520lung%2520cancer%2520cells%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2013%26volume%3D17%26spage%3D854%26epage%3D862%26doi%3D10.1111%2Fjcmm.12068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozovska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patsalias, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajzik, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durinikova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demkova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jargasova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolkova, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plava, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucerova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matuskova, M.</span></span> <span> </span><span class="NLM_article-title">ALDH1A inhibition sensitizes colon cancer cells to chemotherapy</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">656</span>, <span class="refDoi"> DOI: 10.1186/s12885-018-4572-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1186%2Fs12885-018-4572-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=29902974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFWmtLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=656&author=Z.+Kozovskaauthor=A.+Patsaliasauthor=V.+Bajzikauthor=E.+Durinikovaauthor=L.+Demkovaauthor=S.+Jargasovaauthor=B.+Smolkovaauthor=J.+Plavaauthor=L.+Kucerovaauthor=M.+Matuskova&title=ALDH1A+inhibition+sensitizes+colon+cancer+cells+to+chemotherapy&doi=10.1186%2Fs12885-018-4572-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">ALDH1A inhibition sensitizes colon cancer cells to chemotherapy</span></div><div class="casAuthors">Kozovska, Z.; Patsalias, A.; Bajzik, V.; Durinikova, E.; Demkova, L.; Jargasova, S.; Smolkova, B.; Plava, J.; Kucerova, L.; Matuskova, M.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">656/1-656/11</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">In our study we focused on the aldehyde dehydrogenase type 1 (ALDH1) expression in colon cancer-derived cell lines HT-29/eGFP, HCT-116/eGFP and LS-180/eGFP, and its role in the chemoresistance and tumorigenic potential.  The effect of pharmacol. inhibition of ALDH activity by diethylaminobenzaldehyde (DEAB) and also effect of mol. inhibition by specific siRNA was evaluated in vitro in cultures of human colorectal cell lines.  Changes in cell biol. were evaluated by expression anal., western blot and apoptosis assay.  The efficiency of cytotoxic treatment in the presence of different chemotherapeutic drugs was analyzed by fluorimetric assay.  Tumorigenicity of cells with specific ALDH1A1 siRNA was tested in xenograft model in vivo.  Subsequently the mol. inhibition of specific isoforms of ALDH by ALDH1A1 or ALDH1A3 siRNA led to sensitizing of cell lines HT-29/eGFP, HCT- 116/eGFP to capecitabine and 5-FU.  On the model of athymic mice we obsd. the effect of mol. inhibition of ALDH1A1 in HT-29/eGFP cells by siRNA.  We obsd. inhibition of proliferation of s.c. xenografts in comparison to control cells.  This research, verifies the significance of the ALDH1A isoforms in multidrug resistance of human colorectal cancer cells and its potential as a cancer stem cell marker.  This provides the basis for the development of new approaches regarding the treatment of patients with colorectal adenocarcinoma and potentially the treatment of other tumor malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6TSQNzq0hHLVg90H21EOLACvtfcHk0ljgXcvc8sl5pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFWmtLbP&md5=4a13304220c0a974946ecb7a260a66fa</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1186%2Fs12885-018-4572-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-018-4572-6%26sid%3Dliteratum%253Aachs%26aulast%3DKozovska%26aufirst%3DZ.%26aulast%3DPatsalias%26aufirst%3DA.%26aulast%3DBajzik%26aufirst%3DV.%26aulast%3DDurinikova%26aufirst%3DE.%26aulast%3DDemkova%26aufirst%3DL.%26aulast%3DJargasova%26aufirst%3DS.%26aulast%3DSmolkova%26aufirst%3DB.%26aulast%3DPlava%26aufirst%3DJ.%26aulast%3DKucerova%26aufirst%3DL.%26aulast%3DMatuskova%26aufirst%3DM.%26atitle%3DALDH1A%2520inhibition%2520sensitizes%2520colon%2520cancer%2520cells%2520to%2520chemotherapy%26jtitle%3DBMC%2520Cancer%26date%3D2018%26volume%3D18%26spage%3D656%26doi%3D10.1186%2Fs12885-018-4572-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, D.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span> <span> </span><span class="NLM_article-title">The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">17593</span>– <span class="NLM_lpage">17609</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.4307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.18632%2Foncotarget.4307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=26061710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A280%3ADC%252BC2MbitVyrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=17593-17609&author=J.-J.+Chenauthor=N.+Caiauthor=G.-Z.+Chenauthor=C.-C.+Jiaauthor=D.-B.+Qiuauthor=C.+Duauthor=W.+Liuauthor=Y.+Yangauthor=Z.-J.+Longauthor=Q.+Zhang&title=The+neuroleptic+drug+pimozide+inhibits+stem-like+cell+maintenance+and+tumorigenicity+in+hepatocellular+carcinoma&doi=10.18632%2Foncotarget.4307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma</span></div><div class="casAuthors">Chen Jia-Jie; Cai Nan; Chen Guan-Zhong; Jia Chang-Chang; Liu Wei; Yang Yang; Zhang Qi; Chen Jia-Jie; Cai Nan; Jia Chang-Chang; Qiu Dong-Bo; Du Cong; Zhang Qi; Chen Jia-Jie; Long Zi-Jie; Chen Guan-Zhong; Qiu Dong-Bo; Du Cong; Liu Wei; Zhang Qi</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">17593-17609</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug repurposing is currently an important approach for accelerating drug discovery and development for clinical use.  Hepatocellular carcinoma (HCC) presents drug resistance to chemotherapy, and the prognosis is poor due to the existence of liver cancer stem-like cells.  In this study, we investigated the effect of the neuroleptic agent pimozide to inhibit stem-like cell maintenance and tumorigenicity in HCC.  Our results showed that pimozide functioned as an anti-cancer drug in HCC cells or stem-like cells.  Pimozide inhibited cell proliferation and sphere formation capacities in HCC cells by inducing G0/G1 phase cell cycle arrest, as well as inhibited HCC cell migration.  Surprisingly, pimozide inhibited the maintenance and tumorigenicity of HCC stem-like cells, particularly the side population (SP) or CD133-positive cells, as evaluated by colony formation, sphere formation and transwell migration assays.  Furthermore, pimozide was found to suppress STAT3 activity in HCC cells by attenuating STAT3-dependent luciferase activity and down-regulating the transcription levels of downstream genes of STAT3 signaling.  Moreover, pimozide reversed the stem-like cell tumorigenic phenotypes induced by IL-6 treatment in HCC cells.  Further, the antitumor effect of pimozide was also proved in the nude mice HCC xenograft model.  In short, the anti-psychotic agent pimozide may act as a novel potential anti-tumor agent in treating advanced HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJREZ8s_IGh7HHuJhbyicZfW6udTcc2eZ0T4pqBSQj5bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbitVyrtg%253D%253D&md5=bea228d4f6fd873b07b1a1fd6b44bd39</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4307%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.-J.%26aulast%3DCai%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DG.-Z.%26aulast%3DJia%26aufirst%3DC.-C.%26aulast%3DQiu%26aufirst%3DD.-B.%26aulast%3DDu%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DZ.-J.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DThe%2520neuroleptic%2520drug%2520pimozide%2520inhibits%2520stem-like%2520cell%2520maintenance%2520and%2520tumorigenicity%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D17593%26epage%3D17609%26doi%3D10.18632%2Foncotarget.4307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>340</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2013.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2Fj.canlet.2013.07.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=23872274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1WrtbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2013&pages=113-123&author=Y.+Luauthor=H.+Zhuauthor=H.+Shanauthor=J.+Luauthor=X.+Changauthor=X.+Liauthor=J.+Luauthor=X.+Fanauthor=S.+Zhuauthor=Y.+Wangauthor=Q.+Guoauthor=L.+Wangauthor=Y.+Huangauthor=M.+Zhuauthor=Z.+Wang&title=Knockdown+of+Oct4+and+Nanog+expression+inhibits+the+stemness+of+pancreatic+cancer+cells&doi=10.1016%2Fj.canlet.2013.07.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells</span></div><div class="casAuthors">Lu, Yuhua; Zhu, Hui; Shan, Haiyan; Lu, Junjie; Chang, Xu; Li, Xiaohong; Lu, Jingjing; Fan, Xiangjun; Zhu, Shajun; Wang, Yao; Guo, Qingsong; Wang, Lei; Huang, Yan; Zhu, Mingyan; Wang, Zhiwei</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-123</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Pancreatic cancer is notorious for its difficult diagnosis at early stage and poor recurrence-free prognosis.  This study aimed to investigate the possible involvement of Oct4 and Nanog in pancreatic cancer.  The high expressions of Oct4 and Nanog in human pancreatic cancer tissues were found to indicate a worse prognostic value of patients.  The pancreatic cancer stem cells (PCSCs) that isolated from PANC-1 cell line by flow cytometry exhibited high expressions of Oct4 and Nanog.  To investigate whether Oct4 and Nanog play crucial role in maintaining the stemness of PCSCs, double knockdown of Oct4 and Nanog demonstrated that Oct4 and Nanog significantly reduced proliferation, migration, invasion, chemoresistance, and tumorigenesis of PCSCs in vitro and in vivo.  The altered expression of the genes related to pancreatic carcinogenesis, metastasis, drug resistance and epithelial-mesenchymal transdifferentiation (EMT) might affect the biol. characteristics of PCSCs.  Our results suggest that Oct4 and Nanog may serve as a potential marker of prognosis and a novel target of therapy for pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokcOYM0eHQFLVg90H21EOLACvtfcHk0ljSBVxBVPKFWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1WrtbzL&md5=db8be55f62a426df2ac1d6beda29d331</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2013.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2013.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DShan%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DKnockdown%2520of%2520Oct4%2520and%2520Nanog%2520expression%2520inhibits%2520the%2520stemness%2520of%2520pancreatic%2520cancer%2520cells%26jtitle%3DCancer%2520Lett.%26date%3D2013%26volume%3D340%26spage%3D113%26epage%3D123%26doi%3D10.1016%2Fj.canlet.2013.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadpour, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emami Razavi, A.</span></span> <span> </span><span class="NLM_article-title">Association of high expression levels of Sox<sub>2</sub>, Nanog, and Oct4 in gastric cancer tumor tissues with progression and poor prognosis</span>. <i>J. Gastrointest. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1007/s12029-018-00200-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1007%2Fs12029-018-00200-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2020&pages=41-47&author=G.+Basatiauthor=H.+Mohammadpourauthor=A.+Emami+Razavi&title=Association+of+high+expression+levels+of+Sox2%2C+Nanog%2C+and+Oct4+in+gastric+cancer+tumor+tissues+with+progression+and+poor+prognosis&doi=10.1007%2Fs12029-018-00200-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs12029-018-00200-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12029-018-00200-x%26sid%3Dliteratum%253Aachs%26aulast%3DBasati%26aufirst%3DG.%26aulast%3DMohammadpour%26aufirst%3DH.%26aulast%3DEmami%2BRazavi%26aufirst%3DA.%26atitle%3DAssociation%2520of%2520high%2520expression%2520levels%2520of%2520Sox2%252C%2520Nanog%252C%2520and%2520Oct4%2520in%2520gastric%2520cancer%2520tumor%2520tissues%2520with%2520progression%2520and%2520poor%2520prognosis%26jtitle%3DJ.%2520Gastrointest.%2520Surg.%26date%3D2020%26volume%3D51%26spage%3D41%26epage%3D47%26doi%3D10.1007%2Fs12029-018-00200-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perugorria, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaizola, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labiano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esparza-Baquer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzioni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marin, J. J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bujanda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banales, J. M.</span></span> <span> </span><span class="NLM_article-title">Wnt−β-catenin signalling in liver development, health and disease</span>. <i>Nat. Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1038/s41575-018-0075-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1038%2Fs41575-018-0075-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=30451972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlWnsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=121-136&author=M.+J.+Perugorriaauthor=P.+Olaizolaauthor=I.+Labianoauthor=A.+Esparza-Baquerauthor=M.+Marzioniauthor=J.+J.+G.+Marinauthor=L.+Bujandaauthor=J.+M.+Banales&title=Wnt%E2%88%92%CE%B2-catenin+signalling+in+liver+development%2C+health+and+disease&doi=10.1038%2Fs41575-018-0075-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Wnt-β-catenin signalling in liver development, health and disease</span></div><div class="casAuthors">Perugorria, Maria J.; Olaizola, Paula; Labiano, Ibone; Esparza-Baquer, Aitor; Marzioni, Marco; Marin, Jose J. G.; Bujanda, Luis; Banales, Jesus M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-136</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The canonical Wnt-β-catenin pathway is a complex, evolutionarily conserved signalling mechanism that regulates fundamental physiol. and pathol. processes.  Wnt-β-catenin signalling tightly controls embryogenesis, including hepatobiliary development, maturation and zonation.  In the mature healthy liver, the Wnt-β-catenin pathway is mostly inactive but can become re-activated during cell renewal and/or regenerative processes, as well as in certain pathol. conditions, diseases, pre-malignant conditions and cancer.  In hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), the two most prevalent primary liver tumors in adults, Wnt-β-catenin signalling is frequently hyperactivated and promotes tumor growth and dissemination.  A substantial proportion of liver tumors (mainly HCC and, to a lesser extent, CCA) have mutations in genes encoding key components of the Wnt-β-catenin signalling pathway.  Likewise, hepatoblastoma, the most common paediatric liver cancer, is characterized by Wnt-β-catenin activation, mostly as a result of β-catenin mutations.  In this Review, we discuss the most relevant mol. mechanisms of action and regulation of Wnt-β-catenin signalling in liver development and pathophysiol.  Moreover, we highlight important preclin. and clin. studies and future directions in basic and clin. research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnHfSlRdNCxbVg90H21EOLACvtfcHk0ljSBVxBVPKFWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlWnsrvK&md5=65768c2d2f88530de2dacddf5acb089a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fs41575-018-0075-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41575-018-0075-9%26sid%3Dliteratum%253Aachs%26aulast%3DPerugorria%26aufirst%3DM.%2BJ.%26aulast%3DOlaizola%26aufirst%3DP.%26aulast%3DLabiano%26aufirst%3DI.%26aulast%3DEsparza-Baquer%26aufirst%3DA.%26aulast%3DMarzioni%26aufirst%3DM.%26aulast%3DMarin%26aufirst%3DJ.%2BJ.%2BG.%26aulast%3DBujanda%26aufirst%3DL.%26aulast%3DBanales%26aufirst%3DJ.%2BM.%26atitle%3DWnt%25E2%2588%2592%25CE%25B2-catenin%2520signalling%2520in%2520liver%2520development%252C%2520health%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2019%26volume%3D16%26spage%3D121%26epage%3D136%26doi%3D10.1038%2Fs41575-018-0075-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanahan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">The hallmarks of cancer</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)81683-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2FS0092-8674%2800%2981683-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10647931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=57-70&author=D.+Hanahanauthor=R.+A.+Weinberg&title=The+hallmarks+of+cancer&doi=10.1016%2FS0092-8674%2800%2981683-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The hallmarks of cancer</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-70</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review is given with many refs. on principles governing the transformation of normal human cells into malignant cancers.  The authors suggest that research over the past decades has revealed a small no. of mol., biochem., and cellular traits (acquired capabilities) shared by most and perhaps all types of cancer.  Topics included are the acquired capabilities self-sufficiency in growth signals, insensitivity to antigrowth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis followed by genome instability as an enabling characteristic and alternative pathways to cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooXmGqKjM1C7Vg90H21EOLACvtfcHk0lj3SD4GDtk0Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D&md5=1d23c4400dad34c7f32d4a0c41890349</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981683-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981683-9%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DThe%2520hallmarks%2520of%2520cancer%26jtitle%3DCell%26date%3D2000%26volume%3D100%26spage%3D57%26epage%3D70%26doi%3D10.1016%2FS0092-8674%2800%2981683-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, B.</span></span> <span> </span><span class="NLM_article-title">NOR1 suppresses cancer stem-like cells properties of tumor cells <i>via</i> the inhibition of the AKT-GSK-3β-Wnt/β-catenin-ALDH1A1 signal circuit</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>232</i></span>,  <span class="NLM_fpage">2829</span>– <span class="NLM_lpage">2840</span>, <span class="refDoi"> DOI: 10.1002/jcp.25706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1002%2Fjcp.25706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=27891591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFahsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2017&pages=2829-2840&author=W.+Wangauthor=M.+Yiauthor=S.+Chenauthor=J.+Liauthor=H.+Zhangauthor=W.+Xiongauthor=G.+Liauthor=X.+Liauthor=B.+Xiang&title=NOR1+suppresses+cancer+stem-like+cells+properties+of+tumor+cells+via+the+inhibition+of+the+AKT-GSK-3%CE%B2-Wnt%2F%CE%B2-catenin-ALDH1A1+signal+circuit&doi=10.1002%2Fjcp.25706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">NOR1 Suppresses Cancer Stem-Like Cells Properties of Tumor Cells via the Inhibition of the AKT-GSK-3β-Wnt/β-catenin-ALDH1A1 Signal Circuit</span></div><div class="casAuthors">Wang, Wei; Yi, Mei; Chen, Shengnan; Li, Junjun; Zhang, Haijing; Xiong, Wei; Li, Guiyuan; Li, Xiaoling; Xiang, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2829-2840</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) play a key role in tumor radiotherapy and chemotherapy resistance, relapse, and metastasis, and are primarily maintained in a resting state in vivo.  The failure of conventional therapies to target CSCs is the main cause of treatment failure.  The discovery of CSCs in nasopharyngeal carcinoma (NPC) tumors is becoming more prevalent; however, the understanding of the mechanisms underlying the maintenance of tumor stemness is still limited.  We previously cloned NOR1, a tumor suppressor gene downregulated in NPC cell lines and tissues.  In this study, we demonstrate that Wnt/β-catenin and ALDH1A1 form a signal circuit and that NOR1 antagonizes the tumor stem cell-like phenotype in NPC cell lines: the ectopic overexpression of NOR1 reduced β-catenin and ALDH1A1 expression; β-catenin/TCF4 targeted the regulation of ALDH1A1 transcription in NPC cells; silencing ALDH1A1 reduced AKT (total and phosphorylated) and GSK-3β (phosphorylated) expression; and eventually feedback decreased β-catenin expression levels.  We also found that NOR1 expression decreased cancer stem-like cell properties of NPC cells, reduced their ability to form tumor spheroids in vitro, reduced tumorigenicity in nude mice in vivo, and increased sensitivity to chemotherapy agents.  Taken together, our findings illustrated a new function of NOR1 that suppresses cancer stem-like cell properties in tumor cells by inhibiting the AKT-GSK-3β-Wnt/β-catenin-ALDH1A1 signal circuit.  The study suggests that NOR1 deletion expression in NPC cells may be a potential mol. target for cancer stem cell therapy.  J. Cell. Physiol. 9999: 1-12, 2016. © 2016 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjQREwi8U08bVg90H21EOLACvtfcHk0lj3SD4GDtk0Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFahsr0%253D&md5=49109830d2714cadee604a7fff74c3a3</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fjcp.25706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.25706%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYi%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DB.%26atitle%3DNOR1%2520suppresses%2520cancer%2520stem-like%2520cells%2520properties%2520of%2520tumor%2520cells%2520via%2520the%2520inhibition%2520of%2520the%2520AKT-GSK-3%25CE%25B2-Wnt%252F%25CE%25B2-catenin-ALDH1A1%2520signal%2520circuit%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2017%26volume%3D232%26spage%3D2829%26epage%3D2840%26doi%3D10.1002%2Fjcp.25706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedert, M.</span></span> <span> </span><span class="NLM_article-title">GSK3 inhibitors: development and therapeutic potential</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1038/nrd1415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1038%2Fnrd1415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=15173837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVaqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=479-487&author=P.+Cohenauthor=M.+Goedert&title=GSK3+inhibitors%3A+development+and+therapeutic+potential&doi=10.1038%2Fnrd1415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 inhibitors: development and therapeutic potential</span></div><div class="casAuthors">Cohen, Philip; Goedert, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">479-487</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an enzyme involved in the control of glycogen metab.  In recent years it has been shown to have key roles in regulating a diverse range of cellular functions, which have prompted efforts to develop GSK3 inhibitors as therapeutics.  Here, we describe the biol. of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases, and discuss progress in the development of GSK3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL3ua5xi0_qrVg90H21EOLACvtfcHk0lj3SD4GDtk0Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVaqsrs%253D&md5=165d1354bf11faa6021ac4dba797fda2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnrd1415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1415%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DGoedert%26aufirst%3DM.%26atitle%3DGSK3%2520inhibitors%253A%2520development%2520and%2520therapeutic%2520potential%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D479%26epage%3D487%26doi%3D10.1038%2Fnrd1415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mills, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowsheen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonner, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. S.</span></span> <span> </span><span class="NLM_article-title">Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">47</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2011.00047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.3389%2Ffnmol.2011.00047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=22275880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC38XovV2j" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=47&author=C.+N.+Millsauthor=S.+Nowsheenauthor=J.+A.+Bonnerauthor=E.+S.+Yang&title=Emerging+roles+of+glycogen+synthase+kinase+3+in+the+treatment+of+brain+tumors&doi=10.3389%2Ffnmol.2011.00047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors</span></div><div class="casAuthors">Mills, Caroline N.; Nowsheen, Somaira; Bonner, James A.; Yang, Eddy S.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Nov.</span>),
    <span class="NLM_cas:pages">47</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The constitutively active protein glycogen synthase kinase 3 (GSK3), a serine/threonine kinase, acts paradoxically as a tumor suppressor in some cancers while potentiates growth in others.  Deciphering what governs its actions is vital for understanding many pathol. conditions, including brain cancer.  What are seemingly disparate roles of GSK3 stems from the complex regulation of many cellular functions by GSK3.  This review focuses on the regulation of GSK3, its role in survival, apoptosis and DNA damage, and finally its potential therapeutic impact in brain cancer.  A thorough understanding of this versatile protein is crit. for improving the outcome of various diseases, esp. cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDHgnEU2CYbVg90H21EOLACvtfcHk0lg4Pyd8BAa7Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovV2j&md5=a91f52a6292ec3ed914020d19393a989</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2011.00047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2011.00047%26sid%3Dliteratum%253Aachs%26aulast%3DMills%26aufirst%3DC.%2BN.%26aulast%3DNowsheen%26aufirst%3DS.%26aulast%3DBonner%26aufirst%3DJ.%2BA.%26aulast%3DYang%26aufirst%3DE.%2BS.%26atitle%3DEmerging%2520roles%2520of%2520glycogen%2520synthase%2520kinase%25203%2520in%2520the%2520treatment%2520of%2520brain%2520tumors%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2011%26volume%3D4%26spage%3D47%26doi%3D10.3389%2Ffnmol.2011.00047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chua, P. C.</span>; <span class="NLM_string-name">Haddach, M.</span>; <span class="NLM_string-name">Nagasawa, J. Y.</span>; <span class="NLM_string-name">Pierre, F.</span></span> <span> </span><span class="NLM_article-title">Preparation of substituted pyrimidoquinolines and thienoquinolines as serine-threonine protein kinase and PARP modulators</span>. Sep 3, <span class="NLM_year">2009</span>, <span class="NLM_patent">WO 2009108912 A1</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=P.+C.+Chua&author=M.+Haddach&author=J.+Y.+Nagasawa&author=F.+Pierre&title=Preparation+of+substituted+pyrimidoquinolines+and+thienoquinolines+as+serine-threonine+protein+kinase+and+PARP+modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChua%26aufirst%3DP.%2BC.%26atitle%3DPreparation%2520of%2520substituted%2520pyrimidoquinolines%2520and%2520thienoquinolines%2520as%2520serine-threonine%2520protein%2520kinase%2520and%2520PARP%2520modulators%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Livak, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmittgen, T. D.</span></span> <span> </span><span class="NLM_article-title">Analysis of relative gene expression data using Real-time quantitative PCR and the 2<sup>-ΔΔCT</sup> method</span>. <i>Methods</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1006/meth.2001.1262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1006%2Fmeth.2001.1262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=11846609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtFelt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2001&pages=402-408&author=K.+J.+Livakauthor=T.+D.+Schmittgen&title=Analysis+of+relative+gene+expression+data+using+Real-time+quantitative+PCR+and+the+2-%CE%94%CE%94CT+method&doi=10.1006%2Fmeth.2001.1262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method</span></div><div class="casAuthors">Livak, Kenneth J.; Schmittgen, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Methods (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">402-408</span>CODEN:
                <span class="NLM_cas:coden">MTHDE9</span>;
        ISSN:<span class="NLM_cas:issn">1046-2023</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The two most commonly used methods to analyze data from real-time, quant. PCR expts. are abs. quantification and relative quantification.  Abs. quantification dets. the input copy no., usually by relating the PCR signal to a std. curve.  Relative quantification relates the PCR signal of the target transcript in a treatment group to that of another sample such as an untreated control.  The 2-ΔΔCT method is a convenient way to analyze the relative changes in gene expression from real-time quant. PCR expts.  The purpose of this report is to present the derivation, assumptions, and applications of the 2-ΔΔCT method.  In addn., we present the derivation and applications of two variations of the 2-ΔΔCT method that may be useful in the anal. of real-time, quant. PCR data.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXNe1s-mDpprVg90H21EOLACvtfcHk0lg4Pyd8BAa7Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtFelt7s%253D&md5=f849383250ea43f7380ed540db8a64b1</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1006%2Fmeth.2001.1262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fmeth.2001.1262%26sid%3Dliteratum%253Aachs%26aulast%3DLivak%26aufirst%3DK.%2BJ.%26aulast%3DSchmittgen%26aufirst%3DT.%2BD.%26atitle%3DAnalysis%2520of%2520relative%2520gene%2520expression%2520data%2520using%2520Real-time%2520quantitative%2520PCR%2520and%2520the%25202-%25CE%2594%25CE%2594CT%2520method%26jtitle%3DMethods%26date%3D2001%26volume%3D25%26spage%3D402%26epage%3D408%26doi%3D10.1006%2Fmeth.2001.1262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures representing known ATP-competitive CK2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure modification strategy for the target compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Target Compounds</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>1c</b> demonstrates high potency as well as selectivity for CK2α <i>in vitro</i>. (a) Graphical illustration of the kinase inhibition profile of <b>1c</b> with 208 kinases (a list of the tested kinases is shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_001.pdf" class="ext-link">Table S1</a>). The KinMap software tool provided by Cell Signaling Technology, Inc. (<a href="https://www.cellsignal.com" class="extLink">https://www.cellsignal.com</a>) was employed to map the TREEspot image. (b) Hierarchical clustering depicting the inhibition ratio of <b>1c</b> on the top 50 kinases (the higher the level, the better the inhibitory activity). (c) Kinases’ activity less than 50% in the presence of compound <b>1c</b> at 1 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Western blot analysis on the specific CK2 phosphorylation targets: (a) phosphorylation of the Akt1 serine 129 and (b) Cdc37 serine 13 in HCT-116 cells inoculated with varying levels of <b>1c</b> (5, 10, and 20 μM) for 24 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Molecular docking. Docking of <b>1c</b> into (a) CK2α (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6isj">6isj</a>) and (b) Clk2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6khe">6khe</a>) kinase X-ray crystal structure. Potentially relevant residues to the docking are labeled. Interactions are illustrated by dashed lines (H bonds, yellow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Investigation on the inhibition of <b>1c</b> on ALDH1A1. (a) A statistical analysis of the ALDH1A1 inhibitory ratio. (b) Western blotting assessment on expression of ALDH1A1 protein in HCT-116 cells treated with <b>CX-4945</b> (5 μM) and different quantities of <b>1c</b> (5, 10, and 20 μM) for 24 h, respectively. (c) mRNA transcription levels of ALDH1A1 after exposure to <b>CX-4945</b> and <b>1c</b> at 20 μM, respectively, in the HCT-116 cells for 24 h. (d) Inhibition rate of <b>1c</b> and <b>CX-4945</b> at different concentrations on the enzyme activity of ALDH1A1. Data were subjected to statistical analysis by using Student’s <i>t</i> test and given as the mean ± SD (<i>n</i> = 3). *<i>P</i> < 0.05 and **<i>P</i> < 0.01 vs <b>CX-4945</b> group or the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Investigation on the inhibition of cancer cell stemness. (a) A statistical analysis of the CD44<sup>+</sup>/CD133<sup>+</sup> inhibitory ratio. (b) qRT-PCR of mRNA transcription levels of stemness genes after exposure to <b>BBI608</b>, <b>CX-4945</b>, and <b>1c</b>, respectively, at 20 μM in the HCT-116<sup>ALDH+</sup> cells for 24 h. (c) The number and (d) the morphological observation of the HCT-116<sup>AHDH+</sup> cell tumorspheres treated with vehicle (DMSO), <b>BBI608</b> (5 μM), <b>CX-4945</b> (5 μM), and <b>1c</b> (5 μM) for 24 h and then cultivated for 10 days. Comparison of gene expression level was performed using the 2<sup>–ΔΔCt</sup> approach. Data were subjected to statistical analysis by using Student’s <i>t</i> test and given as the mean ± SD (<i>n</i> = 3). *<i>P</i> < 0.05 and **<i>P</i> < 0.01 vs <b>BBI608</b> group or the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>1c</b> regulated the GSK-3β(ser9)-Wnt/β-catenin signaling pathway. Western blotting images of (a) p-GSK-3β(ser9), GSK-3β, (c) DKK1, and β-catenin proteins induced by different concentrations of <b>1c</b> for 24 h in HCT-116 cells. (b) Decreased mRNA levels of Wnt target genes in HCT-116 cells upon exposure to <b>1c</b> (20 μM) for 24 h. (d) Transwell invasion assays. The HCT-116 cells were inoculated with <b>1c</b> and <b>CX-4945</b>, respectively, at 5 μM for 24 h. Data were subjected to statistical analysis by using Student’s <i>t</i> test and given as the mean ± SD (<i>n</i> = 3). *<i>P</i> < 0.05 and **<i>P</i> < 0.01 vs the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Cell apoptosis and cell cycle arrest analysis. (a) Cell apoptosis in HCT-116 cells treated with <b>CX-4945</b> (5 μM) and varying levels of <b>1c</b> (5, 10, and 20 μM) was assessed using flow cytometry (stained with Annexin V-FITC and PI). (b) A statistical analysis of apoptotic ratio. (c) Cell cycle arrest in HCT-116 cells inoculated with <b>CX-4945</b> (20 μM) and <b>1c</b> (20 μM), respectively, for 24 h; stained with PI; and explored with flow cytometry. (d) A statistical analysis of cell cycle arrest. The results were given as the mean ± SD (<i>n</i> = 3). **<i>P</i> < 0.01 vs the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Study on the mechanism of apoptotic pathway. (a) Western blotting assessment of Cyt c, Bcl-2, Bax, pro-caspase 9, cleaved caspase 9, pro-caspase 3, cleaved caspase 3, total PARP, cleaved PARP as well as β-actin after 24 h treatment of HCT-116 cells with <b>CX-4945</b> (20 μM) and <b>1c</b> (20 μM), respectively. (b) Expression levels of (a) acquired from western blotting and standardized with β-actin. The results are given as the mean ± SD (<i>n</i> = 3). **<i>P</i> < 0.01 and *<i>P</i> < 0.05 vs the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/medium/jm1c00131_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. <i>In vivo</i> HCT-116 xenograft model study of <b>1c</b>. Twenty nude mice inoculated with HCT-116 cells in the right armpit were divided into four groups as vehicle (equivalent volume of CMC-Na), <b>CX-4945·Na</b> (60 mg/kg), and <b>1c</b> (60 and 90 mg/kg). Animals were orally administrated twice a day for 4 weeks. (a) Excised tumor images from each group. (b) The relative volume of the tumors. (c) The relative tumor weight resected from all groups of sacrificed mice on the last day. (d) The body weights of each group mice in the period of 28 days. Data are given as the mean ± SD. *<i>P</i> < 0.05 and **<i>P</i> < 0.01 vs the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00131/20210415/images/large/jm1c00131_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00131&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i71">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74783" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74783" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 42 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kossenkov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purandare, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desilva, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jure-Kunkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrilovich, D. I.</span></span> <span> </span><span class="NLM_article-title">Inhibition of casein kinase 2 disrupts differentiation of myeloid cells in cancer and enhances the efficacy of immunotherapy in mice</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">5644</span>– <span class="NLM_lpage">5655</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-1229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1158%2F0008-5472.CAN-18-1229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=30139814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlSju7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=5644-5655&author=A.+Hashimotoauthor=C.+Gaoauthor=J.+Mastioauthor=A.+Kossenkovauthor=S.+I.+Abramsauthor=A.+V.+Purandareauthor=H.+Desilvaauthor=S.+Weeauthor=J.+Huntauthor=M.+Jure-Kunkelauthor=D.+I.+Gabrilovich&title=Inhibition+of+casein+kinase+2+disrupts+differentiation+of+myeloid+cells+in+cancer+and+enhances+the+efficacy+of+immunotherapy+in+mice&doi=10.1158%2F0008-5472.CAN-18-1229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of casein kinase 2 disrupts differentiation of myeloid cells in cancer and enhances the efficacy of immunotherapy in mice</span></div><div class="casAuthors">Hashimoto, Ayumi; Gao, Chan; Mastio, Jerome; Kossenkov, Andrew; Abrams, Scott I.; Purandare, Ashok V.; Desilva, Heshani; Wee, Susan; Hunt, John; Jure-Kunkel, Maria; Gabrilovich, Dmitry I.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5644-5655</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The role of myeloid cells as regulators of tumor progression that significantly impact the efficacy of cancer immunotherapies makes them an attractive target for inhibition.  Here we explore the effect of a novel, potent, and selective inhibitor of serine/threonine protein kinase casein kinase 2 (CK2) on modulating myeloid cells in the tumor microenvironment.  Although inhibition of CK2 caused only a modest effect on dendritic cells in tumor-bearing mice, it substantially reduced the amt. of polymorphonuclear myeloid-derived suppressor cells and tumor-assocd. macrophages.  This effect was not caused by the induction of apoptosis, but rather by a block of differentiation.  Our results implicated downregulation of CCAAT-enhancer binding protein-α in this effect.  Although CK2 inhibition did not directly affect tumor cells, it dramatically enhanced the antitumor activity of immune checkpoint receptor blockade using anti-CTLA-4 antibody.  These results suggest a potential role of CK2 inhibitors in combination therapies against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBY1mwFqvLhLVg90H21EOLACvtfcHk0liF1rd-IlnCEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlSju7rO&md5=bc9ead05597f71437fbf55e6832cc2b8</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-1229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-1229%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DMastio%26aufirst%3DJ.%26aulast%3DKossenkov%26aufirst%3DA.%26aulast%3DAbrams%26aufirst%3DS.%2BI.%26aulast%3DPurandare%26aufirst%3DA.%2BV.%26aulast%3DDesilva%26aufirst%3DH.%26aulast%3DWee%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DJ.%26aulast%3DJure-Kunkel%26aufirst%3DM.%26aulast%3DGabrilovich%26aufirst%3DD.%2BI.%26atitle%3DInhibition%2520of%2520casein%2520kinase%25202%2520disrupts%2520differentiation%2520of%2520myeloid%2520cells%2520in%2520cancer%2520and%2520enhances%2520the%2520efficacy%2520of%2520immunotherapy%2520in%2520mice%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D5644%26epage%3D5655%26doi%3D10.1158%2F0008-5472.CAN-18-1229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issinger, O.-G.</span></span> <span> </span><span class="NLM_article-title">Protein kinase CK2 in human diseases</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1870</span>– <span class="NLM_lpage">1886</span>, <span class="refDoi"> DOI: 10.2174/092986708785132933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.2174%2F092986708785132933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=18691045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVSrsL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1870-1886&author=B.+Guerraauthor=O.-G.+Issinger&title=Protein+kinase+CK2+in+human+diseases&doi=10.2174%2F092986708785132933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase CK2 in human diseases</span></div><div class="casAuthors">Guerra, Barbara; Issinger, Olaf-Georg</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1870-1886</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinase CK2 (formerly referred to as casein kinase II) is an evolutionary conserved, ubiquitous protein kinase.  There are two paralog catalytic subunits, i.e. alpha (A1) and alpha' (A2).  The alpha and alpha' subunits are linked to two beta subunits to produce a heterotetrameric structure.  The catalytic alpha subunits are distantly related to the CMGC subfamily of kinases, such as the Cdk kinases.  There are some peculiarities assocd. with protein kinase CK2, which are not found with most other protein kinases: (1) the enzyme is constitutively active, (2) it can use ATP and GTP and (3) it is found elevated in most tumors investigated and rapidly proliferating tissues.  With the elucidation of the structure of the catalytic subunit, it was possible to explain why the enzyme is constitutively active and why it can bind GTP.  Considerable information on the potential roles of CK2 in various disease processes including cancer has been gained in recent years, and the present review may help to further elucidate its aberrant role in many disease states.  Its peculiar structural features may be advantageous in designing tailor-made compds. with the possibility to specifically target this protein kinase.  Since not all the aspects of what has been published on CK2 can be covered in this review, we would like to recommend the following reviews; (1) for general information on CK2 and (2) with a focus on aberrant CK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHAjFIdLj5brVg90H21EOLACvtfcHk0liF1rd-IlnCEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVSrsL7N&md5=af6ef98b360211abbb0ce5adcfe439e3</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2174%2F092986708785132933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708785132933%26sid%3Dliteratum%253Aachs%26aulast%3DGuerra%26aufirst%3DB.%26aulast%3DIssinger%26aufirst%3DO.-G.%26atitle%3DProtein%2520kinase%2520CK2%2520in%2520human%2520diseases%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D1870%26epage%3D1886%26doi%3D10.2174%2F092986708785132933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nitta, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gholamin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feroze, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheshier, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span> <span> </span><span class="NLM_article-title">Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathway</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">3688</span>– <span class="NLM_lpage">3699</span>, <span class="refDoi"> DOI: 10.1038/onc.2014.299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1038%2Fonc.2014.299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=25241897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyhtL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=3688-3699&author=R.+T.+Nittaauthor=S.+Gholaminauthor=A.+H.+Ferozeauthor=M.+Agarwalauthor=S.+H.+Cheshierauthor=S.+S.+Mitraauthor=G.+Li&title=Casein+kinase+2%CE%B1+regulates+glioblastoma+brain+tumor-initiating+cell+growth+through+the+%CE%B2-catenin+pathway&doi=10.1038%2Fonc.2014.299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathway</span></div><div class="casAuthors">Nitta, R. T.; Gholamin, S.; Feroze, A. H.; Agarwal, M.; Cheshier, S. H.; Mitra, S. S.; Li, G.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3688-3699</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glioblastoma (GBM) is the most common and fatal primary brain tumor in humans, and it is essential that new and better therapies are developed to treat this disease.  Previous research suggests that casein kinase 2 (CK2) may be a promising therapeutic target for GBMs.  CK2 has enhanced expression or activity in numerous cancers, including GBM, and it has been demonstrated that inhibitors of CK2 regressed tumor growth in GBM xenograft mouse models.  Our studies demonstrate that the CK2 subunit, CK2α, is overexpressed in and has an important role in regulating brain tumor-initiating cells (BTIC) in GBM.  Initial studies showed that two GBM cell lines (U87-MG and U138) transduced with CK2α had enhanced proliferation and anchorage-independent growth.  Inhibition of CKα using siRNA or small-mol. inhibitors (TBBz, CX-4945) reduced cell growth, decreased tumor size, and increased survival rates in GBM xenograft mouse models.  We also verified that inhibition of CK2α decreased the activity of a well-known GBM-initiating cell regulator, β-catenin.  Loss of CK2α decreased two β-catenin-regulated genes that are involved in GBM-initiating cell growth, OCT4 and NANOG.  To det. the importance of CK2α in GBM stem cell maintenance, we reduced CK2α activity in primary GBM samples and tumor spheres derived from GBM patients.  We discovered that loss of CK2α activity reduced the sphere-forming capacity of BTIC and decreased numerous GBM stem cell markers, including CD133, CD90, CD49f and A2B5.  Our study suggests that CK2α is involved in GBM tumorigenesis by maintaining BTIC through the regulation of β-catenin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcrw3mE50HGLVg90H21EOLACvtfcHk0ljDRFFAsg7ehA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyhtL7L&md5=892bcf619d64a1a0752beb8cd720814a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fonc.2014.299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2014.299%26sid%3Dliteratum%253Aachs%26aulast%3DNitta%26aufirst%3DR.%2BT.%26aulast%3DGholamin%26aufirst%3DS.%26aulast%3DFeroze%26aufirst%3DA.%2BH.%26aulast%3DAgarwal%26aufirst%3DM.%26aulast%3DCheshier%26aufirst%3DS.%2BH.%26aulast%3DMitra%26aufirst%3DS.%2BS.%26aulast%3DLi%26aufirst%3DG.%26atitle%3DCasein%2520kinase%25202%25CE%25B1%2520regulates%2520glioblastoma%2520brain%2520tumor-initiating%2520cell%2520growth%2520through%2520the%2520%25CE%25B2-catenin%2520pathway%26jtitle%3DOncogene%26date%3D2015%26volume%3D34%26spage%3D3688%26epage%3D3699%26doi%3D10.1038%2Fonc.2014.299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donella-Deana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzzene, M.</span></span> <span> </span><span class="NLM_article-title">Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e49193</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0049193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1371%2Fjournal.pone.0049193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=23145120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCju7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=S.+Zaninauthor=C.+Borgoauthor=C.+Girardiauthor=S.+E.+O%E2%80%99Brienauthor=Y.+Miyataauthor=L.+A.+Pinnaauthor=A.+Donella-Deanaauthor=M.+Ruzzene&title=Effects+of+the+CK2+inhibitors+CX-4945+and+CX-5011+on+drug-resistant+cells&doi=10.1371%2Fjournal.pone.0049193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells</span></div><div class="casAuthors">Zanin, Sofia; Borgo, Christian; Girardi, Cristina; O'Brien, Sean E.; Miyata, Yoshihiko; Pinna, Lorenzo A.; Donella-Deana, Arianna; Ruzzene, Maria</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e49193</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">CK2 is a pleiotropic protein kinase, which regulates many survival pathways and plays a global anti-apoptotic function.  It is highly expressed in tumor cells, and is presently considered a promising therapeutic target.  Among the many inhibitors available for this kinase, the recently developed CX-4945 and CX-5011 have proved to be very potent, selective and effective in inducing cell death in tumor cells; CX-4945 has recently entered clin. trials.  However, no data are available on the efficacy of these compds. to overcome drug resistance, a major reasons of cancer therapy failure.  Here we address this point, by studying their effects in several tumor cell lines, each available as variant R resistant to drug-induced apoptosis, and normal-sensitive variant S.  We found that the inhibition of endogenous CK2 was very similar in S and R treated cells, with more than 50% CK2 activity redn. at sub-micromolar concns. of CX-4945 and CX-5011.  A consequent apoptotic response was induced both in S and R variants of each pairs.  Moreover, the combined treatment of CX-4945 plus vinblastine was able to sensitize to vinblastine R cells that are otherwise almost insensitive to this conventional antitumor drug.  Consistently, doxorubicin accumulation in multidrug resistant (MDR) cells was greatly increased by CX-4945.  In summary, we demonstrated that all the R variants are sensitive to CX-4945 and CX-5011; since some of the treated R lines express the extrusion pump Pgp, often responsible of the MDR phenotype, we can also conclude that the two inhibitors can successfully overcome the MDR phenomenon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMN0ukrWreobVg90H21EOLACvtfcHk0ljDRFFAsg7ehA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCju7fK&md5=7586f90184c89ce05f94a83ed126b93a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0049193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0049193%26sid%3Dliteratum%253Aachs%26aulast%3DZanin%26aufirst%3DS.%26aulast%3DBorgo%26aufirst%3DC.%26aulast%3DGirardi%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BE.%26aulast%3DMiyata%26aufirst%3DY.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26aulast%3DDonella-Deana%26aufirst%3DA.%26aulast%3DRuzzene%26aufirst%3DM.%26atitle%3DEffects%2520of%2520the%2520CK2%2520inhibitors%2520CX-4945%2520and%2520CX-5011%2520on%2520drug-resistant%2520cells%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0049193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litchfield, D. W.</span></span> <span> </span><span class="NLM_article-title">Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1784</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2007.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2Fj.bbapap.2007.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=17931986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlCjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1784&publication_year=2008&pages=33-47&author=J.+S.+Duncanauthor=D.+W.+Litchfield&title=Too+much+of+a+good+thing%3A+the+role+of+protein+kinase+CK2+in+tumorigenesis+and+prospects+for+therapeutic+inhibition+of+CK2&doi=10.1016%2Fj.bbapap.2007.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Too much of a good thing: The role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2</span></div><div class="casAuthors">Duncan, James S.; Litchfield, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1784</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-47</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  CK2 is a highly conserved protein serine/threonine kinase that is ubiquitously distributed in eukaryotes, constitutively active and has been implicated in multiple cellular functions, as well as in tumorigenesis and transformation.  Elevated CK2 activity has been assocd. with the malignant transformation of several tissues and is assocd. with aggressive tumor behavior.  While the precise roles of CK2 in tumorigenesis remain incompletely understood, mounting evidence suggests a role for CK2 in the protection of cells from apoptosis via the regulation of tumor suppressor and oncogene activity.  Consequently, CK2 has emerged as a potential therapeutic target, and strategies to inhibit CK2 have been ongoing in pre-clin. trials.  This review will focus on published evidence highlighting the mol. mechanisms by which CK2 functions in the promotion of tumorigenesis, as well as review current strategies being used to inhibit CK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1OxaWc4qFxrVg90H21EOLACvtfcHk0ljDRFFAsg7ehA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlCjsg%253D%253D&md5=eb3e72e4aeb2e192122002e902ee9d7b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2007.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2007.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DDuncan%26aufirst%3DJ.%2BS.%26aulast%3DLitchfield%26aufirst%3DD.%2BW.%26atitle%3DToo%2520much%2520of%2520a%2520good%2520thing%253A%2520the%2520role%2520of%2520protein%2520kinase%2520CK2%2520in%2520tumorigenesis%2520and%2520prospects%2520for%2520therapeutic%2520inhibition%2520of%2520CK2%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2008%26volume%3D1784%26spage%3D33%26epage%3D47%26doi%3D10.1016%2Fj.bbapap.2007.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Small molecule modulators targeting protein kinase CK1 and CK2</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">111581</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2Fj.ejmech.2019.111581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=31400711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFKjt7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2019&pages=111581&author=Y.+Qiaoauthor=T.+Chenauthor=H.+Yangauthor=Y.+Chenauthor=H.+Linauthor=W.+Quauthor=F.+Fengauthor=W.+Liuauthor=Q.+Guoauthor=Z.+Liuauthor=H.+Sun&title=Small+molecule+modulators+targeting+protein+kinase+CK1+and+CK2&doi=10.1016%2Fj.ejmech.2019.111581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule modulators targeting protein kinase CK1 and CK2</span></div><div class="casAuthors">Qiao, Yuting; Chen, Tingkai; Yang, Hongyu; Chen, Yao; Lin, Hongzhi; Qu, Wei; Feng, Feng; Liu, Wenyuan; Guo, Qinglong; Liu, Zongliang; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111581</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Casein kinase (CK) is a type of conserved serine/threonine protein kinase that phosphorylates many important proteins in body.  Researchers found that CK is involved in a variety of signaling pathways, and also plays an important role in inflammation, cancer, and nervous system diseases.  Thus, it is considered to be a promising target for the treatment of related diseases.  Many CK small mol. inhibitors have been reported so far, and most are ATP competitive inhibitors.  However, these CK inhibitors lack the basic properties required for in vivo use, such as selectivity, cell permeability, metabolic stability, correct pharmacokinetic characteristics, and cellular environment.  But small mol. inhibitors still have an advantage in drug research due to their controllable pharmacol. and pharmacokinetic properties.  CX-4945 discovered by Cylene Pharmaceutical is the only one CK2 inhibitor entering into Phase II clin. trials till now.  In recent years, significant advances have been made in the design of non-competitive inhibitors of CK and in the application of multi-target inhibition strategies.  Here, we review the published CK inhibitors and analyze their structure-activity relationships (SAR).  We also summarized the eutectic structure with identified hot spots to provide a ref. for future drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIgjpzLBZU1rVg90H21EOLACvtfcHk0lj1UZgxawN3jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFKjt7%252FN&md5=95b54cedad246ee9c0784e997194b4ea</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111581%26sid%3Dliteratum%253Aachs%26aulast%3DQiao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DQu%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DSmall%2520molecule%2520modulators%2520targeting%2520protein%2520kinase%2520CK1%2520and%2520CK2%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D181%26spage%3D111581%26doi%3D10.1016%2Fj.ejmech.2019.111581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trembley, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, K.</span></span> <span> </span><span class="NLM_article-title">Protein kinase CK2 in health and disease: CK2: a key player in cancer biology</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1858</span>– <span class="NLM_lpage">1867</span>, <span class="refDoi"> DOI: 10.1007/s00018-009-9154-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1007%2Fs00018-009-9154-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=19387548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsVGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2009&pages=1858-1867&author=J.+H.+Trembleyauthor=G.+Wangauthor=G.+Ungerauthor=J.+Slatonauthor=K.+Ahmed&title=Protein+kinase+CK2+in+health+and+disease%3A+CK2%3A+a+key+player+in+cancer+biology&doi=10.1007%2Fs00018-009-9154-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">CK2: a key player in cancer biology</span></div><div class="casAuthors">Trembley, J. H.; Wang, G.; Unger, G.; Slaton, J.; Ahmed, K.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">11-12</span>),
    <span class="NLM_cas:pages">1858-1867</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  Elevated levels of protein kinase CK2 (formerly casein kinase 2 or II) have long been assocd. with increased cell growth and proliferation both in normal and cancer cells.  The ability of CK2 to also act as a potent suppressor of apoptosis offers an important link to its involvement in cancer since deregulation of both cell proliferation and apoptosis are among the key features of cancer cell biol.  Dysregulated CK2 may impact both of these processes in cancer cells.  All cancers that were examd. show increased CK2 expression, which may also relate to prognosis.  The extensive involvement of CK2 in cancer derives from its impact on diverse mol. pathways controlling cell proliferation and cell death.  Downregulation of CK2 by various approaches results in induction of apoptosis in cultured cell and xenograft cancer models suggesting its potential as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5aEwY88dKgLVg90H21EOLACvtfcHk0lj1UZgxawN3jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsVGjs7g%253D&md5=2b39fc769c570871f2769d3668c53253</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs00018-009-9154-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-009-9154-y%26sid%3Dliteratum%253Aachs%26aulast%3DTrembley%26aufirst%3DJ.%2BH.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DUnger%26aufirst%3DG.%26aulast%3DSlaton%26aufirst%3DJ.%26aulast%3DAhmed%26aufirst%3DK.%26atitle%3DProtein%2520kinase%2520CK2%2520in%2520health%2520and%2520disease%253A%2520CK2%253A%2520a%2520key%2520player%2520in%2520cancer%2520biology%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2009%26volume%3D66%26spage%3D1858%26epage%3D1867%26doi%3D10.1007%2Fs00018-009-9154-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruzzene, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, L. A.</span></span> <span> </span><span class="NLM_article-title">Addiction to protein kinase CK2: a common denominator of diverse cancer cells?</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1804</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">504</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2009.07.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2Fj.bbapap.2009.07.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=19665589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1ynu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1804&publication_year=2010&pages=499-504&author=M.+Ruzzeneauthor=L.+A.+Pinna&title=Addiction+to+protein+kinase+CK2%3A+a+common+denominator+of+diverse+cancer+cells%3F&doi=10.1016%2Fj.bbapap.2009.07.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Addiction to protein kinase CK2: A common denominator of diverse cancer cells?</span></div><div class="casAuthors">Ruzzene, Maria; Pinna, Lorenzo A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1804</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">499-504</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  At variance with most oncogenic protein kinases whose malignancy is generally due to genetic alterations conferring constitutive activity, CK2 is a highly pleiotropic Ser/Thr protein kinase naturally endowed with constitutive activity and lacking gain-of-function mutants.  Nonetheless CK2 is abnormally elevated in a wide variety of tumors and there is strong evidence that it operates as a cancer driver by creating a cellular environment favorable to neoplasia: notably, CK2 plays a global role as an anti-apoptotic and pro-survival agent, it enhances the multi-drug resistance (MDR) phenotype, it assists the chaperone machinery which protects the "onco-kinome" and it promotes neo-angiogenesis.  Based on this scenario we propose that the implication of CK2 in neoplasia is an example of "non oncogene addiction", i.e. over reliance of the perturbed cellular signaling network on high CK2 level for its own maintenance.  Consistent with this, an ample spectrum of diverse types of cancer cells have been already shown to rely on high CK2 level for their survival, as judged from their response to specific CK2 inhibitors and silencing of endogenous CK2 catalytic subunits.  Remarkably, among these are cells whose cancer phenotype arises from the genetic alteration of onco-kinases (e.g. Abl and Alk) different from CK2 and insensitive to the CK2 inhibitors used in those expts.  Based on these premises, CK2 could represent a "multi-purpose" target for the treatment of different kinds of tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryaRBb7mWsWrVg90H21EOLACvtfcHk0lj1UZgxawN3jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1ynu7k%253D&md5=a8088e387d13469774ce9aef315d0ae5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2009.07.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2009.07.018%26sid%3Dliteratum%253Aachs%26aulast%3DRuzzene%26aufirst%3DM.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26atitle%3DAddiction%2520to%2520protein%2520kinase%2520CK2%253A%2520a%2520common%2520denominator%2520of%2520diverse%2520cancer%2520cells%253F%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2010%26volume%3D1804%26spage%3D499%26epage%3D504%26doi%3D10.1016%2Fj.bbapap.2009.07.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perea, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baladrón, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzuela, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, Y.</span></span> <span> </span><span class="NLM_article-title">CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation</span>. <i>Semin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1053/j.seminoncol.2018.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1053%2Fj.seminoncol.2018.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=30318085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtV2ltr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2018&pages=58-67&author=S.+E.+Pereaauthor=I.+Baladr%C3%B3nauthor=C.+Valenzuelaauthor=Y.+Perera&title=CIGB-300%3A+A+peptide-based+drug+that+impairs+the+Protein+Kinase+CK2-mediated+phosphorylation&doi=10.1053%2Fj.seminoncol.2018.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation</span></div><div class="casAuthors">Perea, Silvio E.; Baladron, Idania; Valenzuela, Carmen; Perera, Yasser</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">58-67</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Protein kinase CK2, formerly referred to as casein kinase II, is a serine/threonine kinase often found overexpressed in solid tumors and hematol. malignancies that phosphorylates many substrates integral to the hallmarks of cancer.  CK2 has emerged as a viable oncol. target having been exptl. validated with different kinase inhibitors, including small mol. ATP-competitors, synthetic peptides, and antisense oligonucleotides.  To date only two CK2 inhibitors, CIGB-300 and CX-4945, have entered the clinic in phase 1-2 trials.  This review provides information on CIGB-300, a cell-permeable cyclic peptide that inhibits CK2-mediated phosphorylation by targeting the substrate phosphoacceptor domain.  We review data that support the concept of CK2 as an anticancer target, address the mechanism of action, and summarize preclin. studies showing antiangiogenic and antimetastatic effects as well as synergism with anticancer drugs in preclin. models.  We also summarize early clin. research (phase 1/2 trials) of CIGB-300 in cervical cancer, including data in combination with chemoradiotherapy.  The clin. data demonstrate the safety, tolerability, and clin. effects of intratumoral injections of CIGB-300 and provide the foundation for future phase 3 clin. trials in locally advanced cervical cancer in combination with std. chemoradiotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI8SBguqIb-7Vg90H21EOLACvtfcHk0lj2t57xhEDqUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtV2ltr3F&md5=ce3365d0035b44b315497a0f1ec57e8c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2018.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2018.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DPerea%26aufirst%3DS.%2BE.%26aulast%3DBaladr%25C3%25B3n%26aufirst%3DI.%26aulast%3DValenzuela%26aufirst%3DC.%26aulast%3DPerera%26aufirst%3DY.%26atitle%3DCIGB-300%253A%2520A%2520peptide-based%2520drug%2520that%2520impairs%2520the%2520Protein%2520Kinase%2520CK2-mediated%2520phosphorylation%26jtitle%3DSemin.%2520Oncol.%26date%3D2018%26volume%3D45%26spage%3D58%26epage%3D67%26doi%3D10.1053%2Fj.seminoncol.2018.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Fusco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brear, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iegre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiou, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sore, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyvönen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3471</span>– <span class="NLM_lpage">3482</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.04.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2Fj.bmc.2017.04.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=28495381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntlWktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=3471-3482&author=C.+de%0AFuscoauthor=P.+Brearauthor=J.+Iegreauthor=K.+H.+Georgiouauthor=H.+F.+Soreauthor=M.+Hyv%C3%B6nenauthor=D.+R.+Spring&title=A+fragment-based+approach+leading+to+the+discovery+of+a+novel+binding+site+and+the+selective+CK2+inhibitor+CAM4066&doi=10.1016%2Fj.bmc.2017.04.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066</span></div><div class="casAuthors">De Fusco, Claudia; Brear, Paul; Iegre, Jessica; Georgiou, Kathy Hadje; Sore, Hannah F.; Hyvonen, Marko; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3471-3482</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recently the authors reported the discovery of a potent and selective CK2α inhibitor CAM4066.  This compd. inhibits CK2 activity by exploiting a pocket located outside the ATP binding site (αD pocket).  Here the authors describe in detail the journey that led to the discovery of CAM4066 using the challenging fragment linking strategy.  Specifically, the authors aimed to develop inhibitors by linking a high-affinity fragment anchored in the αD site to a weakly binding warhead fragment occupying the ATP site.  Moreover, the authors describe the remarkable impact that mol. modeling had on the development of this novel chem. tool.  The work described herein shows potential for the development of a novel class of CK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-es_MXrRt5bVg90H21EOLACvtfcHk0lj2t57xhEDqUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntlWktbc%253D&md5=2c4bf2e6b0528149dc09d04badfdeab3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.04.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.04.037%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BFusco%26aufirst%3DC.%26aulast%3DBrear%26aufirst%3DP.%26aulast%3DIegre%26aufirst%3DJ.%26aulast%3DGeorgiou%26aufirst%3DK.%2BH.%26aulast%3DSore%26aufirst%3DH.%2BF.%26aulast%3DHyv%25C3%25B6nen%26aufirst%3DM.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DA%2520fragment-based%2520approach%2520leading%2520to%2520the%2520discovery%2520of%2520a%2520novel%2520binding%2520site%2520and%2520the%2520selective%2520CK2%2520inhibitor%2520CAM4066%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D3471%26epage%3D3482%26doi%3D10.1016%2Fj.bmc.2017.04.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic studies unveiled the drug-drug interaction between trans-2,3,5,4′-tetrahydroxystilbene-2-O-β-d-glucopyranoside and emodin that may contribute to the idiosyncratic hepatotoxicity of polygoni multiflori radix</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">672</span>– <span class="NLM_lpage">680</span>, <span class="refDoi"> DOI: 10.1016/j.jpba.2018.11.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2Fj.jpba.2018.11.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=30472586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ylsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2019&pages=672-680&author=Y.+Xingauthor=L.+Wangauthor=C.+Wangauthor=Y.+Zhangauthor=Y.+Zhangauthor=L.+Huauthor=X.+Gaoauthor=L.+Hanauthor=W.+Yang&title=Pharmacokinetic+studies+unveiled+the+drug-drug+interaction+between+trans-2%2C3%2C5%2C4%E2%80%B2-tetrahydroxystilbene-2-O-%CE%B2-d-glucopyranoside+and+emodin+that+may+contribute+to+the+idiosyncratic+hepatotoxicity+of+polygoni+multiflori+radix&doi=10.1016%2Fj.jpba.2018.11.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic studies unveiled the drug-drug interaction between trans-2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucopyranoside and emodin that may contribute to the idiosyncratic hepatotoxicity of Polygoni Multiflori Radix</span></div><div class="casAuthors">Xing, Yanchao; Wang, Linlin; Wang, Chenxi; Zhang, Youcai; Zhang, Yi; Hu, Limin; Gao, Xiumei; Han, Lifeng; Yang, Wenzhi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">672-680</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Polygoni Multiflori Radix (PMR) has been a reputable tonifying traditional Chinese medicine for a long history.  However, clin. side effects regarding its idiosyncratic hepatotoxicity are occasionally reported.  The contg. anthraquinones, particularly emodin, could cause liver injury in both in vitro and in vivo expts.  It is well-known that some compds. could influence other compds.' pharmacokinetic parameters significantly.  In this work, the influence of trans-2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucopyranoside (TSG) on the pharmacokinetic behavior of emodin in rats was evaluated by an ultra-high performance liq. chromatog./triple quadrupole mass spectrometry (UHPLC/MS-MS) approach.  Pharmacokinetic parameters of emodin, PMR ext., and TSG-free PMR ext. (prepd. by a component "knock-out" strategy with TSG eliminated), in rats after one-day and seven-day administration were detd. and compared.  We found that, after seven-day administration of the whole PMR ext. (rather than TSG-free ext.), emodin in rats was accumulated.  And accordingly, the exposure of emodin in rats pre-treated with single TSG for seven days could be significantly enhanced.  The results indicate that TSG was able to accelerate the exposure and metab. of emodin.  The effect of TSG on the metabolic activities of cytochrome P 450 enzymes was further assessed by an LC-MS cocktail method.  The accelerated exposure and metab. of emodin could result from the up-regulation activity of CYP450s, in particular CYP1A2 isoenzyme.  The findings obtained in this work firstly unveiled DDI between TSG and emodin in the administration of PMR, thus may provide a basis for unveiling the underlying mechanism of PMR-induced liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC4F4HUD-t87Vg90H21EOLACvtfcHk0lj2t57xhEDqUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ylsbrN&md5=3ec3f487fac3c68b09a227d7d3d177a9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2018.11.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2018.11.034%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DW.%26atitle%3DPharmacokinetic%2520studies%2520unveiled%2520the%2520drug-drug%2520interaction%2520between%2520trans-2%252C3%252C5%252C4%25E2%2580%25B2-tetrahydroxystilbene-2-O-%25CE%25B2-d-glucopyranoside%2520and%2520emodin%2520that%2520may%2520contribute%2520to%2520the%2520idiosyncratic%2520hepatotoxicity%2520of%2520polygoni%2520multiflori%2520radix%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2019%26volume%3D164%26spage%3D672%26epage%3D680%26doi%3D10.1016%2Fj.jpba.2018.11.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buontempo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCubrey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzzene, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappellini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelisti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelisti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barata, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A. M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targeting of CK2 in acute and chronic leukemias</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1038%2Fleu.2017.301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=28951560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtlShsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=1-10&author=F.+Buontempoauthor=J.+A.+McCubreyauthor=E.+Orsiniauthor=M.+Ruzzeneauthor=A.+Cappelliniauthor=A.+Lonettiauthor=C.+Evangelistiauthor=F.+Chiariniauthor=C.+Evangelistiauthor=J.+T.+Barataauthor=A.+M.+Martelli&title=Therapeutic+targeting+of+CK2+in+acute+and+chronic+leukemias&doi=10.1038%2Fleu.2017.301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of CK2 in acute and chronic leukemias</span></div><div class="casAuthors">Buontempo, F.; McCubrey, J. A.; Orsini, E.; Ruzzene, M.; Cappellini, A.; Lonetti, A.; Evangelisti, C.; Chiarini, F.; Evangelisti, C.; Barata, J. T.; Martelli, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">CK2 is a ubiquitously expressed, constitutively active Ser/Thr protein kinase, which is considered the most pleiotropic protein kinase in the human kinome.  Such a pleiotropy explains the involvement of CK2 in many cellular events.  However, its predominant roles are stimulation of cell growth and prevention of apoptosis.  High levels of CK2 mRNA and protein are assocd. with CK2 pathol. functions in human cancers.  Over the last decade, basic and translational studies have provided evidence of CK2 as a pivotal mol. driving the growth of different blood malignancies.  CK2 overexpression has been demonstrated in nearly all the types of hematol. cancers, including acute and chronic leukemias, where CK2 is a key regulator of signaling networks crit. for cell proliferation, survival and drug resistance.  The findings that emerged from these studies suggest that CK2 could be a valuable therapeutic target in leukemias and supported the initiation of clin. trials using CK2 antagonists.  In this review, we summarize the recent advances on the understanding of the signaling pathways involved in CK2 inhibition-mediated effects with a particular emphasis on the combinatorial use of CK2 inhibitors as novel therapeutic strategies for treating both acute and chronic leukemia patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1J7PM7mhdwLVg90H21EOLACvtfcHk0lgOIf2iSk6iRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtlShsw%253D%253D&md5=072c052cf8a42b610a533ae0048510fb</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.301%26sid%3Dliteratum%253Aachs%26aulast%3DBuontempo%26aufirst%3DF.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26aulast%3DOrsini%26aufirst%3DE.%26aulast%3DRuzzene%26aufirst%3DM.%26aulast%3DCappellini%26aufirst%3DA.%26aulast%3DLonetti%26aufirst%3DA.%26aulast%3DEvangelisti%26aufirst%3DC.%26aulast%3DChiarini%26aufirst%3DF.%26aulast%3DEvangelisti%26aufirst%3DC.%26aulast%3DBarata%26aufirst%3DJ.%2BT.%26aulast%3DMartelli%26aufirst%3DA.%2BM.%26atitle%3DTherapeutic%2520targeting%2520of%2520CK2%2520in%2520acute%2520and%2520chronic%2520leukemias%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D1%26epage%3D10%26doi%3D10.1038%2Fleu.2017.301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erdreich-Epstein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groshen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garlich, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durden, D. L.</span></span> <span> </span><span class="NLM_article-title">Association of high microvessel αvβ3 and low PTEN with poor outcome in Stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">52193</span>– <span class="NLM_lpage">52210</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.13386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.18632%2Foncotarget.13386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=28881723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A280%3ADC%252BC1cbls1ylsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=52193-52210&author=A.+Erdreich-Epsteinauthor=L.+R.+Singhauthor=S.+Joshiauthor=F.+M.+Vegaauthor=P.+Guoauthor=J.+Xuauthor=S.+Groshenauthor=W.+Yeauthor=M.+Millardauthor=M.+Campanauthor=G.+Moralesauthor=J.+R.+Garlichauthor=P.+W.+Lairdauthor=R.+C.+Seegerauthor=H.+Shimadaauthor=D.+L.+Durden&title=Association+of+high+microvessel+%CE%B1v%CE%B23+and+low+PTEN+with+poor+outcome+in+Stage+3+neuroblastoma%3A+rationale+for+using+first+in+class+dual+PI3K%2FBRD4+inhibitor%2C+SF1126&doi=10.18632%2Foncotarget.13386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126</span></div><div class="casAuthors">Erdreich-Epstein Anat; Guo Pinzheng; Xu Jingying; Millard Melissa; Seeger Robert C; Erdreich-Epstein Anat; Shimada Hiroyuki; Singh Alok R; Joshi Shweta; Vega Francisco M; Durden Donald L; Vega Francisco M; Groshen Susan; Ye Wei; Campan Mihaela; Laird Peter W; Morales Guillermo; Garlich Joseph R; Durden Donald L; Laird Peter W; Laird Peter W; Durden Donald L</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">52193-52210</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Neuroblastoma (NB) is the most common extracranial solid tumor in children.  Our previous studies showed that the angiogenic integrin αvβ3 was increased in high-risk metastatic (stage 4) NB compared with localized neuroblastomas.  Herein, we show that integrin αvβ3 was expressed on 68% of microvessels in MYCN-amplified stage 3 neuroblastomas, but only on 34% (means) in MYCN-non-amplified tumors (p < 0.001; n = 54).  PTEN, a tumor suppressor involved in αvβ3 signaling, was expressed in neuroblastomas either diffusely, focally or not at all (immunohistochemistry).  Integrin αvβ3 was expressed on 60% of tumor microvessels when PTEN was negative or focal, as compared to 32% of microvessels in tumors with diffuse PTEN expression (p < 0.001).  In a MYCN transgenic mouse model, loss of one allele of PTEN promoted tumor growth, illustrating the potential role of PTEN in neuroblastoma pathogenesis.  Interestingly, we report the novel dual PI-3K/BRD4 activity of SF1126 (originally developed as an RGD-conjugated pan PI3K inhibitor).  SF1126 inhibits BRD4 bromodomain binding to acetylated lysine residues with histone H3 as well as PI3K activity in the MYCN amplified neuroblastoma cell line IMR-32.  Moreover, SF1126 suppressed MYCN expression and MYCN associated transcriptional activity in IMR-32 and CHLA136, resulting in overall decrease in neuroblastoma cell viability.  Finally, treatment of neuroblastoma tumors with SF1126 inhibited neuroblastoma growth in vivo.  These data suggest integrin αvβ3, MYCN/BRD4 and PTEN/PI3K/AKT signaling as biomarkers and hence therapeutic targets in neuroblastoma and support testing of the RGD integrin αvβ3-targeted PI-3K/BRD4 inhibitor, SF1126 as a therapeutic strategy in this specific subgroup of high risk neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQyuSQS7mkcmkBuFdjgVNKSfW6udTcc2eYLbylNBu5Hu7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbls1ylsg%253D%253D&md5=87ecbd21fda42aa68e2061a405ede51c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13386%26sid%3Dliteratum%253Aachs%26aulast%3DErdreich-Epstein%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DL.%2BR.%26aulast%3DJoshi%26aufirst%3DS.%26aulast%3DVega%26aufirst%3DF.%2BM.%26aulast%3DGuo%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DGroshen%26aufirst%3DS.%26aulast%3DYe%26aufirst%3DW.%26aulast%3DMillard%26aufirst%3DM.%26aulast%3DCampan%26aufirst%3DM.%26aulast%3DMorales%26aufirst%3DG.%26aulast%3DGarlich%26aufirst%3DJ.%2BR.%26aulast%3DLaird%26aufirst%3DP.%2BW.%26aulast%3DSeeger%26aufirst%3DR.%2BC.%26aulast%3DShimada%26aufirst%3DH.%26aulast%3DDurden%26aufirst%3DD.%2BL.%26atitle%3DAssociation%2520of%2520high%2520microvessel%2520%25CE%25B1v%25CE%25B23%2520and%2520low%2520PTEN%2520with%2520poor%2520outcome%2520in%2520Stage%25203%2520neuroblastoma%253A%2520rationale%2520for%2520using%2520first%2520in%2520class%2520dual%2520PI3K%252FBRD4%2520inhibitor%252C%2520SF1126%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D52193%26epage%3D52210%26doi%3D10.18632%2Foncotarget.13386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zakharia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borad, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, L. R.</span></span> <span> </span><span class="NLM_article-title">Preclinical in vitro and in vivo evidence of an antitumor effect of CX-4945, a casein kinase II inhibitor, in cholangiocarcinoma</span>. <i>Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1016/j.tranon.2018.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2Fj.tranon.2018.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=30316146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A280%3ADC%252BB3czovVChsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=143-153&author=K.+Zakhariaauthor=K.+Miyabeauthor=Y.+Wangauthor=D.+Wuauthor=C.+D.+Moserauthor=M.+J.+Boradauthor=L.+R.+Roberts&title=Preclinical+in+vitro+and+in+vivo+evidence+of+an+antitumor+effect+of+CX-4945%2C+a+casein+kinase+II+inhibitor%2C+in+cholangiocarcinoma&doi=10.1016%2Fj.tranon.2018.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma</span></div><div class="casAuthors">Zakharia Kais; Miyabe Katsuyuki; Wu Dehai; Moser Catherine D; Wang Yu; Borad Mitesh J; Roberts Lewis R</div><div class="citationInfo"><span class="NLM_cas:title">Translational oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">143-153</span>
        ISSN:<span class="NLM_cas:issn">1936-5233</span>.
    </div><div class="casAbstract">PURPOSE:  We investigated the antitumor effect of the casein kinase II (CK2) inhibitor CX-4945 on cholangiocarcinoma (CCA).  METHODS:  We assessed the effect of CX-4945 alone and/or in combination with gemcitabine and cisplatin on cell viability, colony formation, and apoptosis of CCA cell lines and on in vivo growth of HuCCT1 xenografts.  RESULTS:  CX-4945 dose-dependently decreased viability of HuCCT1, EGI-1, and Liv27 and decreased phospho-AKT/total AKT and phospho-PTEN/total PTEN ratios.  CX-4945 significantly increased caspase 3/7 activity in a dose- and time-dependent manner.  CX-4945 significantly enhanced the effect of gemcitabine or cisplatin on HuCCT1, EGI-1, and Liv27 cells and inhibited the phosphorylation of DNA repairing enzymes XRCC1 and MDC1.  Further, CX-4945 alone significantly inhibited growth of HuCCT1 mouse xenograft tumors.  Combining CX-4945 with gemcitabine and cisplatin was more potent than CX-4945 alone or gemcitabine/cisplatin.  The effect of CX-4945 on cell proliferation, apoptosis, the PI3K/AKT pathway, and DNA repair was confirmed in the mouse xenografts.  CONCLUSION:  CX-4945 has an antiproliferative effect on CCA and enhances the effect of gemcitabine and cisplatin through its inhibitory effect on the PI3K/AKT pathway and DNA repair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThvXSGZdJlpxKDYG3bNImrfW6udTcc2eYLbylNBu5Hu7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czovVChsQ%253D%253D&md5=88f383f2a3aced740607c4b76bf6fd11</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.tranon.2018.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tranon.2018.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DZakharia%26aufirst%3DK.%26aulast%3DMiyabe%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DMoser%26aufirst%3DC.%2BD.%26aulast%3DBorad%26aufirst%3DM.%2BJ.%26aulast%3DRoberts%26aufirst%3DL.%2BR.%26atitle%3DPreclinical%2520in%2520vitro%2520and%2520in%2520vivo%2520evidence%2520of%2520an%2520antitumor%2520effect%2520of%2520CX-4945%252C%2520a%2520casein%2520kinase%2520II%2520inhibitor%252C%2520in%2520cholangiocarcinoma%26jtitle%3DTransl.%2520Oncol.%26date%3D2019%26volume%3D12%26spage%3D143%26epage%3D153%26doi%3D10.1016%2Fj.tranon.2018.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iegre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brear, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Fusco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sore, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyvönen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">Second-generation CK2α inhibitors targeting the αD pocket</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3041</span>– <span class="NLM_lpage">3049</span>, <span class="refDoi"> DOI: 10.1039/C7SC05122K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1039%2FC7SC05122K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=29732088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFGls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=3041-3049&author=J.+Iegreauthor=P.+Brearauthor=C.+de+Fuscoauthor=M.+Yoshidaauthor=S.+L.+Mitchellauthor=M.+Rossmannauthor=L.+Carroauthor=H.+F.+Soreauthor=M.+Hyv%C3%B6nenauthor=D.+R.+Spring&title=Second-generation+CK2%CE%B1+inhibitors+targeting+the+%CE%B1D+pocket&doi=10.1039%2FC7SC05122K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation CK2α inhibitors targeting the αD pocket</span></div><div class="casAuthors">Iegre, Jessica; Brear, Paul; De Fusco, Claudia; Yoshida, Masao; Mitchell, Sophie L.; Rossmann, Maxim; Carro, Laura; Sore, Hannah F.; Hyvonen, Marko; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3041-3049</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">CK2 is a crit. cell cycle regulator that also promotes various anti-apoptotic mechanisms.  Development of ATP-non-competitive inhibitors of CK2 is a very attractive strategy considering that the ATP binding site is highly conserved among other kinases.  We have previously utilized a pocket outside the active site to develop a novel CK2 inhibitor, CAM4066.  While CAM4066 bound to this new pocket it was also interacting with the ATP site: herein, we describe an example of a CK2α inhibitor that binds completely outside the active site.  This second generation αD-site binding inhibitor, compd. CAM4712 (IC50 = 7μM, GI50 = 10.0 ± 3.6μM), has numerous advantages over the previously reported CAM4066, including a redn. in the no. of rotatable bonds, the absence of amide groups susceptible to the action of proteases and improved cellular permeability.  Unlike with CAM4066, there was no need to facilitate cellular uptake by making a prodrug.  Moreover, CAM4712 displayed no drop off between its ability to inhibit the kinase in vitro (IC50) and the ability to inhibit cell proliferation (GI50).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprPLu-nG6dLLVg90H21EOLACvtfcHk0lhJuWzYvz6arw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFGls7w%253D&md5=4d57e89546e1c7bcac4868e3a02ba2f8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1039%2FC7SC05122K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7SC05122K%26sid%3Dliteratum%253Aachs%26aulast%3DIegre%26aufirst%3DJ.%26aulast%3DBrear%26aufirst%3DP.%26aulast%3Dde%2BFusco%26aufirst%3DC.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DMitchell%26aufirst%3DS.%2BL.%26aulast%3DRossmann%26aufirst%3DM.%26aulast%3DCarro%26aufirst%3DL.%26aulast%3DSore%26aufirst%3DH.%2BF.%26aulast%3DHyv%25C3%25B6nen%26aufirst%3DM.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DSecond-generation%2520CK2%25CE%25B1%2520inhibitors%2520targeting%2520the%2520%25CE%25B1D%2520pocket%26jtitle%3DChem.%2520Sci.%26date%3D2018%26volume%3D9%26spage%3D3041%26epage%3D3049%26doi%3D10.1039%2FC7SC05122K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel function of CX-4945 as a splicing regulator</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e94978</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0094978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1371%2Fjournal.pone.0094978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=24743259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFemurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=H.+Kimauthor=K.+Choiauthor=H.+Kangauthor=S.-Y.+Leeauthor=S.-W.+Chiauthor=M.-S.+Leeauthor=J.+Songauthor=D.+Imauthor=Y.+Choiauthor=S.+Cho&title=Identification+of+a+novel+function+of+CX-4945+as+a+splicing+regulator&doi=10.1371%2Fjournal.pone.0094978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel function of CX-4945 as a splicing regulator</span></div><div class="casAuthors">Kim, Hyeongki; Choi, Kwangman; Kang, Hyunju; Lee, So-Young; Chi, Seung-wook; Lee, Min-sung; Song, Jaehyoung; Im, Donghwa; Choi, Yura; Cho, Sungchan</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e94978/1-e94978/8, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Alternative splicing is a nearly ubiquitous versatile process that controls gene expression and creates numerous protein isoforms with different functions from a single gene.  The significance of alternative splicing has been confirmed by the increasing no. of human diseases that are caused by misregulation of splicing events.  Very few compds., however, have been reported to act as inhibitors of alternative splicing, and their potential clin. use needs to be evaluated.  Here, we report that CX-4945, a previously well-characterized inhibitor of casein kinase 2 (CK2) and a mol. currently in clin. trials (Phase II) for cancer treatment, regulates splicing in mammalian cells in a CK2-independent manner.  Transcriptome-wide anal. using exon array also showed a widespread alteration in alternative splicing of numerous genes.  We found that CX-4945 potently inhibits the Cdc2-like kinases (Clks) in vitro and in turn, leads to suppression of the phosphorylation of serine/arginine-rich (SR) proteins in mammalian cells.  Surprisingly, the overall efficacy of CX-4945 on Clks (IC50 = 3-90 nM) was stronger than that of TG-003, the strongest inhibitor reported to date.  Of the Clks, Clk2 was most strongly inhibited by CX-4945 in an ATP-competitive manner.  Our research revealed an unexpected activity of the drug candidate CX-4945 as a potent splicing modulator and also suggested a potential application for therapy of diseases caused by abnormal splicing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEmZdGtUZUe7Vg90H21EOLACvtfcHk0lhJuWzYvz6arw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFemurzL&md5=5edb2338401d950cddbcba7d35e57c04</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0094978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0094978%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%26aulast%3DChoi%26aufirst%3DK.%26aulast%3DKang%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DS.-Y.%26aulast%3DChi%26aufirst%3DS.-W.%26aulast%3DLee%26aufirst%3DM.-S.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DIm%26aufirst%3DD.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520a%2520novel%2520function%2520of%2520CX-4945%2520as%2520a%2520splicing%2520regulator%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0094978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui-Jain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drygin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streiner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliesath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huser, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proffitt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaebe, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderes, K.</span></span> <span> </span><span class="NLM_article-title">CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">10288</span>– <span class="NLM_lpage">10298</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-1893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1158%2F0008-5472.CAN-10-1893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=21159648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGrt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=10288-10298&author=A.+Siddiqui-Jainauthor=D.+Dryginauthor=N.+Streinerauthor=P.+Chuaauthor=F.+Pierreauthor=S.+E.+O%E2%80%99Brienauthor=J.+Bliesathauthor=M.+Omoriauthor=N.+Huserauthor=C.+Hoauthor=C.+Proffittauthor=M.+K.+Schwaebeauthor=D.+M.+Ryckmanauthor=W.+G.+Riceauthor=K.+Anderes&title=CX-4945%2C+an+orally+bioavailable+selective+inhibitor+of+protein+kinase+CK2%2C+inhibits+prosurvival+and+angiogenic+signaling+and+exhibits+antitumor+efficacy&doi=10.1158%2F0008-5472.CAN-10-1893"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy</span></div><div class="casAuthors">Siddiqui-Jain, Adam; Drygin, Denis; Streiner, Nicole; Chua, Peter; Pierre, Fabrice; O'Brien, Sean E.; Bliesath, Josh; Omori, Mayuko; Huser, Nanni; Ho, Caroline; Proffitt, Chris; Schwaebe, Michael K.; Ryckman, David M.; Rice, William G.; Anderes, Kenna</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10288-10298</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Malignant transformation and maintenance of the malignant phenotype depends on oncogenic and non-oncogenic proteins that are essential to mediate oncogene signaling and to support the altered physiol. demands induced by transformation.  Protein kinase CK2 supports key prosurvival signaling pathways and represents a prototypical non-oncogene.  In this study, we describe CX-4945, a potent and selective orally bioavailable small mol. inhibitor of CK2.  The antiproliferative activity of CX-4945 against cancer cells correlated with expression levels of the CK2α catalytic subunit.  Attenuation of PI3K/Akt signaling by CX-4945 was evidenced by dephosphorylation of Akt on the CK2-specific S129 site and the canonical S473 and T308 regulatory sites.  CX-4945 caused cell-cycle arrest and selectively induced apoptosis in cancer cells relative to normal cells.  In models of angiogenesis, CX-4945 inhibited human umbilical vein endothelial cell migration, tube formation, and blocked CK2-dependent hypoxia-induced factor 1 alpha (HIF-1α) transcription in cancer cells.  When administered orally in murine xenograft models, CX-4945 was well tolerated and demonstrated robust antitumor activity with concomitant redns. of the mechanism-based biomarker phospho-p21 (T145).  The obsd. antiproliferative and anti-angiogenic responses to CX-4945 in tumor cells and endothelial cells collectively illustrate that this compd. exerts its antitumor effects through inhibition of CK2-dependent signaling in multiple pathways.  Finally, CX-4945 is the first orally bioavailable small mol. inhibitor of CK2 to advance into human clin. trials, thereby paving the way for an entirely new class of targeted treatment for cancer.  Cancer Res; 70(24); 10288-98.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8s0Sa3hOwtbVg90H21EOLACvtfcHk0lhJuWzYvz6arw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGrt7fK&md5=bfcfe06730e099719e752574a6636dfb</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1893%26sid%3Dliteratum%253Aachs%26aulast%3DSiddiqui-Jain%26aufirst%3DA.%26aulast%3DDrygin%26aufirst%3DD.%26aulast%3DStreiner%26aufirst%3DN.%26aulast%3DChua%26aufirst%3DP.%26aulast%3DPierre%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BE.%26aulast%3DBliesath%26aufirst%3DJ.%26aulast%3DOmori%26aufirst%3DM.%26aulast%3DHuser%26aufirst%3DN.%26aulast%3DHo%26aufirst%3DC.%26aulast%3DProffitt%26aufirst%3DC.%26aulast%3DSchwaebe%26aufirst%3DM.%2BK.%26aulast%3DRyckman%26aufirst%3DD.%2BM.%26aulast%3DRice%26aufirst%3DW.%2BG.%26aulast%3DAnderes%26aufirst%3DK.%26atitle%3DCX-4945%252C%2520an%2520orally%2520bioavailable%2520selective%2520inhibitor%2520of%2520protein%2520kinase%2520CK2%252C%2520inhibits%2520prosurvival%2520and%2520angiogenic%2520signaling%2520and%2520exhibits%2520antitumor%2520efficacy%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D10288%26epage%3D10298%26doi%3D10.1158%2F0008-5472.CAN-10-1893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruise, E.</span></span> <span> </span><span class="NLM_article-title">An investigation of the CK2-dependent phosphoproteome using inhibitor refractory CK2-alpha</span>.  <i>Electronic Thesis and Dissertation Repository</i> <span class="NLM_year" style="font-weight: bold;">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=E.+Cruise&title=An+investigation+of+the+CK2-dependent+phosphoproteome+using+inhibitor+refractory+CK2-alpha"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCruise%26aufirst%3DE.%26atitle%3DAn%2520investigation%2520of%2520the%2520CK2-dependent%2520phosphoproteome%2520using%2520inhibitor%2520refractory%2520CK2-alpha%26jtitle%3DElectronic%2520Thesis%2520and%2520Dissertation%2520Repository%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0ljynDDWyRhE8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">The development and therapeutic potential of protein kinase inhibitors</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.1016/S1367-5931(99)80067-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2FS1367-5931%2899%2980067-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10419844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADyaK1MXlt1ejurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1999&pages=459-465&author=P.+Cohen&title=The+development+and+therapeutic+potential+of+protein+kinase+inhibitors&doi=10.1016%2FS1367-5931%2899%2980067-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The development and therapeutic potential of protein kinase inhibitors</span></div><div class="casAuthors">Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">459-465</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Publications</span>)
        </div><div class="casAbstract">A review with 46 refs.  A no. of low-mol.-wt. cell-permeant protein kinase inhibitors have been developed that have the potential for treating a variety of diseases.  The specificity and mechanism of action of several of these drugs has been elucidated and some are undergoing clin. trials in humans.  The role of reversible protein phosphorylation in human diseases (cancer, hypertension, chronic inflammations) and pharmacol. possibilities of its regulation are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgKohAlW0XOrVg90H21EOLACvtfcHk0ljLRE2-eUVIaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlt1ejurw%253D&md5=5929d7d26e30df19a3e49f1dd145a1c8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS1367-5931%2899%2980067-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1367-5931%252899%252980067-2%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DThe%2520development%2520and%2520therapeutic%2520potential%2520of%2520protein%2520kinase%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D1999%26volume%3D3%26spage%3D459%26epage%3D465%26doi%3D10.1016%2FS1367-5931%2899%2980067-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asadzadeh, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansoori, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haji-Asgarzadeh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safarzadeh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokhtarzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duijf, P. H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baradaran, B.</span></span> <span> </span><span class="NLM_article-title">microRNAs in cancer stem cells: biology, pathways, and therapeutic opportunities</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">10002</span>– <span class="NLM_lpage">10017</span>, <span class="refDoi"> DOI: 10.1002/jcp.27885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1002%2Fjcp.27885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=30537109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVGmsbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2019&pages=10002-10017&author=Z.+Asadzadehauthor=B.+Mansooriauthor=A.+Mohammadiauthor=M.+Aghajaniauthor=K.+Haji-Asgarzadehauthor=E.+Safarzadehauthor=A.+Mokhtarzadehauthor=P.+H.+G.+Duijfauthor=B.+Baradaran&title=microRNAs+in+cancer+stem+cells%3A+biology%2C+pathways%2C+and+therapeutic+opportunities&doi=10.1002%2Fjcp.27885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">microRNAs in cancer stem cells: Biology, pathways, and therapeutic opportunities</span></div><div class="casAuthors">Asadzadeh, Zahra; Mansoori, Behzad; Mohammadi, Ali; Aghajani, Marjan; Haji-Asgarzadeh, Khalil; Safarzadeh, Elham; Mokhtarzadeh, Ahad; Duijf, Pascal H. G.; Baradaran, Behzad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">10002-10017</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) are a small subpopulation of tumor cells that have been identified in most types of cancer.  Features that distinguish them from the bulk of tumor cells include their pluripotency, self-renewal capacity, low proliferation rate, and tumor-initiating ability.  CSCs are highly malignant, as they confer drug resistance and facilitate tumor progression, relapse, and metastasis.  The mol. mechanisms underlying CSC biol. are now beginning to be understood.  In this context, microRNAs (miRNAs) occupy a prominent place.  These endogenous, small noncoding RNA mols. control gene expression at the posttranscriptional level.  This study reviews our current understanding of how the misexpression of tumor suppressor and oncogenic miRNAs in CSCs sustain their abundance and malignant properties.  We discuss how they partly do so by acting on major CSC signaling pathways, including the Wnt, Notch, Hedgehog, and BMI-1 pathways.  Our current knowledge of miRNA functions in CSCs may now be used for cancer diagnostic and prognostic purposes.  In addn., when combined with recent tech. advances in the in vivo delivery of miRNAs, we are now in an excellent position to develop strategies that harness miRNA interference and replacement technologies for the therapeutic targeting of CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsTNiKoa2uTrVg90H21EOLACvtfcHk0ljLRE2-eUVIaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVGmsbrL&md5=efbc05e5989b766a310155f1d39cc763</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fjcp.27885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.27885%26sid%3Dliteratum%253Aachs%26aulast%3DAsadzadeh%26aufirst%3DZ.%26aulast%3DMansoori%26aufirst%3DB.%26aulast%3DMohammadi%26aufirst%3DA.%26aulast%3DAghajani%26aufirst%3DM.%26aulast%3DHaji-Asgarzadeh%26aufirst%3DK.%26aulast%3DSafarzadeh%26aufirst%3DE.%26aulast%3DMokhtarzadeh%26aufirst%3DA.%26aulast%3DDuijf%26aufirst%3DP.%2BH.%2BG.%26aulast%3DBaradaran%26aufirst%3DB.%26atitle%3DmicroRNAs%2520in%2520cancer%2520stem%2520cells%253A%2520biology%252C%2520pathways%252C%2520and%2520therapeutic%2520opportunities%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26volume%3D234%26spage%3D10002%26epage%3D10017%26doi%3D10.1002%2Fjcp.27885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pattabiraman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Tackling the cancer stem cells — what challenges do they pose?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">512</span>, <span class="refDoi"> DOI: 10.1038/nrd4253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1038%2Fnrd4253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=24981363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOisbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=497-512&author=D.+R.+Pattabiramanauthor=R.+A.+Weinberg&title=Tackling+the+cancer+stem+cells+%E2%80%94+what+challenges+do+they+pose%3F&doi=10.1038%2Fnrd4253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Tackling the cancer stem cells - what challenges do they pose?</span></div><div class="casAuthors">Pattabiraman, Diwakar R.; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">497-512</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since their identification in 1994, cancer stem cells (CSCs) have been objects of intensive study.  Their properties and mechanisms of formation have become a major focus of current cancer research, in part because of their enhanced ability to initiate and drive tumor growth and their intrinsic resistance to conventional therapeutics.  The discovery that activation of the epithelial-to-mesenchymal transition (EMT) program in carcinoma cells can give rise to cells with stem-like properties has provided one possible mechanism explaining how CSCs arise and presents a possible avenue for their therapeutic manipulation.  Here we address recent developments in CSC research, focusing on carcinomas that are able to undergo EMT.  We discuss the signalling pathways that create these cells, cell-intrinsic mechanisms that could be exploited for selective elimination or induction of their differentiation, and the role of the tumor microenvironment in sustaining them.  Finally, we propose ways to use our current knowledge of the complex biol. of CSCs to design novel therapies to eliminate them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHXcwOZJN_67Vg90H21EOLACvtfcHk0ljLRE2-eUVIaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOisbzI&md5=db211f41b19198981cb37487b7a9abc3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrd4253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4253%26sid%3Dliteratum%253Aachs%26aulast%3DPattabiraman%26aufirst%3DD.%2BR.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DTackling%2520the%2520cancer%2520stem%2520cells%2520%25E2%2580%2594%2520what%2520challenges%2520do%2520they%2520pose%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D497%26epage%3D512%26doi%3D10.1038%2Fnrd4253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martins-Neves, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleton-Jansen, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, C. M. F.</span></span> <span> </span><span class="NLM_article-title">Therapy-induced enrichment of cancer stem-like cells in solid human tumors: where do we stand?</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2018.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2Fj.phrs.2018.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=30316903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKksLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2018&pages=193-204&author=S.+R.+Martins-Nevesauthor=A.-M.+Cleton-Jansenauthor=C.+M.+F.+Gomes&title=Therapy-induced+enrichment+of+cancer+stem-like+cells+in+solid+human+tumors%3A+where+do+we+stand%3F&doi=10.1016%2Fj.phrs.2018.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Therapy-induced enrichment of cancer stem-like cells in solid human tumors: Where do we stand</span></div><div class="casAuthors">Martins-Neves, Sara R.; Cleton-Jansen, Anne-Marie; Gomes, Celia M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">193-204</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of local recurrence and metastatic disease, most probably attributable to the intrinsic or acquired resistance of tumor cells to std. therapy, still constitute the major clin. problem preventing the cure of cancer patients.  Despite progress in the research of new therapeutic targets and compds., resistant cells displaying stem-like properties seem to play a leading role in therapeutic failures and to be the culprit cells responsible for assocd. tumor recurrence.  A whole new plethora of research studies suggest that drug-tolerant cancer stem cells may be induced by conventional cancer chemotherapeutics such as doxorubicin, cisplatinum and ionizing radiation.  This phenotypic plasticity and transition from a differentiated to stem-like cell state assocs. with the activation of diverse stem cell self-renewal (e.g. Notch, Hedgehog, Wnt), drug efflux (e.g. ABC transporters) and survival-related pathways (e.g. TGF-β, ERK, AKT), which may confer resistance and treatment failures in solid tumors.  Therefore, combined therapeutic strategies aiming to simultaneously target drug-sensitive tumor cells and their capacity of phenotypic switching may lead to survival benefits and meaningful disease remissions.  This knowledge can be applicable to the clinic and contribute to better therapeutic outcomes and prevent tumor recurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDE6ThuyN1AbVg90H21EOLACvtfcHk0lg4WHeufVpIFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKksLfJ&md5=f68fae306b461bdd2c3b4496dc89cfe1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2018.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2018.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DMartins-Neves%26aufirst%3DS.%2BR.%26aulast%3DCleton-Jansen%26aufirst%3DA.-M.%26aulast%3DGomes%26aufirst%3DC.%2BM.%2BF.%26atitle%3DTherapy-induced%2520enrichment%2520of%2520cancer%2520stem-like%2520cells%2520in%2520solid%2520human%2520tumors%253A%2520where%2520do%2520we%2520stand%253F%26jtitle%3DPharmacol.%2520Res.%26date%3D2018%26volume%3D137%26spage%3D193%26epage%3D204%26doi%3D10.1016%2Fj.phrs.2018.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tirino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desiderio, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rosa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaccio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Noce, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Francesco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaccio, G.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1096/fj.12-218222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1096%2Ffj.12-218222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=23024375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Gqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=13-24&author=V.+Tirinoauthor=V.+Desiderioauthor=F.+Painoauthor=A.+De+Rosaauthor=F.+Papaccioauthor=M.+La+Noceauthor=L.+Lainoauthor=F.+De+Francescoauthor=G.+Papaccio&title=Cancer+stem+cells+in+solid+tumors%3A+an+overview+and+new+approaches+for+their+isolation+and+characterization&doi=10.1096%2Ffj.12-218222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization</span></div><div class="casAuthors">Tirino, Virginia; Desiderio, Vincenzo; Paino, Francesca; De Rosa, Alfredo; Papaccio, Federica; La Noce, Marcella; Laino, Luigi; De Francesco, Francesco; Papaccio, Gianpaolo</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-24, 10.1096/fj.12-218222</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review.  Primary tumors are responsible for 10% of cancer deaths.  In most cases, the main cause of mortality is the formation of metastases.  Accumulating evidence suggests that a subpopulation of tumor cells with distinct stem-like properties is responsible for tumor initiation, invasive growth, and metastasis formation.  This population is defined as cancer stem cells (CSCs).  Existing therapies have enhanced the length of survival after diagnosis of cancer but have completely failed in terms of recovery.  CSCs appear to be resistant to chemotherapy, may remain quiescent for extended periods, and have affinity for hypoxic environments.  The CSCs can be identified and isolated by different methodologies, including isolation by CSC-specific cell surface marker expression, detection of side population phenotype by Hoechst 33342 exclusion, assessment of their ability to grow as floating spheres, and aldehyde dehydrogenase (ALDH) activity assay.  None of the methods mentioned are exclusively used to isolate the solid tumor CSCs, highlighting the imperative to delineate more specific markers or to use combinatorial markers and methodologies.  This review provides an overview of the main characteristics and approaches used to identify, isolate, and characterize CSCs from solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKHEZT73U6-bVg90H21EOLACvtfcHk0lg4WHeufVpIFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Gqtw%253D%253D&md5=de33a9ff83242808595b3772fac12f5d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1096%2Ffj.12-218222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.12-218222%26sid%3Dliteratum%253Aachs%26aulast%3DTirino%26aufirst%3DV.%26aulast%3DDesiderio%26aufirst%3DV.%26aulast%3DPaino%26aufirst%3DF.%26aulast%3DDe%2BRosa%26aufirst%3DA.%26aulast%3DPapaccio%26aufirst%3DF.%26aulast%3DLa%2BNoce%26aufirst%3DM.%26aulast%3DLaino%26aufirst%3DL.%26aulast%3DDe%2BFrancesco%26aufirst%3DF.%26aulast%3DPapaccio%26aufirst%3DG.%26atitle%3DCancer%2520stem%2520cells%2520in%2520solid%2520tumors%253A%2520an%2520overview%2520and%2520new%2520approaches%2520for%2520their%2520isolation%2520and%2520characterization%26jtitle%3DFASEB%2520J.%26date%3D2013%26volume%3D27%26spage%3D13%26epage%3D24%26doi%3D10.1096%2Ffj.12-218222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanahan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Hallmarks of cancer: The next generation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+cancer%3A+The+next+generation&doi=10.1016%2Fj.cell.2011.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0lg4WHeufVpIFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520cancer%253A%2520The%2520next%2520generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D646%26epage%3D674%26doi%3D10.1016%2Fj.cell.2011.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michael, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M. D.</span></span> <span> </span><span class="NLM_article-title">Clinical and therapeutic implications of cancer stem cells</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">2237</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1804280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1056%2FNEJMra1804280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=31167052" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=2237-2245&author=F.+Michaelauthor=M.+D.+Clarke&title=Clinical+and+therapeutic+implications+of+cancer+stem+cells&doi=10.1056%2FNEJMra1804280"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1804280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1804280%26sid%3Dliteratum%253Aachs%26aulast%3DMichael%26aufirst%3DF.%26aulast%3DClarke%26aufirst%3DM.%2BD.%26atitle%3DClinical%2520and%2520therapeutic%2520implications%2520of%2520cancer%2520stem%2520cells%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26spage%3D2237%26epage%3D2245%26doi%3D10.1056%2FNEJMra1804280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poh, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span> <span> </span><span class="NLM_article-title">Soft fibrin gels promote selection and growth of tumorigenic cells</span>. <i>Nat. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">734</span>– <span class="NLM_lpage">741</span>, <span class="refDoi"> DOI: 10.1038/nmat3361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1038%2Fnmat3361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=22751180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVSrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=734-741&author=J.+Liuauthor=Y.+Tanauthor=H.+Zhangauthor=Y.+Zhangauthor=P.+Xuauthor=J.+Chenauthor=Y.-C.+Pohauthor=K.+Tangauthor=N.+Wangauthor=B.+Huang&title=Soft+fibrin+gels+promote+selection+and+growth+of+tumorigenic+cells&doi=10.1038%2Fnmat3361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Soft fibrin gels promote selection and growth of tumorigenic cells</span></div><div class="casAuthors">Liu, Jing; Tan, Youhua; Zhang, Huafeng; Zhang, Yi; Xu, Pingwei; Chen, Junwei; Poh, Yeh-Chuin; Tang, Ke; Wang, Ning; Huang, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Materials</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">734-741</span>CODEN:
                <span class="NLM_cas:coden">NMAACR</span>;
        ISSN:<span class="NLM_cas:issn">1476-1122</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The identification of stem-cell-like cancer cells through conventional methods that depend on stem cell markers is often unreliable.  We developed a mech. method for selecting tumorigenic cells by culturing single cancer cells in fibrin matrixes of ∼100 Pa in stiffness.  When cultured within these gels, primary human cancer cells or single cancer cells from mouse or human cancer cell lines grew within a few days into individual round colonies that resembled embryonic stem cell colonies.  S.c. or i.v. injection of 10 or 100 fibrin-cultured cells in syngeneic or severe combined immunodeficiency mice led to the formation of solid tumors at the site of injection or at the distant lung organ much more efficiently than control cancer cells selected using conventional surface marker methods or cultured on conventional rigid dishes or on soft gels.  Remarkably, as few as ten such cells were able to survive and form tumors in the lungs of wild-type non-syngeneic mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFB9tpBQLzGrVg90H21EOLACvtfcHk0ljqK5EPfXl3Ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVSrt70%253D&md5=f64f95bdb9acdc0ac162efe6aeee2c39</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnmat3361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmat3361%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DPoh%26aufirst%3DY.-C.%26aulast%3DTang%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DB.%26atitle%3DSoft%2520fibrin%2520gels%2520promote%2520selection%2520and%2520growth%2520of%2520tumorigenic%2520cells%26jtitle%3DNat.%2520Mater.%26date%3D2012%26volume%3D11%26spage%3D734%26epage%3D741%26doi%3D10.1038%2Fnmat3361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaipio, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roering, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huhtinen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkonen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Östling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehtinen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansuri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korpela, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potdar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynninen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auranen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grénman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hautaniemi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpén, O.</span></span> <span> </span><span class="NLM_article-title">ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>250</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1002/path.5356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1002%2Fpath.5356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=31595974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsF2lsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=250&publication_year=2020&pages=159-169&author=K.+Kaipioauthor=P.+Chenauthor=P.+Roeringauthor=K.+Huhtinenauthor=P.+Mikkonenauthor=P.+%C3%96stlingauthor=L.+Lehtinenauthor=N.+Mansuriauthor=T.+Korpelaauthor=S.+Potdarauthor=J.+Hynninenauthor=A.+Auranenauthor=S.+Gr%C3%A9nmanauthor=K.+Wennerbergauthor=S.+Hautaniemiauthor=O.+Carp%C3%A9n&title=ALDH1A1-related+stemness+in+high-grade+serous+ovarian+cancer+is+a+negative+prognostic+indicator+but+potentially+targetable+by+EGFR%2FmTOR-PI3K%2Faurora+kinase+inhibitors&doi=10.1002%2Fpath.5356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors</span></div><div class="casAuthors">Kaipio, Katja; Chen, Ping; Roering, Pia; Huhtinen, Kaisa; Mikkonen, Piia; Oestling, Paeivi; Lehtinen, Laura; Mansuri, Naziha; Korpela, Taina; Potdar, Swapnil; Hynninen, Johanna; Auranen, Annika; Grenman, Seija; Wennerberg, Krister; Hautaniemi, Sampsa; Carpen, Olli</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">250</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-169</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Poor chemotherapy response remains a major treatment challenge for high-grade serous ovarian cancer (HGSC).  Cancer stem cells are the major contributors to relapse and treatment failure as they can survive conventional therapy.  Our objectives were to characterize stemness features in primary patient-derived cell lines, correlate stemness markers with clin. outcome and test the response of our cells to both conventional and exploratory drugs.  Tissue and ascites samples, treatment-naive and/or after neoadjuvant chemotherapy, were prospectively collected.  Primary cancer cells, cultured under conditions favoring either adherent or spheroid growth, were tested for stemness markers; the same markers were analyzed in tissue and correlated with chemotherapy response and survival.  Drug sensitivity and resistance testing was performed with 306 oncol. compds.  Spheroid growth condition HGSC cells showed increased stemness marker expression (including aldehyde dehydrogenase isoform I; ALDH1A1) as compared with adherent growth condition cells, and increased resistance to platinum and taxane.  A set of eight stemness markers sepd. treatment-naive tumors into two clusters and identified a distinct subgroup of HGSC with enriched stemness features.  Expression of ALDH1A1, but not most other stemness markers, was increased after neoadjuvant chemotherapy and its expression in treatment-naive tumors correlated with chemoresistance and reduced survival.  In drug sensitivity and resistance testing, five compds., including two PI3K-mTOR inhibitors, demonstrated significant activity in both cell culture conditions.  Thirteen compds., including EGFR, PI3K-mTOR and aurora kinase inhibitors, were more toxic to spheroid cells than adherent cells.  Our results identify stemness markers in HGSC that are assocd. with a decreased response to conventional chemotherapy and reduced survival if expressed by treatment-naive tumors.  EGFR, mTOR-PI3K and aurora kinase inhibitors are candidates for targeting this cell population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpyFDLnreWCbVg90H21EOLACvtfcHk0ljqK5EPfXl3Ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsF2lsbk%253D&md5=df803ac48a19ddb99a7bbdab45c15c19</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fpath.5356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.5356%26sid%3Dliteratum%253Aachs%26aulast%3DKaipio%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DRoering%26aufirst%3DP.%26aulast%3DHuhtinen%26aufirst%3DK.%26aulast%3DMikkonen%26aufirst%3DP.%26aulast%3D%25C3%2596stling%26aufirst%3DP.%26aulast%3DLehtinen%26aufirst%3DL.%26aulast%3DMansuri%26aufirst%3DN.%26aulast%3DKorpela%26aufirst%3DT.%26aulast%3DPotdar%26aufirst%3DS.%26aulast%3DHynninen%26aufirst%3DJ.%26aulast%3DAuranen%26aufirst%3DA.%26aulast%3DGr%25C3%25A9nman%26aufirst%3DS.%26aulast%3DWennerberg%26aufirst%3DK.%26aulast%3DHautaniemi%26aufirst%3DS.%26aulast%3DCarp%25C3%25A9n%26aufirst%3DO.%26atitle%3DALDH1A1-related%2520stemness%2520in%2520high-grade%2520serous%2520ovarian%2520cancer%2520is%2520a%2520negative%2520prognostic%2520indicator%2520but%2520potentially%2520targetable%2520by%2520EGFR%252FmTOR-PI3K%252Faurora%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Pathol.%26date%3D2020%26volume%3D250%26spage%3D159%26epage%3D169%26doi%3D10.1002%2Fpath.5356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui-Jain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourbon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaebe, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vialettes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darjania, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stansfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliesath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drygin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proffitt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streiner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trent, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckman, D. M.</span></span> <span> </span><span class="NLM_article-title">Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">635</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1021/jm101251q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101251q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2kurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=635-654&author=F.+Pierreauthor=P.+C.+Chuaauthor=S.+E.+O%E2%80%99Brienauthor=A.+Siddiqui-Jainauthor=P.+Bourbonauthor=M.+Haddachauthor=J.+Michauxauthor=J.+Nagasawaauthor=M.+K.+Schwaebeauthor=E.+Stefanauthor=A.+Vialettesauthor=J.+P.+Whittenauthor=T.+K.+Chenauthor=L.+Darjaniaauthor=R.+Stansfieldauthor=K.+Anderesauthor=J.+Bliesathauthor=D.+Dryginauthor=C.+Hoauthor=M.+Omoriauthor=C.+Proffittauthor=N.+Streinerauthor=K.+Trentauthor=W.+G.+Riceauthor=D.+M.+Ryckman&title=Discovery+and+SAR+of+5-%283-chlorophenylamino%29benzo%5Bc%5D%5B2%2C6%5Dnaphthyridine-8-carboxylic+acid+%28CX-4945%29%2C+the+first+clinical+stage+inhibitor+of+protein+kinase+CK2+for+the+treatment+of+cancer&doi=10.1021%2Fjm101251q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer</span></div><div class="casAuthors">Pierre, Fabrice; Chua, Peter C.; O'Brien, Sean E.; Siddiqui-Jain, Adam; Bourbon, Pauline; Haddach, Mustapha; Michaux, Jerome; Nagasawa, Johnny; Schwaebe, Michael K.; Stefan, Eric; Vialettes, Anne; Whitten, Jeffrey P.; Chen, Ta Kung; Darjania, Levan; Stansfield, Ryan; Anderes, Kenna; Bliesath, Josh; Drygin, Denis; Ho, Caroline; Omori, May; Proffitt, Chris; Streiner, Nicole; Trent, Katy; Rice, William G.; Ryckman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">635-654</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we chronicle the discovery of CX-4945 (I), a first-in-class, orally bioavailable ATP-competitive inhibitor of protein kinase CK2 in clin. trials for cancer.  CK2 has long been considered a prime cancer drug target because of the roles of deregulated and overexpressed CK2 in cancer-promoting pro-survival and antiapoptotic pathways.  These biol. properties as well as the suitability of CK2's small ATP binding site for the design of selective inhibitors, led us to fashion novel therapeutic agents for cancer.  The optimization leading to I (Ki = 0.38 nM) was guided by mol. modeling, suggesting a strong binding of I resulting from a combination of hydrophobic interactions, an ionic bridge with Lys68, and hydrogen bonding with the hinge region. I was highly selective, orally bioavailable across species (20-51%) and efficacious in xenograft models.  The discovery of I will allow the therapeutic targeting of CK2 in humans for the first time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoONQeRuenlPrVg90H21EOLACvtfcHk0lhg_R2Rd-p4PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2kurjL&md5=9b0f371ee1a2182b84877743c42dfda1</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm101251q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101251q%26sid%3Dliteratum%253Aachs%26aulast%3DPierre%26aufirst%3DF.%26aulast%3DChua%26aufirst%3DP.%2BC.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BE.%26aulast%3DSiddiqui-Jain%26aufirst%3DA.%26aulast%3DBourbon%26aufirst%3DP.%26aulast%3DHaddach%26aufirst%3DM.%26aulast%3DMichaux%26aufirst%3DJ.%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DSchwaebe%26aufirst%3DM.%2BK.%26aulast%3DStefan%26aufirst%3DE.%26aulast%3DVialettes%26aufirst%3DA.%26aulast%3DWhitten%26aufirst%3DJ.%2BP.%26aulast%3DChen%26aufirst%3DT.%2BK.%26aulast%3DDarjania%26aufirst%3DL.%26aulast%3DStansfield%26aufirst%3DR.%26aulast%3DAnderes%26aufirst%3DK.%26aulast%3DBliesath%26aufirst%3DJ.%26aulast%3DDrygin%26aufirst%3DD.%26aulast%3DHo%26aufirst%3DC.%26aulast%3DOmori%26aufirst%3DM.%26aulast%3DProffitt%26aufirst%3DC.%26aulast%3DStreiner%26aufirst%3DN.%26aulast%3DTrent%26aufirst%3DK.%26aulast%3DRice%26aufirst%3DW.%2BG.%26aulast%3DRyckman%26aufirst%3DD.%2BM.%26atitle%3DDiscovery%2520and%2520SAR%2520of%25205-%25283-chlorophenylamino%2529benzo%255Bc%255D%255B2%252C6%255Dnaphthyridine-8-carboxylic%2520acid%2520%2528CX-4945%2529%252C%2520the%2520first%2520clinical%2520stage%2520inhibitor%2520of%2520protein%2520kinase%2520CK2%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D635%26epage%3D654%26doi%3D10.1021%2Fjm101251q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserü, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. H.</span></span> <span> </span><span class="NLM_article-title">The role of ligand efficiency metrics in drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1038/nrd4163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105-121&author=A.+L.+Hopkinsauthor=G.+M.+Keser%C3%BCauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+role+of+ligand+efficiency+metrics+in+drug+discovery&doi=10.1038%2Fnrd4163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0lhg_R2Rd-p4PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeser%25C3%25BC%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520role%2520of%2520ligand%2520efficiency%2520metrics%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D105%26epage%3D121%26doi%3D10.1038%2Fnrd4163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Au, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoppler, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jablons, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">854</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1111/jcmm.12068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1111%2Fjcmm.12068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=23651443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlCrt77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=854-862&author=S.+Zhangauthor=H.+Longauthor=Y.-L.+Yangauthor=Y.+Wangauthor=D.+Hsiehauthor=W.+Liauthor=A.+Auauthor=H.+J.+Stopplerauthor=Z.+Xuauthor=D.+M.+Jablonsauthor=L.+You&title=Inhibition+of+CK2%CE%B1+down-regulates+Notch1+signalling+in+lung+cancer+cells&doi=10.1111%2Fjcmm.12068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells</span></div><div class="casAuthors">Zhang, Shulin; Long, Hao; Yang, Yi-Lin; Wang, Yucheng; Hsieh, David; Li, Weiming; Au, Alfred; Stoppler, Hubert J.; Xu, Zhidong; Jablons, David M.; You, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">854-862</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Protein kinase CK2 is frequently elevated in a variety of human cancers.  The Notch1 signalling pathway has been implicated in stem cell maintenance and its aberrant activation has been shown in several types of cancer including lung cancer.  Here, we show, for the first time, that CK2α is a pos. regulator of Notch1 signalling in lung cancer cell lines A549 and H1299.  We found that Notch1 protein level was reduced after CK2α silencing.  Down-regulation of Notch1 transcriptional activity was demonstrated after the silencing of CK2α in lung cancer cells.  Furthermore, small-mol. CK2α inhibitor CX-4945 led to a dose-dependent inhibition of Notch1 transcriptional activity.  Conversely, forced overexpression of CK2α resulted in an increase in Notch1 transcriptional activity.  Finally, the inhibition of CK2α led to a reduced proportion of stem-like CD44+ /CD24- cell population.  Thus, we report that the inhibition of CK2α down-regulates Notch1 signalling and subsequently reduces a cancer stem-like cell population in human lung cancer cells.  Our data suggest that CK2α inhibitors may be beneficial to the lung cancer patients with activated Notch1 signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS2z_d0QXEmrVg90H21EOLACvtfcHk0lgQ5cMAFKHIpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlCrt77P&md5=64b28baced76a2a254fc4d99ed30bb4d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.12068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.12068%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.-L.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHsieh%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DAu%26aufirst%3DA.%26aulast%3DStoppler%26aufirst%3DH.%2BJ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DJablons%26aufirst%3DD.%2BM.%26aulast%3DYou%26aufirst%3DL.%26atitle%3DInhibition%2520of%2520CK2%25CE%25B1%2520down-regulates%2520Notch1%2520signalling%2520in%2520lung%2520cancer%2520cells%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2013%26volume%3D17%26spage%3D854%26epage%3D862%26doi%3D10.1111%2Fjcmm.12068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozovska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patsalias, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajzik, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durinikova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demkova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jargasova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolkova, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plava, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucerova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matuskova, M.</span></span> <span> </span><span class="NLM_article-title">ALDH1A inhibition sensitizes colon cancer cells to chemotherapy</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">656</span>, <span class="refDoi"> DOI: 10.1186/s12885-018-4572-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1186%2Fs12885-018-4572-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=29902974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFWmtLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=656&author=Z.+Kozovskaauthor=A.+Patsaliasauthor=V.+Bajzikauthor=E.+Durinikovaauthor=L.+Demkovaauthor=S.+Jargasovaauthor=B.+Smolkovaauthor=J.+Plavaauthor=L.+Kucerovaauthor=M.+Matuskova&title=ALDH1A+inhibition+sensitizes+colon+cancer+cells+to+chemotherapy&doi=10.1186%2Fs12885-018-4572-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">ALDH1A inhibition sensitizes colon cancer cells to chemotherapy</span></div><div class="casAuthors">Kozovska, Z.; Patsalias, A.; Bajzik, V.; Durinikova, E.; Demkova, L.; Jargasova, S.; Smolkova, B.; Plava, J.; Kucerova, L.; Matuskova, M.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">656/1-656/11</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">In our study we focused on the aldehyde dehydrogenase type 1 (ALDH1) expression in colon cancer-derived cell lines HT-29/eGFP, HCT-116/eGFP and LS-180/eGFP, and its role in the chemoresistance and tumorigenic potential.  The effect of pharmacol. inhibition of ALDH activity by diethylaminobenzaldehyde (DEAB) and also effect of mol. inhibition by specific siRNA was evaluated in vitro in cultures of human colorectal cell lines.  Changes in cell biol. were evaluated by expression anal., western blot and apoptosis assay.  The efficiency of cytotoxic treatment in the presence of different chemotherapeutic drugs was analyzed by fluorimetric assay.  Tumorigenicity of cells with specific ALDH1A1 siRNA was tested in xenograft model in vivo.  Subsequently the mol. inhibition of specific isoforms of ALDH by ALDH1A1 or ALDH1A3 siRNA led to sensitizing of cell lines HT-29/eGFP, HCT- 116/eGFP to capecitabine and 5-FU.  On the model of athymic mice we obsd. the effect of mol. inhibition of ALDH1A1 in HT-29/eGFP cells by siRNA.  We obsd. inhibition of proliferation of s.c. xenografts in comparison to control cells.  This research, verifies the significance of the ALDH1A isoforms in multidrug resistance of human colorectal cancer cells and its potential as a cancer stem cell marker.  This provides the basis for the development of new approaches regarding the treatment of patients with colorectal adenocarcinoma and potentially the treatment of other tumor malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6TSQNzq0hHLVg90H21EOLACvtfcHk0lgQ5cMAFKHIpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFWmtLbP&md5=4a13304220c0a974946ecb7a260a66fa</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1186%2Fs12885-018-4572-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-018-4572-6%26sid%3Dliteratum%253Aachs%26aulast%3DKozovska%26aufirst%3DZ.%26aulast%3DPatsalias%26aufirst%3DA.%26aulast%3DBajzik%26aufirst%3DV.%26aulast%3DDurinikova%26aufirst%3DE.%26aulast%3DDemkova%26aufirst%3DL.%26aulast%3DJargasova%26aufirst%3DS.%26aulast%3DSmolkova%26aufirst%3DB.%26aulast%3DPlava%26aufirst%3DJ.%26aulast%3DKucerova%26aufirst%3DL.%26aulast%3DMatuskova%26aufirst%3DM.%26atitle%3DALDH1A%2520inhibition%2520sensitizes%2520colon%2520cancer%2520cells%2520to%2520chemotherapy%26jtitle%3DBMC%2520Cancer%26date%3D2018%26volume%3D18%26spage%3D656%26doi%3D10.1186%2Fs12885-018-4572-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, D.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span> <span> </span><span class="NLM_article-title">The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">17593</span>– <span class="NLM_lpage">17609</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.4307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.18632%2Foncotarget.4307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=26061710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A280%3ADC%252BC2MbitVyrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=17593-17609&author=J.-J.+Chenauthor=N.+Caiauthor=G.-Z.+Chenauthor=C.-C.+Jiaauthor=D.-B.+Qiuauthor=C.+Duauthor=W.+Liuauthor=Y.+Yangauthor=Z.-J.+Longauthor=Q.+Zhang&title=The+neuroleptic+drug+pimozide+inhibits+stem-like+cell+maintenance+and+tumorigenicity+in+hepatocellular+carcinoma&doi=10.18632%2Foncotarget.4307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma</span></div><div class="casAuthors">Chen Jia-Jie; Cai Nan; Chen Guan-Zhong; Jia Chang-Chang; Liu Wei; Yang Yang; Zhang Qi; Chen Jia-Jie; Cai Nan; Jia Chang-Chang; Qiu Dong-Bo; Du Cong; Zhang Qi; Chen Jia-Jie; Long Zi-Jie; Chen Guan-Zhong; Qiu Dong-Bo; Du Cong; Liu Wei; Zhang Qi</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">17593-17609</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug repurposing is currently an important approach for accelerating drug discovery and development for clinical use.  Hepatocellular carcinoma (HCC) presents drug resistance to chemotherapy, and the prognosis is poor due to the existence of liver cancer stem-like cells.  In this study, we investigated the effect of the neuroleptic agent pimozide to inhibit stem-like cell maintenance and tumorigenicity in HCC.  Our results showed that pimozide functioned as an anti-cancer drug in HCC cells or stem-like cells.  Pimozide inhibited cell proliferation and sphere formation capacities in HCC cells by inducing G0/G1 phase cell cycle arrest, as well as inhibited HCC cell migration.  Surprisingly, pimozide inhibited the maintenance and tumorigenicity of HCC stem-like cells, particularly the side population (SP) or CD133-positive cells, as evaluated by colony formation, sphere formation and transwell migration assays.  Furthermore, pimozide was found to suppress STAT3 activity in HCC cells by attenuating STAT3-dependent luciferase activity and down-regulating the transcription levels of downstream genes of STAT3 signaling.  Moreover, pimozide reversed the stem-like cell tumorigenic phenotypes induced by IL-6 treatment in HCC cells.  Further, the antitumor effect of pimozide was also proved in the nude mice HCC xenograft model.  In short, the anti-psychotic agent pimozide may act as a novel potential anti-tumor agent in treating advanced HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJREZ8s_IGh7HHuJhbyicZfW6udTcc2eYuhQHg2oxB0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbitVyrtg%253D%253D&md5=bea228d4f6fd873b07b1a1fd6b44bd39</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4307%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.-J.%26aulast%3DCai%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DG.-Z.%26aulast%3DJia%26aufirst%3DC.-C.%26aulast%3DQiu%26aufirst%3DD.-B.%26aulast%3DDu%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DZ.-J.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DThe%2520neuroleptic%2520drug%2520pimozide%2520inhibits%2520stem-like%2520cell%2520maintenance%2520and%2520tumorigenicity%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D17593%26epage%3D17609%26doi%3D10.18632%2Foncotarget.4307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>340</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2013.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2Fj.canlet.2013.07.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=23872274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1WrtbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2013&pages=113-123&author=Y.+Luauthor=H.+Zhuauthor=H.+Shanauthor=J.+Luauthor=X.+Changauthor=X.+Liauthor=J.+Luauthor=X.+Fanauthor=S.+Zhuauthor=Y.+Wangauthor=Q.+Guoauthor=L.+Wangauthor=Y.+Huangauthor=M.+Zhuauthor=Z.+Wang&title=Knockdown+of+Oct4+and+Nanog+expression+inhibits+the+stemness+of+pancreatic+cancer+cells&doi=10.1016%2Fj.canlet.2013.07.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells</span></div><div class="casAuthors">Lu, Yuhua; Zhu, Hui; Shan, Haiyan; Lu, Junjie; Chang, Xu; Li, Xiaohong; Lu, Jingjing; Fan, Xiangjun; Zhu, Shajun; Wang, Yao; Guo, Qingsong; Wang, Lei; Huang, Yan; Zhu, Mingyan; Wang, Zhiwei</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-123</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Pancreatic cancer is notorious for its difficult diagnosis at early stage and poor recurrence-free prognosis.  This study aimed to investigate the possible involvement of Oct4 and Nanog in pancreatic cancer.  The high expressions of Oct4 and Nanog in human pancreatic cancer tissues were found to indicate a worse prognostic value of patients.  The pancreatic cancer stem cells (PCSCs) that isolated from PANC-1 cell line by flow cytometry exhibited high expressions of Oct4 and Nanog.  To investigate whether Oct4 and Nanog play crucial role in maintaining the stemness of PCSCs, double knockdown of Oct4 and Nanog demonstrated that Oct4 and Nanog significantly reduced proliferation, migration, invasion, chemoresistance, and tumorigenesis of PCSCs in vitro and in vivo.  The altered expression of the genes related to pancreatic carcinogenesis, metastasis, drug resistance and epithelial-mesenchymal transdifferentiation (EMT) might affect the biol. characteristics of PCSCs.  Our results suggest that Oct4 and Nanog may serve as a potential marker of prognosis and a novel target of therapy for pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokcOYM0eHQFLVg90H21EOLACvtfcHk0lh0FeWLlmtYsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1WrtbzL&md5=db8be55f62a426df2ac1d6beda29d331</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2013.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2013.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DShan%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DKnockdown%2520of%2520Oct4%2520and%2520Nanog%2520expression%2520inhibits%2520the%2520stemness%2520of%2520pancreatic%2520cancer%2520cells%26jtitle%3DCancer%2520Lett.%26date%3D2013%26volume%3D340%26spage%3D113%26epage%3D123%26doi%3D10.1016%2Fj.canlet.2013.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadpour, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emami Razavi, A.</span></span> <span> </span><span class="NLM_article-title">Association of high expression levels of Sox<sub>2</sub>, Nanog, and Oct4 in gastric cancer tumor tissues with progression and poor prognosis</span>. <i>J. Gastrointest. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1007/s12029-018-00200-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1007%2Fs12029-018-00200-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2020&pages=41-47&author=G.+Basatiauthor=H.+Mohammadpourauthor=A.+Emami+Razavi&title=Association+of+high+expression+levels+of+Sox2%2C+Nanog%2C+and+Oct4+in+gastric+cancer+tumor+tissues+with+progression+and+poor+prognosis&doi=10.1007%2Fs12029-018-00200-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs12029-018-00200-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12029-018-00200-x%26sid%3Dliteratum%253Aachs%26aulast%3DBasati%26aufirst%3DG.%26aulast%3DMohammadpour%26aufirst%3DH.%26aulast%3DEmami%2BRazavi%26aufirst%3DA.%26atitle%3DAssociation%2520of%2520high%2520expression%2520levels%2520of%2520Sox2%252C%2520Nanog%252C%2520and%2520Oct4%2520in%2520gastric%2520cancer%2520tumor%2520tissues%2520with%2520progression%2520and%2520poor%2520prognosis%26jtitle%3DJ.%2520Gastrointest.%2520Surg.%26date%3D2020%26volume%3D51%26spage%3D41%26epage%3D47%26doi%3D10.1007%2Fs12029-018-00200-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perugorria, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaizola, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labiano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esparza-Baquer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzioni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marin, J. J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bujanda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banales, J. M.</span></span> <span> </span><span class="NLM_article-title">Wnt−β-catenin signalling in liver development, health and disease</span>. <i>Nat. Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1038/s41575-018-0075-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1038%2Fs41575-018-0075-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=30451972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlWnsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=121-136&author=M.+J.+Perugorriaauthor=P.+Olaizolaauthor=I.+Labianoauthor=A.+Esparza-Baquerauthor=M.+Marzioniauthor=J.+J.+G.+Marinauthor=L.+Bujandaauthor=J.+M.+Banales&title=Wnt%E2%88%92%CE%B2-catenin+signalling+in+liver+development%2C+health+and+disease&doi=10.1038%2Fs41575-018-0075-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Wnt-β-catenin signalling in liver development, health and disease</span></div><div class="casAuthors">Perugorria, Maria J.; Olaizola, Paula; Labiano, Ibone; Esparza-Baquer, Aitor; Marzioni, Marco; Marin, Jose J. G.; Bujanda, Luis; Banales, Jesus M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-136</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The canonical Wnt-β-catenin pathway is a complex, evolutionarily conserved signalling mechanism that regulates fundamental physiol. and pathol. processes.  Wnt-β-catenin signalling tightly controls embryogenesis, including hepatobiliary development, maturation and zonation.  In the mature healthy liver, the Wnt-β-catenin pathway is mostly inactive but can become re-activated during cell renewal and/or regenerative processes, as well as in certain pathol. conditions, diseases, pre-malignant conditions and cancer.  In hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), the two most prevalent primary liver tumors in adults, Wnt-β-catenin signalling is frequently hyperactivated and promotes tumor growth and dissemination.  A substantial proportion of liver tumors (mainly HCC and, to a lesser extent, CCA) have mutations in genes encoding key components of the Wnt-β-catenin signalling pathway.  Likewise, hepatoblastoma, the most common paediatric liver cancer, is characterized by Wnt-β-catenin activation, mostly as a result of β-catenin mutations.  In this Review, we discuss the most relevant mol. mechanisms of action and regulation of Wnt-β-catenin signalling in liver development and pathophysiol.  Moreover, we highlight important preclin. and clin. studies and future directions in basic and clin. research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnHfSlRdNCxbVg90H21EOLACvtfcHk0lgJqwlhf7keEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlWnsrvK&md5=65768c2d2f88530de2dacddf5acb089a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fs41575-018-0075-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41575-018-0075-9%26sid%3Dliteratum%253Aachs%26aulast%3DPerugorria%26aufirst%3DM.%2BJ.%26aulast%3DOlaizola%26aufirst%3DP.%26aulast%3DLabiano%26aufirst%3DI.%26aulast%3DEsparza-Baquer%26aufirst%3DA.%26aulast%3DMarzioni%26aufirst%3DM.%26aulast%3DMarin%26aufirst%3DJ.%2BJ.%2BG.%26aulast%3DBujanda%26aufirst%3DL.%26aulast%3DBanales%26aufirst%3DJ.%2BM.%26atitle%3DWnt%25E2%2588%2592%25CE%25B2-catenin%2520signalling%2520in%2520liver%2520development%252C%2520health%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2019%26volume%3D16%26spage%3D121%26epage%3D136%26doi%3D10.1038%2Fs41575-018-0075-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanahan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">The hallmarks of cancer</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)81683-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1016%2FS0092-8674%2800%2981683-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10647931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=57-70&author=D.+Hanahanauthor=R.+A.+Weinberg&title=The+hallmarks+of+cancer&doi=10.1016%2FS0092-8674%2800%2981683-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The hallmarks of cancer</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-70</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review is given with many refs. on principles governing the transformation of normal human cells into malignant cancers.  The authors suggest that research over the past decades has revealed a small no. of mol., biochem., and cellular traits (acquired capabilities) shared by most and perhaps all types of cancer.  Topics included are the acquired capabilities self-sufficiency in growth signals, insensitivity to antigrowth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis followed by genome instability as an enabling characteristic and alternative pathways to cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooXmGqKjM1C7Vg90H21EOLACvtfcHk0lgJqwlhf7keEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D&md5=1d23c4400dad34c7f32d4a0c41890349</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981683-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981683-9%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DThe%2520hallmarks%2520of%2520cancer%26jtitle%3DCell%26date%3D2000%26volume%3D100%26spage%3D57%26epage%3D70%26doi%3D10.1016%2FS0092-8674%2800%2981683-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, B.</span></span> <span> </span><span class="NLM_article-title">NOR1 suppresses cancer stem-like cells properties of tumor cells <i>via</i> the inhibition of the AKT-GSK-3β-Wnt/β-catenin-ALDH1A1 signal circuit</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>232</i></span>,  <span class="NLM_fpage">2829</span>– <span class="NLM_lpage">2840</span>, <span class="refDoi"> DOI: 10.1002/jcp.25706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1002%2Fjcp.25706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=27891591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFahsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2017&pages=2829-2840&author=W.+Wangauthor=M.+Yiauthor=S.+Chenauthor=J.+Liauthor=H.+Zhangauthor=W.+Xiongauthor=G.+Liauthor=X.+Liauthor=B.+Xiang&title=NOR1+suppresses+cancer+stem-like+cells+properties+of+tumor+cells+via+the+inhibition+of+the+AKT-GSK-3%CE%B2-Wnt%2F%CE%B2-catenin-ALDH1A1+signal+circuit&doi=10.1002%2Fjcp.25706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">NOR1 Suppresses Cancer Stem-Like Cells Properties of Tumor Cells via the Inhibition of the AKT-GSK-3β-Wnt/β-catenin-ALDH1A1 Signal Circuit</span></div><div class="casAuthors">Wang, Wei; Yi, Mei; Chen, Shengnan; Li, Junjun; Zhang, Haijing; Xiong, Wei; Li, Guiyuan; Li, Xiaoling; Xiang, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2829-2840</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) play a key role in tumor radiotherapy and chemotherapy resistance, relapse, and metastasis, and are primarily maintained in a resting state in vivo.  The failure of conventional therapies to target CSCs is the main cause of treatment failure.  The discovery of CSCs in nasopharyngeal carcinoma (NPC) tumors is becoming more prevalent; however, the understanding of the mechanisms underlying the maintenance of tumor stemness is still limited.  We previously cloned NOR1, a tumor suppressor gene downregulated in NPC cell lines and tissues.  In this study, we demonstrate that Wnt/β-catenin and ALDH1A1 form a signal circuit and that NOR1 antagonizes the tumor stem cell-like phenotype in NPC cell lines: the ectopic overexpression of NOR1 reduced β-catenin and ALDH1A1 expression; β-catenin/TCF4 targeted the regulation of ALDH1A1 transcription in NPC cells; silencing ALDH1A1 reduced AKT (total and phosphorylated) and GSK-3β (phosphorylated) expression; and eventually feedback decreased β-catenin expression levels.  We also found that NOR1 expression decreased cancer stem-like cell properties of NPC cells, reduced their ability to form tumor spheroids in vitro, reduced tumorigenicity in nude mice in vivo, and increased sensitivity to chemotherapy agents.  Taken together, our findings illustrated a new function of NOR1 that suppresses cancer stem-like cell properties in tumor cells by inhibiting the AKT-GSK-3β-Wnt/β-catenin-ALDH1A1 signal circuit.  The study suggests that NOR1 deletion expression in NPC cells may be a potential mol. target for cancer stem cell therapy.  J. Cell. Physiol. 9999: 1-12, 2016. © 2016 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjQREwi8U08bVg90H21EOLACvtfcHk0liigRVq_ecZLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFahsr0%253D&md5=49109830d2714cadee604a7fff74c3a3</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fjcp.25706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.25706%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYi%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DB.%26atitle%3DNOR1%2520suppresses%2520cancer%2520stem-like%2520cells%2520properties%2520of%2520tumor%2520cells%2520via%2520the%2520inhibition%2520of%2520the%2520AKT-GSK-3%25CE%25B2-Wnt%252F%25CE%25B2-catenin-ALDH1A1%2520signal%2520circuit%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2017%26volume%3D232%26spage%3D2829%26epage%3D2840%26doi%3D10.1002%2Fjcp.25706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedert, M.</span></span> <span> </span><span class="NLM_article-title">GSK3 inhibitors: development and therapeutic potential</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1038/nrd1415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1038%2Fnrd1415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=15173837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVaqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=479-487&author=P.+Cohenauthor=M.+Goedert&title=GSK3+inhibitors%3A+development+and+therapeutic+potential&doi=10.1038%2Fnrd1415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 inhibitors: development and therapeutic potential</span></div><div class="casAuthors">Cohen, Philip; Goedert, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">479-487</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an enzyme involved in the control of glycogen metab.  In recent years it has been shown to have key roles in regulating a diverse range of cellular functions, which have prompted efforts to develop GSK3 inhibitors as therapeutics.  Here, we describe the biol. of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases, and discuss progress in the development of GSK3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL3ua5xi0_qrVg90H21EOLACvtfcHk0liigRVq_ecZLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVaqsrs%253D&md5=165d1354bf11faa6021ac4dba797fda2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnrd1415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1415%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DGoedert%26aufirst%3DM.%26atitle%3DGSK3%2520inhibitors%253A%2520development%2520and%2520therapeutic%2520potential%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D479%26epage%3D487%26doi%3D10.1038%2Fnrd1415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mills, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowsheen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonner, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. S.</span></span> <span> </span><span class="NLM_article-title">Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">47</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2011.00047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.3389%2Ffnmol.2011.00047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=22275880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BC38XovV2j" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=47&author=C.+N.+Millsauthor=S.+Nowsheenauthor=J.+A.+Bonnerauthor=E.+S.+Yang&title=Emerging+roles+of+glycogen+synthase+kinase+3+in+the+treatment+of+brain+tumors&doi=10.3389%2Ffnmol.2011.00047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors</span></div><div class="casAuthors">Mills, Caroline N.; Nowsheen, Somaira; Bonner, James A.; Yang, Eddy S.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Nov.</span>),
    <span class="NLM_cas:pages">47</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The constitutively active protein glycogen synthase kinase 3 (GSK3), a serine/threonine kinase, acts paradoxically as a tumor suppressor in some cancers while potentiates growth in others.  Deciphering what governs its actions is vital for understanding many pathol. conditions, including brain cancer.  What are seemingly disparate roles of GSK3 stems from the complex regulation of many cellular functions by GSK3.  This review focuses on the regulation of GSK3, its role in survival, apoptosis and DNA damage, and finally its potential therapeutic impact in brain cancer.  A thorough understanding of this versatile protein is crit. for improving the outcome of various diseases, esp. cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDHgnEU2CYbVg90H21EOLACvtfcHk0lhmUt5HbBTXwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovV2j&md5=a91f52a6292ec3ed914020d19393a989</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2011.00047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2011.00047%26sid%3Dliteratum%253Aachs%26aulast%3DMills%26aufirst%3DC.%2BN.%26aulast%3DNowsheen%26aufirst%3DS.%26aulast%3DBonner%26aufirst%3DJ.%2BA.%26aulast%3DYang%26aufirst%3DE.%2BS.%26atitle%3DEmerging%2520roles%2520of%2520glycogen%2520synthase%2520kinase%25203%2520in%2520the%2520treatment%2520of%2520brain%2520tumors%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2011%26volume%3D4%26spage%3D47%26doi%3D10.3389%2Ffnmol.2011.00047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chua, P. C.</span>; <span class="NLM_string-name">Haddach, M.</span>; <span class="NLM_string-name">Nagasawa, J. Y.</span>; <span class="NLM_string-name">Pierre, F.</span></span> <span> </span><span class="NLM_article-title">Preparation of substituted pyrimidoquinolines and thienoquinolines as serine-threonine protein kinase and PARP modulators</span>. Sep 3, <span class="NLM_year">2009</span>, <span class="NLM_patent">WO 2009108912 A1</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=P.+C.+Chua&author=M.+Haddach&author=J.+Y.+Nagasawa&author=F.+Pierre&title=Preparation+of+substituted+pyrimidoquinolines+and+thienoquinolines+as+serine-threonine+protein+kinase+and+PARP+modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChua%26aufirst%3DP.%2BC.%26atitle%3DPreparation%2520of%2520substituted%2520pyrimidoquinolines%2520and%2520thienoquinolines%2520as%2520serine-threonine%2520protein%2520kinase%2520and%2520PARP%2520modulators%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Livak, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmittgen, T. D.</span></span> <span> </span><span class="NLM_article-title">Analysis of relative gene expression data using Real-time quantitative PCR and the 2<sup>-ΔΔCT</sup> method</span>. <i>Methods</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1006/meth.2001.1262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=10.1006%2Fmeth.2001.1262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=11846609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtFelt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2001&pages=402-408&author=K.+J.+Livakauthor=T.+D.+Schmittgen&title=Analysis+of+relative+gene+expression+data+using+Real-time+quantitative+PCR+and+the+2-%CE%94%CE%94CT+method&doi=10.1006%2Fmeth.2001.1262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method</span></div><div class="casAuthors">Livak, Kenneth J.; Schmittgen, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Methods (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">402-408</span>CODEN:
                <span class="NLM_cas:coden">MTHDE9</span>;
        ISSN:<span class="NLM_cas:issn">1046-2023</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The two most commonly used methods to analyze data from real-time, quant. PCR expts. are abs. quantification and relative quantification.  Abs. quantification dets. the input copy no., usually by relating the PCR signal to a std. curve.  Relative quantification relates the PCR signal of the target transcript in a treatment group to that of another sample such as an untreated control.  The 2-ΔΔCT method is a convenient way to analyze the relative changes in gene expression from real-time quant. PCR expts.  The purpose of this report is to present the derivation, assumptions, and applications of the 2-ΔΔCT method.  In addn., we present the derivation and applications of two variations of the 2-ΔΔCT method that may be useful in the anal. of real-time, quant. PCR data.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXNe1s-mDpprVg90H21EOLACvtfcHk0lhmUt5HbBTXwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtFelt7s%253D&md5=f849383250ea43f7380ed540db8a64b1</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1006%2Fmeth.2001.1262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fmeth.2001.1262%26sid%3Dliteratum%253Aachs%26aulast%3DLivak%26aufirst%3DK.%2BJ.%26aulast%3DSchmittgen%26aufirst%3DT.%2BD.%26atitle%3DAnalysis%2520of%2520relative%2520gene%2520expression%2520data%2520using%2520Real-time%2520quantitative%2520PCR%2520and%2520the%25202-%25CE%2594%25CE%2594CT%2520method%26jtitle%3DMethods%26date%3D2001%26volume%3D25%26spage%3D402%26epage%3D408%26doi%3D10.1006%2Fmeth.2001.1262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6isj" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6isj','PDB','6isj'); return false;">PDB: 6isj</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6khe" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6khe','PDB','6khe'); return false;">PDB: 6khe</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4x4l" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4x4l','PDB','4x4l'); return false;">PDB: 4x4l</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i68"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00131">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_44444"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00131?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00131</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthetic route of <b>BTE</b> and <b>CX-4945</b>, representative flow cytometry figures from the Aldefluor assays, docking of <b>1c</b> into ALDH1A1 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4x4l">4x4l</a>) kinase X-ray crystal structure, Annexin CD44-FITC and CD133-PI staining results of <b>1c</b> in the HCT-116<sup>ALDH+</sup> cells, HE staining internal organs and tumor tissues in the animal xenograft model of HCT-116, the inhibitory rate of the synthesized compounds on PC-3, HCT-116, MCF-7, HT-29, T24, and LO2 cells at different concentrations, the inhibitory rate of the synthesized compounds on CK2 and Clk2 at different concentrations, schematic diagram of the inhibition activity detection of compounds against CK2 and Clk2, table of the percent inhibition of compound <b>1c</b> against 208 kinases, table of the primer sequences used for qRT-PCR, table of the <i>in vivo</i> blood concentration results of <b>CX-4945·Na</b> and <b>1c</b>, table of the inhibitory effects of the measured samples on the HCT-116 cancer cell xenograft mice model, figures of <sup>1</sup>H and <sup>13</sup>C NMR, HR-MS spectra, and RP-HPLC chromatograms (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_002.csv">CSV</a>)</p></li><li><p class="inline">PDB file of <b>1c</b>-CK2α (PDB ID: 6isj) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_003.pdb">PDB</a>)</p></li><li><p class="inline">PDB file of <b>1c</b>-Clk2 (PDB ID: 6khe) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_004.pdb">PDB</a>)</p></li><li><p class="inline">PDB file of <b>1c</b>-ALDH1A1 (PDB ID: 4x4l) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_005.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_001.pdf">jm1c00131_si_001.pdf (12.3 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_002.csv">jm1c00131_si_002.csv (4.08 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_003.pdb">jm1c00131_si_003.pdb (264.92 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_004.pdb">jm1c00131_si_004.pdb (279.79 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00131/suppl_file/jm1c00131_si_005.pdb">jm1c00131_si_005.pdb (618.86 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00131&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-8%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00131" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00131" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6679883888e924b2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
